



US 20110263026A1

(19) **United States**

(12) **Patent Application Publication**

Inoue et al.

(10) **Pub. No.: US 2011/0263026 A1**

(43) **Pub. Date: Oct. 27, 2011**

(54) **CONSTRUCTION OF PROTEIN-RESPONSIVE
SHRNA/RNAI CONTROL SYSTEM USING
RNP MOTIF**

(75) Inventors: **Tan Inoue**, Kyoto (JP); **Hirohide
Saito**, Kyoto (JP); **Shunichi
Kashida**, Kyoto (JP); **Karin
Hayashi**, Kyoto (JP)

(73) Assignee: **JAPAN SCIENCE AND
TECHNOLOGY AGENCY**,
Saitama (JP)

(21) Appl. No.: **13/133,709**

(22) PCT Filed: **Dec. 9, 2009**

(86) PCT No.: **PCT/JP2009/070580**

§ 371 (c)(1),
(2), (4) Date: **Jul. 13, 2011**

(30) **Foreign Application Priority Data**

Dec. 9, 2008 (JP) 2008-312951

Publication Classification

(51) **Int. Cl.**
C07H 21/02 (2006.01)
C12N 15/63 (2006.01)
C12N 5/071 (2010.01)
C07K 14/00 (2006.01)

(52) **U.S. Cl. 435/455**; 536/24.5; 530/358; 435/320.1;
435/375

(57) **ABSTRACT**

An object of the present invention is to provide an RNAi control system using an RNA-protein interaction motif. The present invention provides an shRNA comprising: a guide strand having a sequence complementary to a target sequence; a passenger strand which forms a duplex with the guide strand; and a linker strand which links the guide strand and the passenger strand, wherein the linker strand comprises an RNP-derived protein-binding motif sequence. The present invention also provides an RNAi control system comprising: the shRNA; and an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.

FIG.1




FIG.2(A)




FIG.2(B)




FIG.2(C)





FIG.3(A)



Comments for pENTR™/H1/TO
3869 nucleotides

- mb T2 transcription terminator: bases 268-295 (C)
- mb T1 transcription terminator: bases 427-470
- SV40 polyadenylation signal: bases 513-642 (C)
- Zeocin[™] resistance gene: bases 772-1146 (C)
- EM7 promoter: bases 1147-1213 (C)
- SV40 early promoter and origin: bases 1268-1578 (C)
- M13 forward (-20) priming site: bases 1648-1863
- oriL1: bases 1680-1779 (C)
- H1/TO promoter: bases 1836-1935
 - letO₂ site: bases 1885-1903
 - TATA box: bases 1908-1910
 - letO₂ site: bases 1913-1931
- H1 forward priming site: bases 1856-1875
- 5' overhang: bases 1932-1935 (C)
- 5' overhang: bases 1936-1939
- Pol III transcription terminator: bases 1936-1941
- oriL2: bases 1994-2093
- M13 reverse priming site: bases 2134-2150
- Kanamycin resistance gene: bases 2263-3072
- pUC origin: bases 3193-3868

(C) = complementary strand

FIG.3(B)




FIG.4

pcDNA3.1-L7Ae -myc-His6




FIG.5(A)

<shRNA-GFP (59mer), GFP RNAi Positive Control>




FIG.5(B)

<shRNA-GFP mut (59mer), GFP RNAi Negative Control>




FIG.5(C)

<shRNA-BoxC/D-GFP (63mer)>




FIG.5(D)

<shRNA-BoxC/D-mut-GFP (62mer) >




FIG.6




FIG.7




FIG.8




FIG.9




FIG.10




FIG.11(A)
Mock




FIG.11(B)
shRNA-U1A-4




FIG.11(C)
shRNA-BoxC/D-GFP




FIG.12




FIG.13(A)




FIG.13(B)




FIG.13(C)




FIG.14




FIG. 15




FIG.16





FIG.18



CONSTRUCTION OF PROTEIN-RESPONSIVE SHRNA/RNAI CONTROL SYSTEM USING RNP MOTIF

TECHNICAL FIELD

[0001] The present invention relates to the construction of a protein-responsive shRNA and RNAi control system using an RNP motif.

BACKGROUND ART

[0002] RNA interference (hereinafter, referred to as RNAi) is a phenomenon in which translation is transiently inhibited by cleaving mRNA in a sequence-specific manner. An approach called knockdown, which causes this RNAi by introducing an RNA duplex such as short hairpin RNA (hereinafter, referred to as shRNA), has been established in various organism species. RNAi has been diffused widely, including study on its application to medical treatment, in a period as short as 10 years from its discovery as the convenient and potent approach of transiently inhibiting gene expression. However, its mechanisms or introduction techniques still remain to be evolved. Moreover, at this time, the theme of RNAi centers on studies for making knockdown strongly effective or the development of delivery techniques for delivering RNA to a site of interest.

[0003] Chung et al. have prepared artificial RNA in which the binding site of theophylline known as a caffeine-like low-molecular-weight compound has been introduced in the loop portion of shRNA, and have revealed that RNAi is inhibited in a theophylline concentration-dependent manner (see Non-Patent Document 1).

[0004] Non-Patent Document 1: Chung-II An, Vu B. Trinh, and Yohei Yokobayashi, RNA, May 2006; 12: 710-716

DISCLOSURE OF THE INVENTION

Problems to be Solved by the Invention

[0005] An object of the present invention is to provide an RNAi control system using RNP for the purpose of newly designing and preparing a translational control mechanism using RNAs or proteins as inhibitors and incorporating such an artificial translational control system into a living body.

Means for Solving the Problems

[0006] The present invention has been achieved for attaining the object. Specifically, according to one embodiment, the present invention relates to an shRNA comprising: a guide strand having a sequence complementary to a target sequence; a passenger strand which forms a duplex with the guide strand; and a linker strand which links the guide strand and the passenger strand, wherein the linker strand comprises an RNP-derived protein-binding motif sequence. In the present specification, this shRNA is also referred to as a sensor shRNA.

[0007] It is preferred that the RNP-derived protein-binding motif sequence should be a Box C/D sequence.

[0008] According to an alternative aspect, the present invention relates to an RNAi control system comprising: the sensor shRNA; and an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.

[0009] According to an alternative aspect, the present invention relates to an RNAi control system comprising: a vector for expression of the sensor shRNA; and a vector for

expression of an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.

[0010] According to a further alternative aspect, the present invention relates to an RNAi control method comprising the steps of: contacting the sensor shRNA with an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA, in a solution; and introducing the solution containing the shRNA and the protein into a cell.

[0011] According to a further alternative aspect, the present invention relates to an intracellular RNAi control method comprising the steps of: introducing a vector for expression of the sensor shRNA into a cell; introducing a vector for expression of an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA, into the cell; and causing their expressions from the vector for expression of the shRNA and the vector for expression of the protein.

[0012] According to a further alternative aspect, the present invention provides an RNAi control system responsive to a protein expressed in a cell, the system comprising: the sensor shRNA in which RNP-derived protein-binding motif sequence is a sequence specifically binding to the protein expressed in the cell, or a vector for expression of the shRNA, and also provides an RNAi control method responsive to a protein expressed in a cell, the method comprising the step of: introducing the sensor shRNA in which RNP-derived protein-binding motif sequence is a sequence specifically binding to the protein expressed in the cell, or a vector for expression of the shRNA, into a cell.

[0013] According to a further alternative aspect, the present invention provides the RNAi control system which controls the expression of an apoptosis regulatory protein wherein the target sequence of the shRNA is Bcl-xL mRNA, and also provides an artificial protein information conversion system using the shRNA, wherein information of a protein specifically binding to an RNP-derived protein-binding motif sequence is converted to information of a protein encoded by an RNA of the target sequence of the shRNA.

Advantageous Effects of the Invention

[0014] As an advantageous effects of the present invention, use of the sensor shRNA described above enables RNAi control such that RNAi is inhibited in a manner dependent on a protein specifically binding to the shRNA. This means that in the presence of the sensor shRNA, use of a particular protein as an input signal can inhibit the RNAi of particular mRNA and relatively increase the amount of proteins expressed from the particular mRNA. The sensor shRNA according to the present invention used in combination with the particular protein is useful in the construction of biosensors for quantifying the expression of intracellular marker proteins without destroying cells or artificial gene circuits capable of activating the translation of proteins of interest in response to the expression level of marker proteins. For example, the present invention produces significant advantageous effects that lead to the treatment of diseases such as cancer or Alzheimer's disease by activating apoptosis-inducing proteins in response to the expression of cancer marker proteins.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 schematically shows an shRNA according to the first embodiment;

[0016] FIG. 2(A) schematically shows an shRNA constituting an RNAi control system according to the second embodiment, FIG. 2(B) schematically shows an RNP-derived protein 4 constituting the RNAi control system according to the second embodiment, and FIG. 2(C) schematically shows a complex of the shRNA and the protein 4 in a system in which the shRNA and the protein 4 coexist;

[0017] FIG. 3(A) shows a pENTR (trademark)/H1/TO vector sold by Invitrogen Corp., FIG. 3(B) schematically shows a DNA duplex inserted to the pENTR (trademark)/H1/TO vector;

[0018] FIG. 4 shows a preparation example of a protein expression vector;

[0019] FIG. 5(A) shows the secondary structure sequence of shRNA-GFP for EGFP knockdown, FIG. 5(B) shows the secondary structure sequence of shRNA-GFP-mut used as a negative control that does not cause EGFP knockdown, FIG. 5(C) shows the secondary structure sequence of shRNA-Box C/D-GFP that is expected to specifically bind at the Box C/D sequence to an L7Ae protein, and FIG. 5(D) shows the secondary structure sequence of shRNA-Box C/D-mut-GFP that does not bind to L7Ae. In FIGS. 5(A) to 5(D), the wedge-shaped mark represents the position of cleavage by Dicer;

[0020] FIG. 6 shows the binding of shRNA-GFP, shRNA-Box C/D-GFP, and shRNA-Box C/D mut-GFP to L7Ae by gel shift assay;

[0021] FIG. 7 shows results of the inhibition of Dicer cleavage of shRNA-Box C/D-GFP by L7Ae using an in-vitro reconstituted Dicer system;

[0022] FIG. 8 is a graph showing results of RT-PCR-analyzing RNAi inhibition by L7Ae;

[0023] FIG. 9 is a graph showing results of FACS-analyzing RNAi inhibition by L7Ae;

[0024] FIG. 10 is a superimposed image of fluorescence and phase-contrast images of intracellular GFP in Example 2;

[0025] FIG. 11 is a graph showing results of FACS-analyzing fluorescence intensity distribution in Example 2;

[0026] FIG. 12 is a fluorescence image of EGFP showing the inhibitory effect of AsRed2-L7Ae on the knockdown function of shRNA-Box C/D-GFP;

[0027] FIG. 13(A) shows the secondary structure sequence of shRNA-Bc1xL for Bc1xL knockdown, FIG. 13(B) shows the secondary structure sequence of shRNA-Box C/D-Bc1xL that is expected to specifically bind at the Box C/D sequence to an L7Ae protein, and FIG. 13(C) shows the secondary structure sequence of shRNA-Box C/D mut-Bc1xL that does not bind to L7Ae. In FIGS. 13(A) to 13(C), the arrowheads indicate Dicer cleavage site;

[0028] FIG. 14 shows results of the inhibition of Dicer cleavage of shRNA-Box C/D-Bc1-xL and shRNA-Box C/D mut-Bc1-xL by L7Ae using an in-vitro reconstituted Dicer system;

[0029] FIG. 15 shows intracellular Bc1-xL expression;

[0030] FIG. 16 shows results of adding up the intensities of detected Bc1-xL bands;

[0031] FIG. 17 shows intracellular Bc1-xL expression; and

[0032] FIG. 18 shows results of adding up the intensities of detected Bc1-xL bands.

[0037] 3 passenger strand

[0038] 4 protein

[0039] a Dicer cleavage site

[0040] b Dicer cleavage site

[0041] 1d guide strand-encoding DNA sequence

[0042] 2d linker strand-encoding DNA sequence

[0043] 3d passenger strand-encoding DNA sequence

BEST MODE FOR CARRYING OUT THE INVENTION

[0044] Hereinafter, the present invention will be described in detail with reference to embodiments. However, the present invention is not intended to be limited to the description below.

[0045] In recent years, various noncoding RNAs that function in vivo have been discovered, and their roles have received attention. However, these RNAs often form a complex with a protein (RNP) in vivo. Thus, artificial RNP has been expected as a novel nanoblock capable of controlling cell functions. Naturally occurring RNP is found to form many complexes using an RNA-protein interaction motif (RNP motif) composed of a relatively short sequence. For example, HIV Rev proteins interact with high affinity with RNA motifs that recognize Rev. Thus, RNP has been expected to be used as a research material for synthetic biology (field in which biological molecules or the systems of life are constituted through the procedures of artificially creating biological molecules to induce new technologies).

[0046] To develop a system for controlling the translation of proteins of interest in response to proteins expressed in cells, the present inventors have come up with the idea that RNA interference is controlled using this RNA-protein interaction motif, thereby controlling the translation of proteins of interest. Based on this idea, the present invention has been completed.

[0047] According to a first embodiment, the present invention provides an shRNA comprising: a guide strand having a sequence complementary to a target sequence; a passenger strand which forms a duplex with the guide strand; and a linker strand which links the guide strand and the passenger strand, wherein the linker strand comprises an RNP-derived protein-binding motif sequence.

[0048] The shRNA according to the first embodiment is schematically shown in FIG. 1. The shRNA according to the first embodiment comprises a guide strand 1, a linker strand 2, and a passenger strand 3 in this order from the 3' end. The linker strand 2 has an RNP-derived protein-binding motif sequence 21 in the strand.

[0049] The guide strand 1 may be an RNA nucleotide sequence of approximately 21 bases to 26 bases and may be located at the 3' end in the shRNA. The guide strand 1 has a sequence complementary to a particular sequence of mRNA to be controlled (hereinafter, referred to as a target sequence). The mRNA to be controlled can be selected appropriately by those skilled in the art according to the purpose. Examples of the mRNA to be controlled include, but not limited to, mRNAs of apoptosis-inducing genes, mRNAs of apoptosis-

DESCRIPTION OF SYMBOLS

[0033] 1 guide strand

[0034] 2 linker strand

[0035] 20 base sequence

[0036] 21 protein-binding motif sequence

suppressing genes, and mRNAs of cancer marker genes. More specific examples of the mRNA to be controlled include GFP mRNA, BimEL mRNA, and Bcl-xL mRNA. Moreover, in these mRNAs, a sequence used as the target sequence can be selected appropriately by those skilled in the art by using design software based on information about the constitution and type of its primary gene sequence in view of inhibited off-target effect and the more efficiently inhibited expression of the target gene. The guide strand must be completely complementary to the target sequence. This is to cause the RNAi effect. At least 2 bases of the 3'-terminal in the guide strand **1** may form overhang that does not form complementary strands with the passenger strand. The guide strand **1** is a portion that becomes siRNA after cleavage by Dicer.

[0050] The passenger strand **3** may be an RNA nucleotide sequence of approximately 21 bases to 26 bases and may be located at the 5' end of the shRNA. When the passenger strand **3** is, for example, of 21 bases, bases 3 to 21 from the 3' end of the passenger strand **3** have a sequence that forms complementary strands with bases 3 to 21 from the 3' end of the guide strand **1**. When the passenger strand **3** is composed of 21 bases, usually, the guide strand is also composed of 21 bases. The numbers of bases constituting the passenger strand **3** and the guide strand **1** may be 22, 23, 24, 25, or 26. In either case, the numbers of bases of the passenger strand **3** and the guide strand **5** are usually equal. Moreover, as shown in FIG. 1, base 3 from the 3' end to the base at the 5' end of the passenger strand **3** has a sequence that forms complementary strands with the base at the 5' end to base 3 from the 3' end of the guide strand **1**. In this case, the passenger strand may be permitted to contain a 1-base to 2-base mismatch to the guide strand. After cleavage by Dicer, the passenger strand **3** may have, at the 3' end, overhang of at least 2 bases that forms complementary strands neither with a portion of the guide strand **1** nor with a portion of the linker strand. The passenger strand **3** may be also a portion that becomes siRNA after cleavage by Dicer.

[0051] The linker strand **2** serves as a linker between the guide strand **1** and the passenger strand **3**. The linker strand **2** may be bound to the 5' end of the guide strand **1** and the 3' end of the passenger strand **3**. In other words, the linker strand **2** may be a portion that is cleaved off from the guide strand **1** and the passenger strand **3** after cleavage by Dicer. The linker strand **2** may constitute the major part of the nonhybridized loop portion, as shown in the drawing, in the sensor shRNA according to the present invention. A portion of the nonhybridized loop portion may be derived from a portion of the 3' end of the passenger strand **3**. Alternatively, the linker strand **2** may constitute the whole nonhybridized loop portion, and a few bases at the 3' end of the linker strand **2** and a few bases at the 5' end of the linker strand **2** may form a portion of the stem portion of the hairpin structure through hybridization therebetween, though this structure is not shown in the drawings.

[0052] The linker strand **2** may comprise a base sequence **20** and an RNP-derived protein-binding motif sequence **21**. In this context, the base sequence **20** in the present invention refers to a portion of the sequence constituting the linker strand and a portion that is not derived from the RNP-derived protein-binding motif sequence **21**. In another embodiment, the linker strand **2** may be composed only of the RNP-derived protein-binding motif sequence **21**. When the linker strand **2** comprises the base sequence **20** and the RNP-derived protein-binding motif sequence **21** or when the linker strand **2** is

composed only of the RNP-derived protein-binding motif sequence **21**, the linker strand **2** may have, in its sequence, a sequence that does not form complementary strands, and this sequence may constitute the loop portion of the shRNA. The sequence that does not form complementary strands may be of 4 to 20 bases, preferably 4 to 11 bases, and the types of the bases are not limited. Preferable examples of the sequence that does not directly form complementary strands include, but not limited to, 5'-AGCAUAG-3' and 5'-GAAA-3'.

[0053] The 3'-terminal 2 bases of the linker strand **2** may form complementary strands with the 3'-terminal 2 bases of the passenger strand **3**. Furthermore, bases 3 to 7 bases may from the 3' end of the linker strand **2** may form complementary strands with bases 1 to 4 from the 5' end of the linker strand **2**. In this case, the number of bases forming complementary strands is 4. However, this number is not limited to 4 and can be determined between 1 and 8 bases.

[0054] When the protein-binding motif sequence **21** is introduced to the base sequence **20**, the introduction position of the protein-binding motif sequence **21** is not limited and may be a range which maintains recognition by Dicer described later. Moreover, when the linker strand is free from the base sequence, the protein-binding motif sequence **21** can be bound directly to the guide strand **1** and the passenger strand **3**.

[0055] In this context, examples of the protein-binding motif sequence **21** include nucleotide sequences derived from RNA-protein complex interaction motifs (RNP motifs), and nucleotide sequences mutated from these nucleotide sequences. In the present invention, the nucleotide sequences derived from RNA-protein complex interaction motifs encompass: nucleotide sequences known as the RNA sequences of RNA-protein interaction motifs in known natural RNA-protein complexes; and nucleotide sequences as the RNA sequences of artificial RNA-protein complex interaction motifs obtained by an in-vitro evolution method. The RNA-protein complexes are a large number of associates of proteins and RNAs that have been confirmed in vivo, and are 3D objects having a complicated structure. The nucleotide sequences derived from natural RNA-protein complex interaction motifs are usually composed of approximately 10 to 80 bases and known to form specific binding in a noncovalent manner, i.e., through a hydrogen bond, with a particular amino acid sequence of a particular protein. Such nucleotide sequences derived from natural RNA-protein complex interaction motifs can be selected from Tables 1 and 2 below and the database: <http://gibk26.bse.kyutech.ac.jp/jouhou/image/dna-protein/rna/ma.html> that is available on the website. The protein-binding motif sequence **21** as an RNA-protein interaction motif-derived nucleotide sequence preferably used in the present embodiment is a sequence that can be recognized by Dicer described below in detail to cause RNAi when incorporated in the shRNA. For conformational conditions, it is preferred that such a protein-binding motif sequence **21** should form a characteristic RNA tertiary structure comprising nonnatural base pairs and be highly specific for a protein binding to this site. Moreover, it is preferred that the RNA-protein interaction motif should have Kd of, but not limited to, approximately 0.1 nM to approximately 1 μM.

TABLE 1

RNA name	Protein name	Kd	Document
5S RNA (<i>Xenopus laevis</i> oocyte)	5R1	0.64 ± 0.10	nM Nat Struct Biol. 1998 Jul; 5(7): 543-6
5S RNA (<i>Xenopus laevis</i> oocyte)	5R2	0.35 ± 0.03	nM Nat Struct Biol. 1998 Jul; 5(7): 543-6
dsRNA	B2	1.4 ± 0.13	nM Nat Struct Mol Biol. 2005 Nov; 12(11): 952-7
RNA splicing motif with UGC AUGU element	Fox-1	0.49 nM at 150 mM salt	EMBO J. 2006 Jan 11; 25(1): 163-73.
TGE	GLD-1	9.2 ± 2	nM J Mol Biol. 2005 Feb 11; 346(1): 91-104.
sodB mRNA	Hfq	1.8	nM EMBO J. 2004 Jan 28; 23(2): 396-405.
RyhB (siRNA) mRNA	Hfq	1500	nM Annu Rev Microbiol. 2004; 58: 303-28
S domain of 7S RNA	HuD	0.7 ± 0.02	nM Nat Struct Biol. 2001 Feb; 8(2): 141-5
Large subunit of SRP RNA	human SRP19		RNA. 2005 Jul; 11(7): 1043-50. Epub 2005 May 31
23S rRNA	human SRP19	2	nM Nat Struct Biol. 2001 Jun; 8(6): 515-20
23S rRNA	L1		Nat Struct Biol. 2003 Feb; 10(2): 104-8
23S rRNA	L11		Nat Struct Biol. 2000 Oct; 7(10): 834-7
5S rRNA	L18		Biochem J. 2002 May 1; 363(Pt 3): 553-61
23S rRNA	L20	13 ± 2	nM J Biol Chem. 2003 Sep 19; 278(38): 36522-30.
Own mRNA site1	L20	88 ± 23	nM J Biol Chem. 2003 Sep 19; 278(38): 36522-30.
Own mRNA site2	L20	63 ± 23	nM Mol Microbiol. 2005 Jun; 56(6): 1441-56
23S rRNA	L23		J Biomol NMR. 2003 Jun; 26(2): 131-7
5S rRNA	L25		EMBO J. 1999 Nov 15; 18(22): 6508-21
Own mRNA	L30		Nat Struct Biol. 1999 Dec; 6(12): 1081-3.
mRNA	LicT		EMBO J. 2002 Apr 15; 21(8): 1987-97
Own mRNA	MS2 coat	39 ± 5	nM FEBS J. 2006 Apr; 273(7): 1463-75
Stem-loop RNA motif	Nova-2		Cell. 2000 Feb 4; 100(3): 323-32
SL2	Nucleocapsid	110 ± 50	nM J Mol Biol. 2000 Aug 11; 301(2): 491-511
Pre-rRNA	Nucleolin		EMBO J. 2000 Dec 15; 19(24): 6870-81
Box C/D	p19	0.17 ± 0.02	nM Cell. 2003 Dec 26; 115(7): 799-811
	L7Ae	0.9 ± 0.2	nM RNA. 2005 Aug; 11(8): 1192-200.

TABLE 2

RNA name	Protein name	Kd	Document
siRNA with the characteristic two-base 3' overhangs	PAZ (PiWi Argonaut and Zwillig)		Nat Struct Biol. 2003 Dec; 10(12): 1026-32.
dsRNA	Rnase III		Cell. 2006 Jan 27; 124(2): 355-66
HIV-1 RRE (IIB)	RR1-38	3-8 nM	Nat Struct Biol. 1998 Jul; 5(7): 543-6
Own mRNA	S15	5 nM	EMBO J. 2003 Apr 15; 22(8): 1898-908
16S rRNA	S15	6 nM	Nat Struct Biol. 2000 Apr; 7(4): 273-277.
Own mRNA	S15	43 nM	EMBO J. 2003 Apr 15; 22(8): 1898-908
16S rRNA	S4	6.5 μM in 4° C., 1.7 nM in 42° C.	J Biol Chem. 1979 Mar 25; 254(6): 1775-7
16S rRNA	S4	18 μM	J Biol Chem. 1979 Mar 25; 254(6): 1775-7
16S rRNA	S8	26 ± 7 nM	J Mol Biol. 2001 Aug 10; 311(2): 311-24
mRNA	S8	200 nM	RNA. 2004 Jun; 10(6): 954-64
mRNA	SacY	1400 nM	EMBO J. 1997 Aug 15; 16(16): 5019-29
SnRNA	Sm		Cold Spring Harb Symp Quant Biol. 2006; 71: 313-20.
tmRNA	SmpB	21 ± 7 nM	J Biochem (Tokyo). 2005 Dec; 138(6): 729-39
TD3 of tmRNA	SmpB	650 nM	J Biochem (Tokyo). 2005 Dec; 138(6): 729-39
U1 snRNA	snRNP U1A	0.032 ± 0.007 nM (salt dependence)	Nat Struct Biol. 2000 Oct; 7(10): 834-7
S domain of 7S RNA	SRP54	500 nM	RNA. 2005 Jul; 11(7): 1043-50.
TAR	Tat	200-800 nM	Nucleic Acids Res. 1996 Oct 15; 24(20): 3974-81
BIV TAR	Tat	1.3 nM or 8 nM or 60 nM (depending on difference in Mg)	Mol Cell. 2000 Nov; 6(5): 1067-76
tRNA ^{Thr}	ThrRS	500 nM	Nat Struct Biol. 2002 May; 9(5): 343-7
thrS mRNA operator	ThrRS	10 nM	Trends Genet. 2003 Mar; 19(3): 155-61
Single stranded mRNA	TIS11d		Nat Struct Mol Biol. 2004 Mar; 11(3): 257-64.
PSTVd	Vip1	500 nM	Nucleic Acids Res. 2003 Oct 1; 31(19): 5534-43
RNA hairpin; Smaug recognition element (SRE)	Vts1p	30 nM	Nat Struct Mol Biol. 2006 Feb; 13(2): 177-8.
□ BoxB	□ N	90 nM	Cell. 1998 Apr 17; 93(2): 289-99

[0056] The nucleotide sequences derived from artificial RNA-protein complex interaction motifs are the RNA nucleotide sequences of RNA-protein interaction motifs in artificially designed RNA-protein complexes. Such nucleotide

sequences are usually composed of approximately 10 to 80 bases and designed to form specific binding in a noncovalent manner, i.e., through a hydrogen bond, with a particular amino acid sequence of a particular protein. Examples of such

nucleotide sequences derived from artificial RNA-protein complex interaction motifs include, but not limited to, RNA aptamers specifically binding to the apoptosis-inducing protein Bcl-2 family, and RNA aptamers specifically recognizing cancer cell surface antigens. Moreover, nucleotide sequences listed in Table 3 below are also known, and these can also be used as the RNA-protein complex interaction motif-derived nucleotide sequence 2 of the present invention.

TABLE 3

RNA name	Protein name	Kd	Document
Rev aptamer 5	Rev	190 nM	RNA. 2005 Dec; 11(12): 1848-57
Aptamer	p50	5.4 ± 2.2 nM	Proc Natl Acad Sci USA. 2003 Aug 5; 100(16): 9268-73.
BMV Gag aptamer	BMV Gag	20 nM	RNA. 2005 Dec; 11(12): 1848-57
BMV Gag aptamer	CCMV Gag	260 nM	RNA. 2005 Dec; 11(12): 1848-57
CCMV Gag aptamer	CCMV Gag	280 nM	RNA. 2005 Dec; 11(12): 1848-57
CCMV Gag aptamer	BMV Gag	280 nM	RNA. 2005 Dec; 11(12): 1848-57

[0057] The artificial RNA-protein complexes can be prepared by using a molecular design method and an in-vivo evolution method in combination. The in-vivo evolution method can produce aptamers or ribozymes by selecting functional RNAs from molecular libraries having various sequence diversities, and repeating the reactions of amplification and transcription of their genes (DNAs). Thus, RNA-protein interaction motifs adapted to RNP having a functional structure of interest can be extracted in advance from natural RNP molecules by molecular design or prepared artificially by the in-vitro evolution method. In the present embodiment, for the RNA-protein complex interaction motif-derived nucleotide sequence 2, it is preferred that the RNA-protein complex from which the nucleotide sequence is derived should have a dissociation constant Kd of approximately 0.1 nM to approximately 1 μM. Specific examples of the protein-binding motif sequence 21 include a Box CD sequence: 5'-GGGCGUGAUGCGAAAGCUGACCC-3' (SEQ ID NO: 2), which is a nucleotide sequence binding to L7Ae (SEQ ID NO: 1) (Moore T et al., Structure Vol. 12, pp. 807-818 (2004)) known to participate in RNA modifications such as RNA methylation or pseudouridylation.

[0058] The constitution of the shRNA according to the present embodiment can be obtained by molecular design. The sensor shRNA of the present embodiment can be obtained, for example, by introducing a protein-binding motif sequence to a sequence portion forming the linker strand, based on the sequence of known natural or nonnatural shRNA, or by replacing a protein-binding motif sequence for a sequence portion forming the linker strand, based on the sequence of known natural or nonnatural shRNA. In this procedure, the type and introduction position of the protein-binding motif sequence can be determined in view of the appropriate placement of RNP of interest such that the function of the Dicer protein can be inhibited.

[0059] Alternatively, the nucleotide sequence of the guide strand can be determined according to the desired target sequence to design the linker strand and the passenger strand by computer-aided molecular modeling. In this procedure,

particular attention may be paid to the correct formation of a duplex structure by the guide strand and the passenger strand.

[0060] The shRNA according to the first embodiment may be stably present through the formation of the hairpin structure shown in FIG. 1 under physiological conditions involving pH 6.5 to 8.0 and a temperature of 4 to 42° C., preferably pH 7.3 to 7.5 and a temperature of 4 to 37° C. When the shRNA according to the first embodiment may be present in this form in vivo, this shRNA is recognized by an RNA duplex-cleaving enzyme Dicer. Then, the shRNA may be cleaved at positions shown by arrowheads a and b in FIG. 1 to form an RNA duplex of approximately 19 to 24 bases in the length of each strand having a 2-base protruding end. As a result, the guide RNA complementary to the target mRNA can be transferred from RLC to RISC to inhibit the translation of the mRNA to be controlled by its cleavage.

[0061] Thus, the shRNA according to the first embodiment is characterized in that the shRNA in the form shown in the drawing, i.e., in the form in which the protein-binding motif sequence 21 is unbound to the particular protein, functions in the same way as known natural shRNA.

[0062] Next, according to the second embodiment, the present invention provides an RNAi control system comprising: the shRNA according to the first embodiment; and an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.

[0063] The shRNA constituting the RNAi control system according to the present embodiment is schematically shown in FIG. 2(A), and an RNP-derived protein 4 is schematically shown in FIG. 2(B). The shRNA is as described in the first embodiment, and its description is omitted here. The same reference numerals will be used to designate the same components as those in FIG. 1.

[0064] The protein 4 shown in FIG. 2(B) is a protein that is derived from RNP and specifically binds to the protein-binding motif sequence 21 on the shRNA. Accordingly, this protein 4 can be determined in a manner specific for a sequence selected as the protein-binding motif sequence 21. Specifically, when Box C/D (SEQ ID NO: 2) is selected as the protein-binding motif sequence 21, the protein 4 is L7Ae (SEQ ID NO: 1). The protein 4 may also be a fusion protein containing the protein specifically binding to the protein-binding motif sequence 21 or may be a protein having an additional peptide added to the protein specifically binding to the protein-binding motif sequence 21. This is because the protein 4 needs only to be capable of inhibiting recognition by Dicer described below.

[0065] In the state shown in FIG. 2(A), the shRNA according to the present embodiment functions in the same way as known natural shRNA, as described in the first embodiment, in the absence of the protein 4 to cause RNAi such that the translational function of particular mRNA is inhibited.

[0066] Next, the states of the shRNA according to the present embodiment and the protein 4 in a system in which these molecules coexist will be described. FIG. 2(C) schematically shows the shRNA and the protein 4 in the system in which the shRNA and the protein 4 coexist. The shRNA and the protein 4 may be stably present in the form of an RNP complex formed by specific binding under physiological conditions involving pH 6.5 to 8.0 and a temperature of 4 to 42° C., preferably pH 7.0 to 7.5 and a temperature of 4 to 37° C.

[0067] The present embodiment is characterized in that when the protein-binding motif sequence 21 on the shRNA specifically bind the protein 4 to form an RNP by specific

binding, Dicer fails to recognize the shRNA in this RNP form. As a result, the Dicer fails to cleave the shRNA. Then, it cannot proceed to the next step of RNAi such that mRNA to be controlled is made insusceptible to cleavage. In other words, the coexistence of the shRNA according to the present embodiment with the protein 4 can inhibit RNAi. Moreover, according to the embodiment the protein 4 as input information is transformed to RNAi inhibition as output.

[0068] In this context, the system in which the shRNA and the protein 4 coexist may be a mixture of separately prepared shRNA and protein 4 molecules in a medium. Alternatively, a vector for expression of the shRNA molecule may be designed, and a vector for expression of the molecule of the protein 4 may be designed. These vectors may be introduced into the same cell, and their expressions can also be caused to achieve the system in which the shRNA and the protein 4 coexist. The vector design will be described in detail in Examples described later.

[0069] The RNAi control system according to the second embodiment of the present invention can achieve the inhibition of shRNA-mediated RNAi in a protein-specific manner.

[0070] Next, according to the third embodiment, the present invention relates to an RNAi control method comprising the steps of: contacting the sensor shRNA according to the first embodiment with an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA, in a solution; and introducing the solution containing the shRNA and the protein into a cell. The combination of the sensor shRNA and the protein used in the present embodiment can be selected based on the first and second embodiments to determine their sequences.

[In-Vitro Synthesis of a Sensor ShRNA]

[0071] In this context, the sensor shRNA can be obtained by an in-vitro synthesis method called in-vitro transcription. Single-stranded DNA in which a 19-base antisense sequence (TATAGTGAGTCGTATTAGC; SEQ ID NO: 3) of a T7 promoter sequence may be bound to the 3' end of a sequence serving as a template of shRNA is artificially synthesized (Hokkaido System Science Co., Ltd.), and this may be associated with a 19-base T7 promoter sequence (GCTAATACGACTCACTATA (SEQ ID NO: 4)) artificially synthesized in the same way. This associate may be mixed with ribonucleic acids, salts, and T7 RNA polymerase and reacted at 37° C., as specifically described in detail in Examples to obtain the sensor shRNA.

[Production of Protein]

[0072] On the other hand, the protein can be obtained by preparing a vector for expression of the protein and causing its expression using *E. coli*, followed by purification. For example, a vector for expression of L7Ae (SEQ ID NO: 2), which is a protein specifically binding to a Box-C/D motif represented by SEQ ID NO: 1, can be prepared with reference to Nucleic Acid Research, 2003, Vol. 31, No. 3 869-877. One example of the vector for expression of L7Ae (SEQ ID NO: 2) in *E. coli* is shown in SEQ ID NO: 5.

[0073] In the present embodiment, the contacting step may be performed by mixing the thus-prepared sensor shRNA and protein in the same solution system. The mixing of the shRNA and the protein may be performed under physiological conditions involving pH 6.5 to 8.0 and a temperature of 4 to 42° C., preferably pH 7.3 to 7.5 and a temperature of 4 to

37° C. As a result, the shRNA and the protein may specifically interact with each other to form an RNP complex.

[0074] RNAi may be inhibited in the presence of Dicer, ATP, and Mg ions and under appropriate physiological conditions, in addition to the conditions described above. Accordingly, in the contacting step, the sensor shRNA and the protein may be mixed to form an RNP complex, and then, the step of introduction into a cell can be carried out. The concentration of the RNP complex introduced into a cell is, for example, 1 nM to 40 nM shRNA, preferably 1 nM to 20 nM shRNA, and a protein concentration of preferably, but not limited to, that about 1 to 10 times the shRNA concentration. The introduction of the RNP complex into a cell can be performed by, but not limited to, transfection using liposomes and can be performed by those skilled in the art using general methods for introduction of an RNP into cells known in the art.

[0075] After the introduction of the RNP complex into a cell, the phenomenon described in the first embodiment with reference to FIG. 2 may take place in the cell containing Dicer. Specifically, Dicer neither recognizes the RNA cleavage site in the prepared complex of the sensor shRNA and the protein nor cleaves the shRNA. Then, mRNA complementary to the guide strand may not undergo RNAi. Thus, the expression of a protein encoded by this mRNA may be inhibited.

[0076] According to the third embodiment of the present invention, RNAi can be inhibited in vitro.

[0077] In an modification of the third embodiment, the protein alone can be administered directly to a cell. This modification involves, after the introduction of the protein into a cell, forming an RNP complex of the sensor shRNA and the protein in the cell, and differs in this point from the third embodiment which involves forming an RNP complex and then introducing it into a cell. In this modification, the sensor shRNA can be introduced into the cell before or after the introduction of the protein into the cell. When the sensor shRNA is introduced into the cell before the protein introduction, a vector for expression of the shRNA may be designed such that the expression of the shRNA in this vector introduced into the cell can be controlled using a small molecule such as tetracycline. In this method, the shRNA can be expressed using tetracycline after the protein introduction. When the sensor shRNA is introduced into the cell after the protein introduction, the shRNA may be introduced directly into the cell or a vector for expression of the shRNA may be introduced into the cell. The protein introduced in the cell forms an RNP complex with the sensor shRNA and enables the expression of a gene of interest to be controlled by RNAi in the cell. Thus, the present embodiment seems to be effective in the development of protein drugs or the treatment of diseases such as cancer.

[0078] According to the fourth embodiment, the present invention relates to an intracellular RNAi control method comprising the steps of: introducing a vector for expression of the shRNA according to the first embodiment into a cell; introducing a vector for expression of an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA, into the cell; and causing their expressions from the vector for expression of the shRNA and the vector for expression of the protein.

[0079] The vector for expression of the sensor shRNA can be prepared based on the primary structure sequence of the sensor shRNA determined as described in the first embodiment. One example of the vector preparation method is shown

in FIG. 3. FIG. 3(A) shows a pENTR (trademark)/H1/TO vector (SEQ ID NO: 8) sold by Invitrogen Corp. A DNA sequence encoding the shRNA of the present invention may be inserted to the site shown by the arrow of FIG. 3(A). The inserted DNA duplex is schematically shown in FIG. 3(B). The upper strand shown in FIG. 3(B) comprises overhang CACC, a guide strand-encoding DNA sequence 1*d*, a linker strand-encoding DNA sequence 2*d*, and a passenger strand-encoding DNA sequence 3*d* located in this order from the 5' end. The lower DNA strand shown in the drawing is a strand complementary to the upper strand and has overhang AAAA located at the 5' end. Those skilled in the art can obtain the desired sensor shRNA by inserting the desired sequence into commercially available plasmids to prepare plasmids producing the desired sensor shRNA.

[0080] The protein expression vector can be prepared by incorporating a DNA sequence encoding a protein to be expressed, into vectors for mammalian expression. A vector preparation example is shown in FIG. 4. The vector shown in this drawing is a vector for expression of L7Ae (SEQ ID NO: 2), which is a protein specifically binding to a Box-C/D motif represented by SEQ ID NO: 1. The sequence of the vector is shown in SEQ ID NO: 6. Such a vector can be prepared with reference to Nucleic Acid Research, 2003, Vol. 31, No. 3 869-877, and a gene can be extracted therefrom and recombined to mammalian expression vector. This vector can be prepared using a pcDNA3.1 (+) myc His A vector (SEQ ID NO: 7) commercially available from Invitrogen Corp.

[0081] The present embodiment is characterized by introducing the vector for expression of the shRNA and the vector for expression of the protein into the same cell and causing their expressions. The introducing step can be carried out by transfection. Examples of the transfection include, but not limited to, transfection using liposomes, direct injection, electroporation, and a lentiviral transfection method. The amounts of the shRNA expression vector and the protein expression vector introduced into a cell may differ depending on the purpose and are, for example, the amount of the L7Ae protein expression vector ¼ times to 10 times, preferably 1 time to 4 times that of the shRNA expression vector.

[0082] According to the fourth embodiment, RNAi can be inhibited by causing the intracellular expressions of the shRNA and the protein. Examples of a practical application of the embodiment include the treatment of cancer. Moreover, an RNAi control system can also be prepared by combining the vector for expression of the sensor shRNA and the protein expression vector used in the present embodiment.

[0083] In a modification, shRNA can be designed such that the protein specifically binding to the protein-binding motif sequence shown in FIGS. 1 and 2 is, for example, a biological molecule expressed only in cancer cells, and the target sequence of the guide strand is an apoptosis-promoting gene. In this case, the shRNA may be introduced directly or via a vector into a cancer cell to form an RNP complex with a biological molecule expressed only in cancer, in the cancer cell. As a result, the shRNA may be made unsusceptible to recognition by Dicer. Then, in the cancer cell, the RNAi of the apoptosis-promoting gene may be inhibited, resulting in the selective expression of the apoptosis-promoting gene to promote the apoptosis of the cancer cell. On the other hand, in a normal cell, which may be free from the biological molecule expressed only in cancer, RNAi may not be inhibited even if the same shRNA is introduced thereinto directly or via a

vector. Therefore, the expression of the apoptosis-promoting gene may be inhibited by RNAi.

[0084] Moreover, in a further modification of this embodiment, shRNA can be designed such that the protein specifically binding to the protein-binding motif shown in FIGS. 1 and 2 is, for example, a biological molecule that becomes no longer expressed by carcinogenesis, and the target sequence of the guide strand may be an apoptosis-suppressing gene. In this case, the shRNA is introduced directly or via a vector into a normal cell to form an RNP complex with a biological molecule that becomes no longer expressed by carcinogenesis, in the normal cell. As a result, the shRNA may be made unsusceptible to recognition by Dicer. Then, in the normal cell, the RNAi of the apoptosis-suppressing gene may be inhibited, resulting in the selective expression of the apoptosis-suppressing gene to suppress the apoptosis of the normal cell. On the other hand, in a cancer cell, which may be free from the biological molecule that becomes no longer expressed by carcinogenesis, RNAi may not be inhibited even if the same shRNA is introduced thereinto directly or via a vector. Therefore, the expression of the apoptosis-suppressing gene may be inhibited by RNAi.

[0085] Furthermore, a cancer control system using L7Ae may be constructed. The same promoter as that expressing such a cancer-related protein is incorporated upstream of the L7Ae protein expression vector. As a result, the RNAi function of apoptosis-controlling sensor shRNA comprising Box C/D incorporated in the linker strand can be regulated freely by regulating the expression of L7 in response to the expression of the cancer-related protein.

Example 1

Design of Protein Molecule-Responsive shRNA

[0086] An shRNA-GFP sequence for EGFP knockdown (shRNA-GFP (59 mer) GGCAUCAAGGUGAACUUCAGCAUCCAGCAUAGGGAUUCUUGAAGUUCACCUUGAUGCCAG; FIG. 5A (SEQ ID NO: 10)) was kindly provided by Dr. Tsutomu Suzuki and Dr. Takayuki Kato, the University of Tokyo. For shRNA-GFP-mut (shRNA-GFP-mut (59 mer) GCACUAGCGUAUGAAUGAAAGAUGCCAGCAUAGGGAUUCUUCAUUCAUACGCUA GUGCAG; FIG. 5B (SEQ ID NO: 12)), first, a guide strand in which three sequences complementary to the stop codons were inserted in the reading frame of three codons one for each was designed, and this was replaced for the guide strand of shRNA-GFP to design the shRNA-GFP-mut sequence. This shRNA-GFP-mut was used as a negative control that did not cause EGFP knockdown. Next, from the structure of an RNP motif L7Ae-Box C/D, the RNA sequence of Box C/D was obtained and inserted such that it was located as close to a Dicer protein cleavage site in shRNA as possible and the duplex structure of guide and passenger strands was maintained to design shRNA-Box C/D-GFP (shRNA-Box C/D-GFP (63 mer) GGCAUCAAGGUGAACUUCAGCUGACCCGAAAGGGCGUGAUGCUGAAGUUCACCUUGAUGCCAG; FIG. 5C (SEQ ID NO: 9)) that was expected to specifically bind at the Box C/D sequence to an L7Ae protein. In its guide strand, the 3'-terminal 21 bases of the guide strand of shRNA-GFP were used. Furthermore, shRNA in which adenine at base 24 from the 5' end of this shRNA-Box C/D-GFP was deleted and guanine at base 38 was replaced by cytosine was designed as shRNA-Box C/D-mut-GFP (shRNA-Box C/D-mut-GFP (62 mer) GGCAU-

CAAGGUGAACUUCAGCUGC-
CCGAAAGGGCGUCAUGCUGAAGUUCACCU
UGAUGCCAG; FIG. 5(D) (SEQ ID NO: 11)) that did not
bind to L7Ae.

[In-Vitro Synthesis of shRNA]

[shRNA-Box C/D-GFP]

[0087] 5.25 μ L of L7Aer template (100 μ M, 5'-CTGGCAT-
CAAGGTGAACCTTCAGCATCACGC-
CCTTTCGGGTCAGCTGAAGTTCACC TTTGATGC-
CTATAGTGAGTCGTATTAGC-3; SEQ ID NO: 13) as
template DNA of shRNA, 5.25 μ L of T7 sense primer (100
 μ M, 5'-GCTAATACGACTCACTATA-3; SEQ ID NO: 4), 30
 μ L of T7 RNA polymerase, 5 μ L of 1 mg/mL pyrophos-
phatase (ROCHE), 1.75 μ L of 20 mg/mL BSA, 28 μ L of 1 M
Hepes-KOH, 14 μ L of 1 M MgCl₂, 3.5 μ L of 1 M DTT, 14 μ L
of 0.1 M spermidine, 33.6 μ L of 0.1 M ATP (the same holds
true for CTP and UTP), 8.96 μ L of 0.1 M GTP, 89.6 μ L of 0.1
M GMP, and 385 μ L of ultrapure water were mixed and
reacted overnight at 37° C. After the reaction, 10 μ L of
TURBO DNase was added thereto and reacted at 37° C. for 30
minutes to degrade the template DNA. After the reaction,
phenol extraction and chloroform extraction were performed,
and the supernatant was charged into a PD-10 column (GE
Healthcare) equilibrated with a PD-10 buffer (0.3 M potas-
sium acetate, 15% (v/v) ethanol, pH 6.0), and washed with 3
mL of PD-10 buffer, followed by elution with 500 μ L of
PD-10 buffer twice. Then, to the eluate, an equal amount of
ethanol was added to perform ethanol precipitation. The
supernatant was discarded, and the pellet was dried and then
dissolved in 20 μ L of 5 \times dye solution (0.25% BPB, 30%
glycerol). The solution was layered on a nondenaturing 15%
polyacrylamide (1/30 bisacrylamide) gel and electrophore-
sed at room temperature for 50 minutes for separation. A band
with the size of interest was excised, and 500 μ L of elution
buffer (0.5 M NaCl, 0.1% SDS, 1 mM EDTA) was added
thereto, followed by elution overnight at 37° C. Then, a
microfilter (22 μ m Millex GP) was attached to a 5-mL syringe
(TERUMO CORP.), and the eluate was added to the syringe
and filtered through the filter. To this filtrate, a 2.5-fold vol-
ume of ethanol was added to perform ethanol precipitation.
The supernatant was discarded, and the pellet was dried and
then dissolved in 22 μ L of ultrapure water. After concentra-
tion measurement, this solution was used in subsequent
experiments.

[shRNA-Box C/D mut-GFP]

[0088] 5.25 μ L of L7AerN template (100 μ M, 5'-CTG-
GCATCAAGGTGAACCTTCAGCATGACGC-
CCTTTCGGGTCAGCTGAAGTTCACCT TGATGCCTAT-
AGTGAGTCGTATTAGC-3; SEQ ID NO: 15) as template
DNA of shRNA and 5.25 μ L of T7 sense primer (100 μ M,
SEQ ID NO: 4) were used to perform transcription/synthesis
and purification in the same way as in shRNA-Box C/D-GFP.
The purification product was dissolved in 22 μ L of ultrapure
water. After concentration measurement, this solution was
used in subsequent experiments.

[shRNA-GFP]

[0089] 5.25 μ L of 481P template (100 μ M, 5'-CTGGCAT-
CAAGGTGAACCTTCAAGATCCCTATGCTG-
GATCTTGAAGTTCACCTTGA TGCCTATAGT-
GAGTCGTATTAGC-3; SEQ ID NO: 16) as template DNA
of shRNA and 5.25 μ L of T7 sense primer (100 μ M, SEQ ID
NO: 4) were used to perform transcription/synthesis and puri-
fication in the same way as in shRNA-Box C/D-GFP. The
purification product was dissolved in 22 μ L of ultrapure

water. After concentration measurement, this solution was
used in subsequent experiments.

[Expression and Purification of L7Ae Protein]

[0090] Plasmids comprising a gene of the L7Ae protein
incorporated in pET-28b+, kindly provided by Dr. Hutten-
hofer were amplified. From a -80° C. glycerol bacterial stock
of *E. coli* BL21 (DE3) pLysS transformed with the pET-28b+
L7Ae plasmid (SEQ ID NO: 5), the bacterial cells were
inoculated to 5 mL of medium and shaken-cultured overnight
at 37° C. Subsequently, the whole amount of the culture
solution was inoculated to 500 mL of LB medium containing
50 μ g/mL kanamycin and 100 μ g/mL chloramphenicol. The
bacterial cells were shake-cultured at 37° C. until O.D.₆₀₀
became 0.6 to 0.7. Then, 500 μ L of 1 M IPTG was added (final
concentration: 1 mM) thereto for inducing expression, and
the cells were shake-cultured overnight at 30° C. The bacte-
rial cells were collected by centrifugation (4° C., 6000 rpm,
20 minutes). After addition of 5 mL of sonication buffer (50
mM Na phosphate, 0.3 M NaCl, 2.5 mM imidazole, pH 8.0),
sonication was performed to disrupt the bacterial cells. In this
sonication, the procedure of cooling on ice and then irradiation
with ultrasonic waves for 15 seconds was repeated 6
times. Then, impurity proteins were denatured at 80° C. for 15
minutes. The supernatant was collected by centrifugation (4°
C., 6000 rpm, 20 minutes), and histidine-tagged proteins
were purified by the batch method using an Ni-NTA column
(Qiagen). Specifically, first, the supernatant and 1 mL of
Ni-NTA were mixed and stirred at 4° C. for 1 hour. Then, the
mixture was charged into the column and washed twice with
4 mL of wash buffer (50 mM Na phosphate, 0.3 M NaCl, 20
mM imidazole, pH 8.0). Stepwise elution was performed with
1 mL each of 50 mM, 100 mM, 200 mM, and 300 mM
imidazole elution buffers (prepared by adding imidazole to 50
mM Na phosphate, 0.3 M NaCl, pH 8.0) in each of two runs.
The proteins of interest were confirmed by 15% SDS-PAGE.
Subsequently, Microcon YM-3 (Millipore Corp.) was used to
concentrate the proteins, followed by buffer replacement by a
dialysis buffer (20 mM Hepes-KOH, 1.5 mM MgCl₂, 150
mM KCl, 5% glycerol, pH 7.5). Moreover, the protein con-
centration was determined by the Bradford method using
Protein Assay (Bio-Rad Laboratories, Inc.).

[Confirmation of RNP Complex by Gel Shift Assay]

[0091] The binding between each shRNA and the protein
was confirmed as follows: after dilution with a dialysis buffer
to bring the protein concentration to concentrations 25 times
the final concentrations of 80 to 640 nM, 2 μ L of the protein
solution with each concentration, 2 μ L of 1 μ M shRNA-Box
C/D-GFP, 6 μ L of ultrapure water, and 40 μ L of Opti-MEM I
(trademark, Invitrogen Corp.) were mixed and left standing at
room temperature for 30 minutes to bind shRNA (40 nM) to
L7Ae (80 nM, 160 nM, 320 nM, or 640 nM). shRNA-GFP
and shRNA-Box C/D mut-GFP were bound to L7Ae in the
same way. To each solution, 13 μ L of 5 \times dye solution (0.25%
BPB, 30% glycerol) was added and mixed, and 15 μ L of this
mixed solution was layered on a nondenaturing 15% poly-
acrylamide (1/30 bisacrylamide) gel and electrophoresed at
250 V at 4° C. for 50 minutes. After the electrophoresis, the
gel was stained with SYBR Green for 15 minutes, and bands
were confirmed using FLA-7000 (FUJI FILM). FIG. 6 shows
the binding of shRNA-GFP, shRNA-Box C/D-GFP, and
shRNA-Box C/D mut-GFP to L7Ae by gel shift assay. The

results suggested that shRNA-Box C/D-GFP is bound to L7Ae in a sequence-specific manner.

[Confirmation of Dicer Cleavage Inhibition by In-Vitro Dicer Cleavage Assay]

[0092] The inhibition of Dicer cleavage of shRNA-Box C/D-GFP and shRNA-Box C/D mut-GFP by L7Ae was confirmed as follows using GTS, Inc. Recombinant Human Dicer Enzyme Kit according to the protocol: first, 0.4 μ L of 4 μ M shRNA, 2 μ L of 4 μ M or 8 μ M L7Ae, 1 μ L of 10 mM ATP, 0.5 μ L of 50 mM $MgCl_2$, 4 μ L of Dicer Reaction Buffer (GTS, Inc.), 2 μ L of 0.5 unit/ μ L Recombinant Dicer Enzyme, and 0.1 μ L of ultrapure water were mixed and reacted at 37° C. for 15 hours. Then, 2 μ L of Dicer Stop Solution was added thereto and mixed. To 8 μ L of this mixed solution, 2 μ L of 5 \times dye solution was added, and the mixture was layered on a nondenaturing 15% polyacrylamide (1/30 bisacrylamide) gel and electrophoresed at 4° C. for 50 minutes. After the electrophoresis, the gel was stained with SYBR Green, and bands were confirmed using FLA-7000 (FUJI FILM). FIG. 7 shows results of the inhibition of Dicer cleavage of shRNA-Box C/D-GFP and shRNA-Box C/D mut-GFP by L7Ae using an in-vitro reconstituted Dicer system. In FIG. 7, the mark + in L7Ae represents a sample prepared from 4 μ M L7Ae, the mark ++ represents a sample prepared from 8 μ M L7Ae, and the mark – represents that L7Ae was not used. Likewise, the mark + in Dicer represents that Dicer was used, and the mark – represents that Dicer was not used. The results suggested that upon sequence-specific binding to L7Ae, shRNA-Box C/D-GFP is made insensitive to cleavage by Dicer.

[Construction/Synthesis of shRNA Expression Plasmid]

[Synthesis of pENTR/H1/TO-shRNA-Box C/D-GFP (SEQ ID NO: 17)]

[0093] 5 μ L of pENTR L7Aer Top strand (200 μ M, 5'-CACCGGCATCAAGGTGAACTTCAGCTGAC-CCGAAAGGGCGTGATGCTGAAGTTC ACCTTGATGCC-3; SEQ ID NO: 18) as single-stranded DNA containing an shRNA-encoding sequence for insertion to pENTR/H1/TO vectors (Invitrogen Corp.), 5 μ L of pENTR L7Aer Bottom strand (200 μ M, 5'-AAAAGGCATCAAGGTGAACTTCAGCATCACGCCCTTTCGGGTCAGCTGAAGTTCA CCTTGATGCC-3; SEQ ID NO: 19) as single-stranded DNA containing a complementary strand thereof, 2 μ L of 10 \times Oligo Annealing Buffer (Invitrogen Corp.), and 2 μ L of ultrapure water were mixed, incubated at 95° C. for 4 minutes, and then left standing at room temperature for 5 minutes to form a DNA duplex. This duplex is a duplex shown in FIG. 3(B). This DNA duplex solution was diluted 100-fold with ultrapure water, and then, 1 μ L of the diluted solution was diluted 100-fold by mixing with 10 μ L of 10 \times Oligo Annealing Buffer and 89 μ L of ultrapure water. Then, 4 μ L of 5 \times Ligation Buffer, 2 μ L of 0.75 ng/ μ L pENTR/H1/TO vectors, 5 μ L of the 10,000-fold diluted DNA solution, 8 μ L of ultrapure water, and 1 μ L of 1 U/ μ L T4 DNA Ligase were mixed and left standing at room temperature for 5 minutes to incorporate the shRNA-encoding sequence into the pENTR/H1/TO vectors. 4 μ L of this reaction solution was added to TOP 10 Competent *E. coli* for transformation. After addition of 250 μ L of S.O.C. medium, the bacterial cells were shake-cultured for 1 hour, then seeded over an LB plate containing 50 μ g/mL kanamycin, and cultured overnight at 37° C. The formed colonies were confirmed, and the insert in the plasmid vectors was confirmed by colony PCR using H1 Forward Primer (10 μ M, 5'-TGTCTGGGAAATCACCATA-3; SEQ ID NO: 20),

M13 Reverse Primer (10 μ M, 5'-CAGGAAACAGCTATGAC-3; SEQ ID NO: 21), and KOD-Plus-ver. 2 (TOYOBO CO., LTD.). This colony was inoculated to 50 mL of LB medium containing 50 μ g/mL kanamycin and shake-cultured at 37° C. for 16 hours. The bacterial cells were collected by centrifugation (4° C., 6000 rpm, 15 minutes) and purified according to the protocol of Plasmid Purification Kit (Qiagen), followed by isopropanol precipitation. The supernatant was discarded, and the pellet was dried and then dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this was used in subsequent experiments.

[Synthesis of pENTR/H1/TO-shRNA-Box C/D-mut-GFP (SEQ ID NO: 22)]

[0094] pENTR/H1/TO-shRNA-Box C/D-mut-GFP was synthesized and purified in the same way as above using 5 μ L of pENTR L7AerN Top strand (200 μ M, 5'-CACCGGCATCAAGGTGAACTTCAGCTGC-CCGAAAGGGCGTCATGCTGAAGTTCAC CTTGATGCC-3; SEQ ID NO: 23) as single-stranded DNA containing an shRNA-encoding sequence for insertion to pENTR/H1/TO vectors (Invitrogen Corp.) and pENTR L7AerN Bottom strand (200 μ M, 5'-AAAAGGCATCAAGGTGAACTTCAGCATGACGCCCTTTCGGGTCAGCTGAAGTTCAC CTTGATGCC-3; SEQ ID NO: 24) as single-stranded DNA containing a complementary strand thereof, and dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this was used in subsequent experiments.

[Synthesis of pENTR/H1/TO-shRNA-GFP (SEQ ID NO: 25)]

[0095] pENTR/H1/TO-shRNA-GFP was synthesized and purified in the same way as above using 5 μ L of pENTR 481P Top strand (200 μ M, 5'-CACCGGCATCAAGGTGAACTTCAGCATCCAGCATAGGGATCTGAAAGTTCACCTTGATGCC-3; SEQ ID NO: 26) as single-stranded DNA containing an shRNA-encoding sequence for insertion to pENTR/H1/TO vectors (Invitrogen Corp.) and pENTR 481P Bottom strand (200 μ M, 5'-AAAAGGCATCAAGGTGAACTTCAGCATCCATCCCTATGCTGGATCTGAAAGTTCACCTTGATGCC-3; SEQ ID NO: 27) as single-stranded DNA containing a complementary strand thereof, and dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this was used in subsequent experiments.

[Synthesis of pENTR/H1/TO-shRNA-GFP-mut (SEQ ID NO: 28)]

[0096] pENTR/H1/TO-shRNA-GFP-mut was synthesized and purified in the same way as above using 5 μ L of pENTR Sk-7N Top strand (200 μ M, 5'-CACCGCACTAGCGTATGAATGAAAGATCCAGCATAGG-GATCTTTCATTCATACGC TAGTGC-3; SEQ ID NO: 29) as single-stranded DNA containing an shRNA-encoding sequence for insertion to pENTR/H1/TO vectors (Invitrogen Corp.) and pENTR Sk-7N Bottom strand (200 μ M, 5'-AAAAGCACTAGCGTATGAATGAAAGATCCATGCTGGATCTTTCATTCATACGC TAGTGC-3; SEQ ID NO: 30) as single-stranded DNA containing a complementary strand thereof, and dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this was used in subsequent experiments.

[Synthesis of pcDNA3.1-L7Ae-myc-His6 (SEQ ID NO: 6)]

[0097] PCR was performed using pET-28b+L7Ae (SEQ ID NO: 5) as template DNA and BamHI-NdeI-NotI-L7Ae-

primer (5'-AAGGATCCATCATATGCGGCCGCTTATG-TACGTGAGATTTGAGG-3') (SEQ ID NO: 32) and L7Ae-EcoRI-XhoI-primer (5'-CACTCGAGTTGAATCTCTTCTGAAGGCCTTAAATC-3') (SEQ ID NO: 33) as primers. 50 μ L of this reaction solution contained a mixture of 2.5 μ L of 10 ng/ μ L template DNA, 1.5 μ L of each 10 μ M DNA primer, 5 μ L of 2 mM dNTPs, 5 μ L of 10 \times KOD-PLUS-buffer ver. 2, 2 μ L of 25 mM MgSO₄, 1 μ L of KOD-PLUS-DNA Polymerase, and 31.5 μ L of ultrapure water. The reaction was performed by initial incubation at 94° C. for 2 minutes, followed by 36 cycles each involving 98° C. for 10 seconds, 55° C. for 30 seconds, and 68° C. for 1 minute. From the resulting PCR product, DNA was purified using PCR Purification Kit (QIAGEN). However, elution was performed with 30 μ L of ultrapure water, and this DNA was used as a template in restriction enzyme treatment. 27 μ L of the template, 5 μ L of B Buffer (ROCHE), 1 μ L of 10 U/ μ L BamHI (ROCHE), 1 μ L of 10 U/ μ L XhoI (ROCHE), and 16 μ L of ultrapure water were mixed and reacted at 37° C. for 2 hours for restriction enzyme treatment. Also for pcDNA3.1 (+) myc H is A vectors (Invitrogen Corp.), 1.88 μ L of 1.6 μ g/ μ L pcDNA vectors, 5 μ L of B Buffer, 1 μ L of 10 U/ μ L BamHI, 1 μ L of 10 U/ μ L XhoI, and 41.12 μ L of ultrapure water were mixed, and restriction enzyme treatment was performed in the same way. These treatment products were purified using PCR Purification Kit (QIAGEN). However, for elution, DNA was eluted into 10 μ L of ultrapure water.

[0098] 1.75 μ L of the PCR product thus subjected to restriction enzyme treatment, 0.25 μ L of the vectors thus subjected to restriction enzyme treatment, and 2 μ L of Ligation High were mixed and incubated at 16° C. for 30 minutes. To the whole amount of this ligation reaction solution, 20 μ L of Top10 Chemically competent cells (Invitrogen Corp.) was added. The cells were left standing on ice for 45 minutes, then placed in water bath at 42° C. for 1 minute, and left standing again on ice for 2 minutes for transformation. After further addition of 160 μ L of LB medium, the cells were seeded over an LB plate containing 50 μ g/mL ampicillin and incubated overnight at 37° C. The formed colonies were subjected to colony PCR using Extaq (TAKARA BIO INC.) and the DNA primers described above to check the insert. A colony in which the insert was confirmed was inoculated to 50 mL of LB medium containing 50 μ g/mL ampicillin and shake-cultured overnight at 37° C. The bacterial cells were collected by centrifugation (4° C., 6000 rpm, 15 minutes) and purified according to the protocol of Plasmid Purification Kit (Qiagen), followed by isopropanol precipitation. The supernatant was discarded, and the pellet was dried and then dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this plasmid vector was sequenced using T7 promoter primer (5'-TAATAC-GACTCACTATAGGG-3; SEQ ID NO: 34) and BGH rev primer (5'-GCTGGCAACTAGAAGGCACAG-3; SEQ ID NO: 35) and used in subsequent experiments.

[Confirmation of Knockdown Function Control by Fluorescence Microscope Image]

[0099] On the day before transfection, HeLa cells were seeded over a 24-well plate at a concentration of 0.8×10^5 cells/well and cultured in a CO₂ incubator at 37° C. On the next day, the cells were cotransfected with each pENTR/H1/TO shRNA expression vector, pcDNA3.1-AsRed2-L7Ae-myc-His6 (SEQ ID NO: 40), and pcDNA3.1-EGFP-myc-

His6 (SEQ ID NO: 41) using Lipofectamine 2000 (Invitrogen Corp.) (trademark). To 0.3 μ g each of pENTR-shRNA-GFP, pENTR-shRNA-GFP mut, pENTR-shRNA-Box C/D-GFP, and pENTR-shRNA-Box C/D mut-GFP, 0.3 μ g of pcDNA3.1-AsRed2-L7Ae-myc-His6 or pcDNA3.1-AsRed2-myc-His6 (SEQ ID NO: 42) and 0.2 μ g of pcDNA3.1-EGFP-myc-His6 were added, and 1.25 μ L of Lipofectamine 2000 was added per sample. These DNA-lipid complexes were incubated at room temperature for 20 minutes and added dropwise to the medium for HeLa cells. 4 hours later, medium replacement was performed. 24 hours later, the fluorescence microscope image of the cells was obtained using a fluorescence microscope (OLYMPUS IX-81) to observe the inhibition of shRNA-Box C/D-GFP function by AsRed2-L7Ae expression.

[0100] FIG. 12 is an EGFP fluorescence image obtained through a 510-550 nm wavelength filter by irradiation with excitation light having a wavelength around 488 nm. In FIG. 12, the mark "+" below each panel represents high fluorescence intensity, and the mark "-" represents low fluorescence intensity. This image demonstrated the inhibitory effect of AsRed2-L7Ae on the knockdown function of shRNA-Box C/D-GFP.

[Confirmation of RNAi Control by RT-PCR Analysis]

[0101] Change in GFP mRNA level caused by RNAi control by L7Ae was determined by real-time PCR.

[0102] On the previous day, HeLa-GFP cells were seeded over a 6-well plate at a concentration of 0.5×10^6 cells/well and cultured in a CO₂ incubator at 37° C. Then, the cells were cotransfected with each pENTR/H1/TO shRNA expression vector and pcDNA3.1-L7Ae-myc-His6. To 4 μ g each of pENTR-shRNA-Box C/D-GFP and pENTR-shRNA-Box C/D mut-GFP, 0, 2, or 4 μ g of pcDNA3.1-L7Ae-myc-His6 was added, and 5 μ L of Lipofectamine 2000 was added per sample. These DNA-lipid complexes were incubated at room temperature for 20 minutes and added dropwise to the cells. 4 hours later, medium replacement was performed. 24 hours after the transfection, the cells were collected, and RNA extraction and DNA removal were performed using RNAqueous 4PCR Kit (Ambion, Inc. (trademark)).

[0103] 1.5 μ g (or 0.5 μ g) of the extracted RNA was used as a template to synthesize cDNA using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems Inc. (trademark)), random primers, and reverse transcriptase. Real-time PCR was performed using 1/20-diluted cDNA as a template and LightCycler 480 Taqman probe (Roche) (trademark). PCR reaction and real-time fluorescence detection were carried out using LightCycler 480 (Roche) (trademark). The reaction conditions involved an initial denaturation step at 95° C. for 5 minutes and an amplification step of 45 cycles each involving denaturation at 95° C. for 10 seconds and annealing/elongation at 60° C. for 25 seconds. Finally, the reaction solution was cooled at 50° C. for 15 seconds to terminate the measurement. The Ct value was determined by the Abs Quant/fit point method. The GFP gene of interest was amplified using 481P Fwd (5'-CAAGGAGGACGGCAACA-3') (SEQ ID NO: 36) and Rev (5'-CCTTGATGCCGTCTCTTCTGC-3') (SEQ ID NO: 37). A reference gene GAPDH was amplified using GAPDH Fwd (5'-AGCCACATCGCTCAGACAC-3') (SEQ ID NO: 38) and GAPDH Rev (5'-GCCAATACGACCAAATCC-3') (SEQ ID NO: 39). The amplification efficiency of GFP mRNA and GAPDH mRNA was determined using Universal probe Library probe #148

(ROCHE) and Universal probe Library probe #60 (ROCHE), respectively. The amplification product was confirmed by electrophoresis to be the single product of interest, and the results were evaluated by relative quantification. The EGFP level was normalized with GAPDH, and this normalized value was used in comparison among samples with the GFP mRNA relative level of a sample supplemented only with pENTR-shRNA-GFP mut as 1. FIG. 8 shows results of RT-PCR-analyzing RNAi inhibition by L7Ae. The difference in expression level among the samples suggested that the GFP mRNA level recovers at the time of cotransfection with pENTR-shRNA-Box C/D-GFP and pcDNA3.1-L7Ae-myc-His6 and that RNAi is inhibited in a Box C/D sequence-specific manner in the presence of L7Ae.

[Confirmation of RNAi Control of L7Ae by FACS Analysis]

[0104] On the day before transfection, HeLa-GFP cells were seeded over a 24-well plate at a concentration of 0.5×10^5 cells/well and cultured in a CO₂ incubator at 37° C. On the next day, the cells were cotransfected with each pENTR/H1/TO shRNA expression vector and pcDNA3.1-L7Ae-myc-His6 using Lipofectamine 2000 (Invitrogen Corp.) (trademark). To 0.8 µg each of pENTR-shRNA-Box C/D-GFP and pENTR-shRNA-Box C/D mut-GFP, 0, 0.40, or 0.80 µg of pcDNA3.1-L7Ae-myc-His6 was added, and 2 µl of Lipofectamine 2000 was added per sample. These DNA-lipid complexes were incubated at room temperature for 20 minutes and added dropwise to the cells. 4 hours later, medium replacement was performed.

[0105] 24 hours after the transfection, the medium in each well was removed, and the cells were dissociated using 200 µl of Trypsin-EDTA and suspended by the addition of 200 µl of DMEM/F12. The cell suspension was transferred to a FACS tube and analyzed using FACS Aria (BD). In this context, live cells were gated, and FITC was determined for 20000 cells. The analysis was conducted using a general method comprising calculating a mean value of the fluorescence intensities of all the measured cells. FIG. 9 shows the results of FACS analysis (results showing a mean value of GFP intensities of 20000 cells per sample). The results demonstrated that recovery in GFP expression is seen in a manner specific for cells cotransfected with pcDNA3.1-L7Ae-myc-His6 and pENTR-shRNA-Box C/D-GFP. This suggested that as in the results of RT-PCR analysis, RNAi is inhibited in a Box C/D sequence-specific manner in the presence of L7Ae.

Example 2

Design of Protein Molecule-Responsive shRNA

[0106] shRNA-U1A-4 for EGFP knockdown (5'-GGCAU-CAAGGUGAACUUCAGGGCGAAAGC-CCUGAAGUUCACCUUGAUGCCAG-3'; SEQ ID NO: 14) was designed. The shRNA-U1A-4 comprised: 5'-terminal 24 bases which were the same as those in the passenger strand of shRNA-GFP shown in FIG. 5(A) used in Example 1; a guide strand which formed a duplex therewith; and a nonhybridized loop structure GAAA. This shRNA-U1A-4 was functionally similar to shRNA-GFP and was used as a negative control. Moreover, shRNA-Box C/D-GFP (SEQ ID NO: 9) of FIG. 5(C) designed in Example 1 was used.

[In-Vitro Synthesis of shRNA]

[shRNA-U1A-4]

[0107] 5.25 µL of template single-stranded DNA of shRNA-U1A-4 (100 µM, 5'-CTGGCATCAAGGTGAACT-

TCAGGGCTTTCGCCCTGAAGTTCACCT-TGATGCCTAT AGTGAGTCGTATTAGC-3' SEQ ID NO: 31) and 5.25 µL of T7 sense primer (SEQ ID NO: 4) were used to perform transcription/synthesis and purification in the same way as in shRNA-Box C/D-GFP. The purification product was dissolved in 22 µL of ultrapure water. After concentration measurement, this solution was used in subsequent experiments.

[shRNA-Box C/D-GFP]

[0108] It was produced according to the in-vitro synthesis method described in Example 1.

[Expression and Purification of L7Ae Protein]

[0109] It was produced according to the L7Ae protein expression and purification using *E. coli* described in Example 1.

[Evaluation in Cultured Cell System and RNP]

[Confirmation of RNAi Inhibition of L7Ae-shRNA Complex by Observation Under Fluorescence Microscope]

[0110] On the day before transfection, HeLa-GFP cells were seeded over a 24-well plate at a concentration of 0.5×10^5 cells/well and cultured in a CO₂ incubator at 37° C. In this context, the HeLa-GFP cell strain was HeLa cells in which GFP was stably expressed in a hygromycin-resistant manner, and was kindly provided by Dr. T. Suzuki. On the next day, the medium in the 24 wells was replaced by 500 µl of Opti-MEM (Invitrogen Corp.). At the same time, complexes of shRNA-Box C/D-GFP and the L7Ae protein were introduced into the cells by transfection using Lipofectamine 2000 (Invitrogen Corp.) (trademark). 0.6 µl of 10 µM shRNA-Box C/D-GFP, 0 µl, 0.6 µl, 1.2 µl, 2.4 µl, 4.8 µl, or 9.6 µl of 20 µM L7Ae protein, and 2 µl of 5× binding buffer were mixed, and ultrapure water was added thereto to bring the whole amount to 10 µl (for 9.6 µl of the L7Ae protein, the whole amount was brought to 12.2 µl without the addition of ultrapure water). 40 µl (for 9.6 µl of the L7Ae protein, 37.8 µl) of Opti-MEM was further added thereto and mixed, and the mixture was left standing at 4° C. for 30 minutes to form RNA-protein complexes. 48 µl of Opti-MEM and 2 µl of Lipofectamine 2000 were mixed and left standing at room temperature for 5 minutes. To this mixture, 50 µl of the RNA-protein complex solution was added and mixed, and the mixture was left standing at room temperature for 20 minutes to form RNA-protein-lipid complexes, which were in turn added dropwise to the cells. 4 hours later, the medium was replaced by 500 µl of DMEM/F12. An shRNA-free molecule (Mock) and shRNA-U1A-4 were mixed with the L7Ae protein in the same way to form RNA-protein complexes, which were in turn introduced into the cells by transfection.

[0111] 45 hours after the transfection, the cells were observed under a fluorescence microscope. The intracellular GFP fluorescence was photographed with settings of 20× magnification and 488 nm excitation wavelength on a fluorescence microscope (OLYMPUS) per sample. At the same time, a phase-contrast image of the cells was also taken using transmitted light. FIG. 10 shows a superimposed image of the fluorescence and phase-contrast images.

[Confirmation of RNAi Inhibition of L7Ae-shRNA Complex by FACS Analysis]

[0112] 47 hours after the transfection, the medium in each well was removed, and the cells were dissociated using 200 µl

of Trypsin-EDTA and suspended by the addition of 200 μ l of DMEM/F12. The cell suspension was transferred to a FACS tube and analyzed using FACSAria (BD). The FACS is a method comprising irradiating, with laser light, free cells passing through a thin tube and analyzing the intensity of fluorescence emitted from the cells. In this context, live cells were gated, and FITC was determined for 10000 cells. FIG. 11 shows results of FACS-analyzing fluorescence intensity distribution. The results demonstrated that recovery in GFP expression was observed in a manner specific for the cells transfected with the complex of L7Ae and shRNA-Box C/D-GFP. This suggested that RNAi is inhibited in a Box C/D sequence-specific manner in the presence of L7Ae. For Mock, RNAi did not occur, and thus, GFP expression is seen in an L7Ae concentration-independent manner. On the other hand, for shRNA-U1A-4, RNAi was not inhibited, and thus, GFP expression was inhibited in an L7Ae concentration-independent manner.

Example 3

Design of Protein Molecule-Responsive shRNA

[0113] shRNA-Box C/D-Bc1-xL (FIG. 13(B)) and shRNA-Box C/D mut-Bc1-xL (FIG. 13(C)) were designed by replacing a duplex site comprising the 5'-terminal 21 bases of shRNA-Box C/D-GFP or shRNA-Box C/D mut-GFP, by a duplex comprising a sequence of bases 365 to 385 of the Bc1-xL gene.

[Synthesis of shRNA]

[shRNA-Box C/D-Bc1-xL (FIG. 13(B) (SEQ ID NO: 43))]

[0114] 5.25 μ l of shRNA-Box C/D-Bc1xL template (100 μ M, 5'-CTGCTTTGAACAGGTAGTGAATGATCACGCCCTTTCGGGTCACATTCACCTGTTCAAAGCTATAGTGAGTCGTATTAGC-3' (SEQ ID NO: 44)) as template DNA of shRNA and 5.25 μ l of T7 sense primer (100 μ M, 5'-GCTAATACGACTCACTATA-3' (SEQ ID NO: 4)) were used to perform transcription/synthesis and purification in the same way as in shRNA-Box C/D-GFP. The purification product was dissolved in 22 μ l of ultrapure water. After concentration measurement, this solution was used in subsequent experiments.

[shRNA-Box C/D mut-Bc1-xL (FIG. 13(C) (SEQ ID NO: 45))]

[0115] 5.25 μ l of shRNA-Box C/D mut-Bc1xL template (100 μ M, 5'-CTGCTTTGAACAGGTAGTGAATGATCACGCCCTTTCGGGTCACATTCACCTGTTCAAAGCTATAGTGAGTCGTATTAGC-3' (SEQ ID NO: 46)) as template DNA of shRNA and 5.25 μ l of T7 sense primer (100 μ M, 5'-GCTAATACGACTCACTATA-3' (SEQ ID NO: 4)) were used to perform transcription/synthesis and purification in the same way as in shRNA-Box C/D-GFP. The purification product was dissolved in 22 μ l of ultrapure water. After concentration measurement, this solution was used in subsequent experiments.

[shRNA-Bc1-xL (FIG. 13(A) (SEQ ID NO: 47))]

[0116] 5.25 μ l of shRNA-Bc1-xL template (100 μ M, 5'-CTGCTTTGAACAGGTAGTGAATGAACTC-TATGCTAGTTCATTCACCTGTTCAA AGCTATAGTGAGTCGTATTAGC-3' (SEQ ID NO: 48)) as template DNA of shRNA and 5.25 μ l of T7 sense primer (100 μ M, 5'-GCTAATACGACTCACTATA-3' (SEQ ID NO: 4)) were used to perform transcription/synthesis and purification in the same way as in shRNA-Box C/D-GFP. The purification prod-

uct was dissolved in 22 μ l of ultrapure water. After concentration measurement, this solution was used in subsequent experiments.

[Confirmation of knockdown of Bc1-xL by shRNA-Bc1-xL]

[0117] On the day before transfection, HeLa-GFP cells were seeded over a 24-well plate at a concentration of 0.5×10^5 cells/well and cultured in a CO₂ incubator at 37° C. On the next day, the cells were cotransfected with Bc1-xL, expression vectors, and shRNA using Lipofectamine 2000 (Invitrogen Corp.). 0 or 0.4 μ g of pBc1-xL and 10 μ M shRNA-Bc1-xL were mixed and brought to 50 μ l with Opti-MEM I medium (Invitrogen Corp.). Then, a mixture of 1 μ l of Lipofectamine 2000 supplemented with 49 μ l of Opti-MEM I medium was added per sample. These DNA-lipid complexes were incubated at room temperature for 20 minutes. After addition of 400 μ l of Opti-MEM I medium, the mixture was added dropwise to the cells. 4 hours later, medium replacement was performed.

[0118] 24 hours after the transfection, the medium in each well was collected. Then, the cells were dissociated using 200 μ l of Trypsin-EDTA and suspended by the addition of each medium collected in the previous step. The cell suspension was subjected to centrifugal sedimentation at 500 \times g at 4° C. for 5 minutes and washed with 500 μ l of PBS. Then, to the cell pellet, 30 μ l of RIPA buffer (1 \times PBS, 1% NP40, 0.5% Sodium deoxycholate, 0.1% SDS, 0.3 mg/ml PMSF+2 μ g/ml Aprotinin) was added, and the mixture was left standing on ice for 30 minutes. The supernatant was collected by centrifugation (4° C., 15000 g, 20 minutes). The protein concentration was determined by the Lowry method using DC-Protein Assay (Bio-Rad Laboratories, Inc.).

[0119] Bc1-xL was detected by western blotting. Proteins extracted from the cells were developed by SDS-PAGE and subjected to western blotting. A primary antibody Anti-Bc1-xL (SC-634) (Santa Cruz Biotechnology, Inc.) (1/500) and a secondary antibody Goat Anti-Rabbit IgG (H+L)-HRP conjugate (Bio-Rad Laboratories, Inc.) (1/2000) were used. Color was developed using ECL Plus (GE Healthcare) (trademark) and detected using LAS3000 (FUJI FILM). By virtue of the cotransfection of shRNA-Bc1-xL with pBc1-xL, a band showing the expression of Bc1-xL did not appear. The results demonstrated Bc1-xL knockdown by shRNA-Bc1-xL in the HeLa cells.

[Confirmation of Dicer Cleavage Inhibition by In-Vitro Dicer Cleavage Assay]

[0120] The inhibition of Dicer cleavage of shRNA-Box C/D-Bc1-xL and shRNA-Box C/D mut-Bc1-xL by L7Ae was confirmed as follows using GTS, Inc. Recombinant Human Dicer Enzyme Kit according to the protocol: first, 0.4 μ l of 1 μ M shRNA, 2 μ l of 4 μ M or 8 μ M L7Ae, 1 μ l of 10 mM ATP, 0.5 μ l of 50 mM MgCl₂, 4 μ l of Dicer Reaction Buffer (GTS, Inc.), 2 μ l of 0.5 unit/ μ l Recombinant Dicer Enzyme, and 0.1 μ l of ultrapure water were mixed and reacted at 37° C. for 14 hours. Then, 2 μ l of Dicer Stop Solution was added thereto and mixed. To 8 μ l of this mixed solution, 2 μ l of 5 \times dye solution was added, and the mixture was layered on a non-denaturing 15% polyacrylamide (1/30 bisacrylamide) gel and electrophoresed at 4° C. for 50 minutes. After the electrophoresis, the gel was stained with SYBR Green, and bands were confirmed using FLA-7000 (FUJI FILM). FIG. 14 shows results of the inhibition of Dicer cleavage of shRNA-Box C/D-Bc1-xL and shRNA-Box C/D mut-Bc1-xL by L7Ae using an in-vitro reconstituted Dicer system. In FIG.

14, the mark “-” in L7Ae represents that L7Ae was not used. Likewise, the mark “+” in Dicer represents that Dicer was used, and the mark “-” represents that Dicer was not used. The results suggested that upon sequence-specific binding to L7Ae, shRNA-Box C/D-Bc1-xL is made insusceptible to cleavage by Dicer.

Construction/Synthesis of shRNA Expression Plasmid
[Synthesis of pENTR/H1/TO-shRNA-Box C/D-Bc1-xL (SEQ ID NO: 49)]

[0121] pENTR/H1/TO-shRNA-Box C/D-Bc1-xL was synthesized and purified in the same way as above using 5 μ L of Box C/D Bc1-xL Top strand (200 μ M, 5'-CAC-CGCTTTGAACAGGTAGTGAATGTGAC-CCGAAAGGGCGTGATCATTCACTACC TGT-TCAAAGC-3' (SEQ ID NO: 50)) as single-stranded DNA containing an shRNA-encoding sequence for insertion to pENTR/H1/TO vectors (Invitrogen Corp.) and Box C/D Bc1-xL Bottom strand (200 μ M, 5'-AAAAGCTTTGAACAGGTAGTGAATGATCACGCCCTTTCGGGTCA-CATTCACTACC TGTTCAAAGC-3' (SEQ ID NO: 51)) as single-stranded DNA containing a complementary strand thereof, and dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this was used in subsequent experiments.

[Synthesis of pENTR H1 TO-shRNA-Box C/D mut-Bc1-xL (SEQ ID NO: 52)]

[0122] pENTR/H1/TO-Box C/D mut-Bc1-xL was synthesized and purified in the same way as above using 5 μ L of Box C/D mut Bc1-xL Top strand (200 μ M, 5'-CAC-CGCTTTGAACAGGTAGTGAATGTGC-CCGAAAGGGCGTCATCATTCACTACCT GTTCAAAGC-3' (SEQ ID NO: 53)) as single-stranded DNA containing an shRNA-encoding sequence for insertion to pENTR/H1/TO vectors (Invitrogen Corp.) and Box C/D mut Bc1-xL Bottom strand (200 μ M, 5'-AAAAGCTTTGAA-CAGGTAGTGAATGATGACGC-CCTTTCGGGCACATCATTCACTACCT GTTCAAAGC-3' (SEQ ID NO: 54)) as single-stranded DNA containing a complementary strand thereof, and dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this was used in subsequent experiments. [Synthesis of pENTR/H1/TO-shRNA-Bc1-xL (SEQ ID NO: 55)]

[0123] pENTR/H1/TO-shRNA-Bc1-xL was synthesized and purified in the same way as above using 5 μ L of Bc1-xL Top strand (200 μ M, 5'-CACCGCTTTGAACAGGTAGTGAATGAACTAGCATAGAGTTCATTCACTACCTGTTCAAAGC-3' (SEQ ID NO: 56)) as single-stranded DNA containing an shRNA-encoding sequence for insertion to pENTR/H1/TO vectors (Invitrogen Corp.) and Bc1-xL Bottom strand (200 μ M, 5'-AAAAGCTTTGAACAGGTAGTGAATGAACTCTATGCTAGTTCATTCACTACCTGTTCAAAGC-3' (SEQ ID NO: 57)) as single-stranded DNA containing a complementary strand thereof, and dissolved by the addition of 55 μ L of ultrapure water. After plasmid vector concentration measurement, this was used in subsequent experiments.

[Experiment of RNA-Protein Complex Introduction]

[0124] To confirm the control of Bc1-xL knockdown by the binding between the L7Ae protein and shRNA-Box C/D-Bc1-xL in cultured human cancer cells, RNA-protein complexes were introduced into the cells, and the expression of Bc1-xL was detected by western blotting.

[0125] On the previous day, uterine cervix cancer-derived HeLa cells were seeded over a 24-well plate at a concentration of 1.0×10^5 cells/well and cultured in a CO₂ incubator at 37° C. On the next day, transfection was performed twice using Lipofectamine 2000 (Invitrogen Corp.) (trademark). To 0.4 μ g of pBc1-xL or pBimEL, 1 μ L of Lipofectamine 2000 was added. These DNA-lipid complexes were incubated at room temperature for 20 minutes and added dropwise to the medium for HeLa cells. 4.5 hours later, medium replacement was performed. Immediately thereafter, the second transfection was performed. 2.5 pmol (concentration in the medium: 5 nM) of shRNA-Box C/D-Bc1-xL or shRNA-Box C/D mut-Bc1-xL and 0 or 200 pmol (concentration in the medium: 400 nM) of the purified L7Ae protein were mixed to form complexes. To the complexes, 1 μ L of Lipofectamine 2000 was added, and the complexes were incubated at room temperature for 20 minutes and added dropwise to the medium for HeLa cells. 5 hours later, medium replacement was performed.

[0126] 22 hours after the second transfection, the medium in each well was collected. Then, the cells were dissociated using 200 μ L of Trypsin-EDTA and suspended by the addition of each medium collected in the previous step. The cell suspension was subjected to centrifugal sedimentation at $500 \times g$ at 4° C. for 5 minutes and washed with 500 μ L of PBS. Then, to the cell pellet, 30 μ L of RIPA buffer (1 \times PBS, 1% NP40, 0.5% Sodium deoxycholate, 0.1% SDS, 0.3 mg/ml PMSF+2 g/ml Aprotinin) was added, and the mixture was left standing on ice for 30 minutes. The supernatant was collected by centrifugation (4° C., $15000 \times g$, 20 minutes). The protein concentration was determined by the Lowry method using DC-Protein Assay (Bio-Rad Laboratories, Inc.).

[0127] Bc1-xL or GAPDH was detected by western blotting. Proteins extracted from the cells were developed by SDS-PAGE and subjected to western blotting. A primary antibody Anti-Bc1-xL (SC-634) (Santa Cruz Biotechnology, Inc.) (1/500) and a secondary antibody Goat Anti-Rabbit IgG (H+L)-HRP conjugate (Bio-Rad Laboratories, Inc.) (1/2000) were used. Color was developed using ECL Plus (GE Healthcare) (trademark) and detected using LAS3000 (FUJI FILM). Likewise, GAPDH was subjected to western blotting using a primary antibody Anti-GAPDH (MAB374) (Chemicon International, Inc.) (1/2000) and a secondary antibody Goat Anti-Mouse IgG (H+L)-HRP conjugate (Bio-Rad Laboratories, Inc.) (1/2000). These results demonstrated that Bc1-xL knockdown was inhibited (lane 3) by the binding between the L7Ae protein and shRNA-Box C/D-Bc1-xL in the HeLa cells. Protein extraction from cells and L7Ae detection shown below were performed in the same way. FIG. 15 shows intracellular Bc1-xL expression. It was also confirmed that the protein expression level of GAPDH used as a standard control did not change. The intensities of detected Bc1-xL bands were added up. The results are shown in FIG. 16. In FIGS. 15 and 16, sh is an abbreviation of “shRNA”.

[Experiment of Plasmid Introduction]

[0128] To confirm the control of Bc1-xL knockdown by the binding between the L7Ae protein and shRNA-Box C/D-Bc1-xL in cultured human cancer cells, the cells were cotransfected with plasmids for expressions of Bc1-xL, L7Ae, and shRNA, and the expression of Bc1-xL was detected by western blotting.

[0129] On the previous day, uterine cervix cancer-derived HeLa cells were seeded over a 12-well plate at a concentra-

tion of 3.0×10^5 cells/well and cultured in a CO_2 incubator at $37^\circ C$. On the next day, transfection was performed using Lipofectamine 2000 (Invitrogen Corp.) (trademark). $0.2 \mu g$ of pBc1-xL, $0.4 \mu g$ of pcDNA3.1-L7Ae, and $0.6 \mu g$ of pENTR/H1/TO-shRNA-Box C/D-Bc1-xL were mixed, and $2.5 \mu l$ of Lipofectamine 2000 was added thereto. These DNA-lipid complexes were incubated at room temperature for 20 minutes and added dropwise to the medium for HeLa cells. For pENTR/H1/TO-shRNA-Box C/D-mut Bc1-xL, pENTR/H1/TO-shRNA-Bc1-xL, and pENTR/H1/TO-shRNA-GFP mut (negative control), the same procedures were also performed. $0.25 \mu g$ of pcDNA-AmCyan-myc-His6 ((SEQ ID NO: 58) or $0.2 \mu g$ of pBc1-xL were introduced alone as a control plasmid into the cells. 4 hours later, medium replacement was performed.

[0130] 24 hours after the transfection, the medium in each well was collected. Then, the cells were dissociated using $200 \mu l$ of Trypsin-EDTA and suspended by the addition of each medium collected in the previous step. The cell suspension was subjected to centrifugal sedimentation at $500 \times g$ at $4^\circ C$. for 5 minutes and washed with $500 \mu l$ of PBS. Then, to the cell pellet, $100 \mu l$ of RIPA buffer ($1 \times$ PBS, 1% NP40, 0.5% Sodium deoxycholate, 0.1% SDS, 0.3 mg/ml PMSF+ $2 \mu g/ml$ Aprotinin) was added, and the mixture was left standing on ice for 30 minutes. The supernatant was collected by centrifugation ($4^\circ C$., $15000 g$, 20 minutes). The protein concentration was determined by the Lowry method using DC-Protein Assay (Bio-Rad Laboratories, Inc.).

[0131] Bc1-xL or GAPDH was detected by western blotting. Proteins extracted from the cells were developed by SDS-PAGE and subjected to western blotting. A primary antibody Anti-Bc1-xL (SC-634) (Santa Cruz Biotechnology, Inc.) (1/500) and a secondary antibody Goat Anti-Rabbit IgG (H+L)-HRP conjugate (Bio-Rad Laboratories, Inc.) (1/2000) were used. Color was developed using ECL Plus (GE Healthcare) (trademark) and detected using LAS3000 (FUJI FILM). Likewise, GAPDH was subjected to western blotting using a primary antibody Anti-GAPDH (MAB374) (Chemicon International, Inc.) (1/2000) and a secondary antibody Goat Anti-Mouse IgG (H+L)-HRP conjugate (Bio-Rad Laboratories, Inc.) (1/2000). These results demonstrated that Bc1-xL knockdown was inhibited (lane 5) by the binding between the L7Ae protein and shRNA-Box C/D-Bc1-xL in the HeLa cells. FIG. 17 shows intracellular Bc1-xL expression. It was also confirmed that the protein expression level of GAPDH used as a standard control did not change. The intensities of detected Bc1-xL bands were added up. The results are shown in FIG. 18. In FIG. 18, sh in the lanes 3 to 6 is an abbreviation of "shRNA".

[Experiment of Cell Death Control by Bc1-xL Expression Level Control Responsive to L7Ae Protein]

[0132] An apoptosis-promoting protein Bim-EL and an apoptosis-suppressing protein Bc1-xL have antagonistic effect on each other, and a relatively larger amount of the protein affects the fate of cells. Thus, an experiment was conducted which involved controlling Bc1-xL expression levels using the control of Bc1-xL knockdown by the binding between the L7Ae protein and shRNA-Box C/D-Bc1-xL in cultured human cancer cells, and controlling cell death by changing the relative amount of Bc1-xL to Bim-EL.

[0133] On the previous day, uterine cervix cancer-derived HeLa cells were seeded over a 24-well plate at a concentration of 0.5×10^5 cells/well and cultured in a CO_2 incubator at

$37^\circ C$. On the next day, transfection was performed using Lipofectamine 2000 (Invitrogen Corp.) (trademark). To $0.3 \mu g$ of pENTR/H1/TO-shRNA-Box C/D-Bc1-xL, $0.2 \mu g$ of pBc1-xL, $0.2 \mu g$ of pBimEL, and $0.2 \mu g$ of pcDNA3.1-AsRed2-L7Ae were added and mixed with a medium, and $1.25 \mu l$ of Lipofectamine 2000 was added thereto. These DNA-lipid complexes were incubated at room temperature for 20 minutes and added dropwise to the medium for HeLa cells. Approximately 4 hours later, medium replacement was performed. For pcDNA3.1 (+) myc His A vectors (Invitrogen Corp., control vector), pENTR/H1/TO-shRNA-Box C/D-mut Bc1-xL, pENTR/H1/TO-shRNA-Bc1-xL, and pENTR/H1/TO-shRNA-GFP mut (negative control), the same procedures were also performed.

[0134] 24 hours after the transfection, the medium in each well was collected. Then, the cells were dissociated using $200 \mu l$ of Trypsin-EDTA and suspended by the addition of each medium collected in the previous step. The cell suspension was subjected to centrifugal sedimentation at $500 \times g$ at $4^\circ C$. for 3 minutes and washed with $300 \mu l$ of PBS. Then, to the cell pellet, a mixed solution of $3 \mu l$ of annexin V, Pacific Blue conjugate for flow cytometry (Invitrogen Corp.) and $50 \mu l$ of annexin-binding buffer ($10 mM$ HEPES, $140 mM$ NaCl, $2.5 mM$ $CaCl_2$, pH 7.4) was added. After tapping, the mixture was left standing at room temperature for 30 minutes for staining. Then, each sample was suspended by the addition of $200 \mu l$ of annexin-binding buffer. The cell suspension was transferred to a FACS tube and analyzed using FACS Aria (BD). In this context, measurement was conducted for 30000 cells. For the analysis, first, cells emitting red fluorescence attributed to AsRed2-L7 were gated, and blue fluorescence intensity derived from Pacific Blue was measured for the cells within the gate using a filter at an excitation wavelength of $405 nm$ and a fluorescence wavelength of $430-470 nm$. The ratio of the number of cells having this fluorescence intensity larger than the reference was measured. As the reference for determining cell death, phosphatidylserine, which is a lipid present in a manner specific for the outer membranes of dead cells, was stained with annexin V, Pacific Blue conjugate for flow cytometry (Invitrogen Corp.), and cells in which blue fluorescence intensity was larger than the upper limit of intensities of untreated cell samples stained in the same way were counted as dead cells.

[0135] As a result, the sample supplemented with the control vector (pcDNA3.1 (+) myc His A vector) had a dead cell ratio of 8.3%, the sample supplemented with pENTR/H1/TO-shRNA-GFP mut (negative control) had a dead cell ratio of 10.1%, and the sample supplemented with pENTR/H1/TO-shRNA-Box C/D-Bc1-xL had a dead cell ratio of 13.4%. By contrast, the sample supplemented with pENTR/H1/TO-shRNA-Bc1-xL had a dead cell ratio of 34.5%, and the sample supplemented with pENTR/H1/TO-shRNA-Box C/D-mut Bc1-xL had a dead cell ratio of 42.5%. This experimental result and the Bc1-xL detection results shown in FIGS. 17 and 18 demonstrated that cells in which Bc1-xL expression level was suppressed by knockdown died approximately 3 to 4 times more than cells maintaining the expression of Bc1-xL. From the results showing that the sample supplemented with pENTR/H1/TO-shRNA-Box C/D-Bc1-xL had a dead cell ratio of 13.4%, whereas the sample supplemented with pENTR/H1/TO-shRNA-Box C/D-mut Bc1-xL had a dead cell ratio of 42.5%, it was further confirmed that

cell death could be controlled suppressively by inhibiting Bcl-xL protein knockdown by L7Ae in a Box C/D sequence-specific manner.

INDUSTRIAL APPLICABILITY

[0136] According to a protein-responsive shRNA and an RNAi control system using an RNP motif according to the present invention, a sensor shRNA and a protein specifically binding to it can control RNAi and are thus useful in the

construction of biosensors for quantifying the expression of intracellular marker proteins without destroying cells or artificial gene circuits capable of activating the translation of proteins of interest in response to the expression level of marker proteins. For example, the present invention produces significant effect that leads to the treatment of diseases such as cancer or Alzheimer's disease by activating apoptosis-inducing proteins in response to the expression of cancer marker proteins or as a basic technique for developing protein drugs.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 58

<210> SEQ ID NO 1

<211> LENGTH: 139

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 1

```

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
 1          5          10          15
Arg Gly Ser His Met Tyr Val Arg Phe Glu Val Pro Glu Asp Met Gln
 20          25          30
Asn Glu Ala Leu Ser Leu Leu Glu Lys Val Arg Glu Ser Gly Lys Val
 35          40          45
Lys Lys Gly Thr Asn Glu Thr Thr Lys Ala Val Glu Arg Gly Leu Ala
 50          55          60
Lys Leu Val Tyr Ile Ala Glu Asp Val Asp Pro Glu Ile Val Ala
 65          70          75          80
His Leu Pro Leu Leu Cys Glu Glu Lys Asn Val Pro Tyr Ile Tyr Val
 85          90          95
Lys Ser Lys Asn Asp Leu Gly Arg Ala Val Gly Ile Glu Val Pro Cys
100          105          110
Ala Ser Ala Ala Ile Ile Asn Glu Gly Glu Leu Arg Lys Glu Leu Gly
115          120          125
Ser Leu Val Glu Lys Ile Lys Gly Leu Gln Lys
130          135

```

<210> SEQ ID NO 2

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 2

gggcgugaug cgaaagcuga ccc

23

<210> SEQ ID NO 3

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: T7 promoter primer antisense

<400> SEQUENCE: 3

tatagtgagt cgtattagc

19

<210> SEQ ID NO 4

- continued

```

<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: T7 sense primer

<400> SEQUENCE: 4

gctaatacga ctcaactata                               19

<210> SEQ ID NO 5
<211> LENGTH: 5653
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pET-28b+L7Ae

<400> SEQUENCE: 5

tggcgaatgg gacgcgcctt gtagcggcgc attaagcgcg gcggtgtgg tggttacgcg    60
cagcgtgacc gctacacttg ccagcgcctt agcgcctcct cctttcgctt tcttcccttc    120
ctttctcgcc acgttcgccc gctttccccg tcaagctcta aatcgggggc tccctttagg    180
gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc    240
acgtagtggg ccatacgcct gatagacggt ttttcgcctt ttgacgttgg agtccacggt    300
ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggctctattc    360
ttttgattta taagggattt tgccgatttc ggccctattgg ttaaaaaatg agctgattta    420
acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaatttcag gtggcacttt    480
tcggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta    540
tccgctcatg aattaattct tagaaaaact catcgagcat caaatgaaac tgcaatttat    600
tcataatcag attatcaata ccataatttt gaaaaagccg tttctgtaat gaaggagaaa    660
actcaccgag gcagttccat aggatggcaa gatcctggta tcggtctgcg attccgactc    720
gtccaacatc aatacaacct attaatcttc cctcgtcaaa aataaggtta tcaagtgaga    780
aatcaccatg agtgacgact gaatccggtg agaatggcaa aagtttatgc atttcttttc    840
agacttgctc aacaggccag ccattacgct cgtcatcaaa atcaactcga tcaaccaaac    900
cgttattcat tcgtgattgc gcctgagcga gacgaaatac gcgatcctcg ttaaaaggac    960
aattacaaac aggaatcgaa tgcaaccggc gcaggaacac tgccagcgcg tcaacaatat   1020
tttcaactga atcaggatat tcttctaata cctggaatgc tgttttcccc gggatcgcag   1080
tggtgagtaa ccatgcatca tcaggagtac ggataaaatg cttgatggtc ggaagaggca   1140
taaatccggt cagccagttt agtctgacca tctcatctgt aacatcattg gcaacgctac   1200
ctttgccatg tttcagaaac aactctggcg catcgggctt cccatacaat cgatagattg   1260
tcgcacctga ttgcccgaca ttatcgcgag cccatttata cccatataaa tcagcatcca   1320
tggtggaatt taatcgcggc ctgagcaag acgtttcccg ttgaatatgg ctcataaac   1380
ccottgtatt actgtttatg taagcagaca gttttattgt tcatgaccaa aatcccttaa   1440
cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga   1500
gatccttttt ttctgcgctt aatctgctgc ttgcaaaaaa aaaaaccacc gctaccagcg   1560
tgggtttggt tgccggatca agagctacca actctttttc cgaaggtaac tggcttcagc   1620
agagcgcaga taccaaatat tgccttcta gtgtagccgt agttaggcca ccacttcaag   1680

```

-continued

aactctgtag	caccgcctac	atacctcgct	ctgctaatec	tgttaccagt	ggetgctgcc	1740
agtggcgata	agtcgtgtct	taccgggttg	gactcaagac	gatagttacc	ggataaggcg	1800
cagcggtcgg	gctgaacggg	gggttcgtgc	acacagccca	gcttggagcg	aacgacctac	1860
accgaactga	gataacctaca	gcgtgagcta	tgagaaagcg	ccacgcttcc	cgaagggaga	1920
aaggcggaca	ggatccgggt	aagcggcagg	gtcggaaacag	gagagcgcac	gagggagctt	1980
ccagggggaa	acgcctggta	tctttatagt	cctgtcgggt	ttcgccacct	ctgacttgag	2040
cgtcgatttt	tgtgatgctc	gtcagggggg	cggagcctat	ggaaaaacgc	cagcaacgcg	2100
gcctttttac	ggttcctggc	cttttgctgg	ccttttgctc	acatgttctt	tctcgctta	2160
tcccctgatt	ctgtggataa	ccgtattacc	gcctttgagt	gagctgatac	cgctcggcgc	2220
agccgaacga	ccgagcgcag	cgagtcagtg	agcgaggaag	cggaaagagcg	cctgatgctg	2280
tatthttctc	ttacgcatct	gtcgggtatt	tcacaccgca	tatatggtgc	actctcagta	2340
caatctgctc	tgatgccgca	tagttaagcc	agtatacact	ccgctatcgc	taegtgactg	2400
ggtcattggc	gcgccccgac	accgcgcaac	accgcctgac	gcgcccctgac	gggcttgtct	2460
gctcccggca	tccgcttaca	gacaagctgt	gaccgtctcc	gggagctgca	tgtgtcagag	2520
gttttcaccg	tcatacccca	aacgcgcgag	gcagctgctg	taaagctcat	cagcgtggtc	2580
gtgaagcgat	tcacagatgt	ctgcctgttc	atccgcgtcc	agctcgttga	gtttctccag	2640
aagcgttaat	gtctggcttc	tgataaagcg	ggccatgcta	agggcggttt	tttctgttt	2700
ggtcactgat	gcctccgtgt	aagggggatt	tctgttcag	ggggaatga	taccgatgaa	2760
acgagagagg	atgctcacga	tacgggttac	tgatgatgaa	catgcccgtt	tactggaacg	2820
ttgtgaggg	aaacaactgg	cggtatggat	gcggcgggac	cagagaaaaa	tcactcaggg	2880
tcaatgccag	cgcttcgtta	atacagatgt	aggtgttcca	cagggtagcc	agcagcatcc	2940
tgcgatgcag	atccggaaca	taatggtgca	gggcgctgac	ttccgcgttt	ccagacttta	3000
cgaaacacgg	aaaccgaaga	ccattcatgt	tgttgctcag	gtcgcagacg	ttttgcagca	3060
gcagtcgctt	cacgttcgct	cgcgtatcgg	tgattcattc	tgctaaccag	taaggcaacc	3120
ccgccagcct	agccgggttc	tcaacgacag	gagcacgata	atgcgcaccc	gtggggcgc	3180
catgcccggc	ataatggcct	gcttctcgcc	gaaacgtttg	gtggcgggac	cagtgaacgaa	3240
ggcttgagcg	agggcgtgca	agattccgaa	taccgcaagc	gacaggccga	tcacgtctgc	3300
gctccagcga	aagcggctct	cgccgaaaat	gaccagagc	gctgcggca	cctgtcctac	3360
gagttgcatg	ataaagaaga	cagtcataag	tgccgagcag	atagtcatgc	cccgcgcca	3420
ccggaaggag	ctgactgggt	tgaaggctct	caaggcctc	ggctgagatc	ccggtgctta	3480
atgagtgagc	taacttacat	taattgcgtt	gcgctcactg	cccgtttcc	agtcgggaaa	3540
cctgtcgtgc	cagctgcatt	aatgaatcgg	ccaacgcgcg	gggagaggcg	gtttgcgtat	3600
tgggcgccag	gggtgttttt	cttttcacca	gtgagacggg	caacagctga	ttgccctta	3660
ccgcctggcc	ctgagagagt	tgcagcaagc	ggtccacgct	ggtttgccc	agcaggcgaa	3720
aatcctgttt	gatggtgggt	aacggcggga	tataacatga	gctgtcttcg	gtatcgtcgt	3780
atcccactac	cgagatatcc	gcaccaacgc	gcagcccga	ctcggtaatg	gcgcgcattg	3840
cgcccagcgc	catctgatcg	ttggcaacca	gcacgcagc	gggaacgatg	ccctcattca	3900
gcatttgc	ggtttgtga	aaaccggaca	tggcactcca	gtcgccttcc	cgttccgcta	3960

- continued

```

tcggctgaat ttgattgcga gtgagatatt tatgccagcc agccagacgc agacgcgccg 4020
agacagaact taatgggccc gctaacagcg cgatttgctg gtgacccaat gcgaccagat 4080
gctccacgcc cagtcgcgta ccgtcttcat gggagaaaaa aatactgttg atgggtgtct 4140
ggtcagagac atcaagaaat aacgccgga ctagtgca ggcagcttcc acagcaatgg 4200
catcctggtc atccagcgga tagttaatga tcagcccact gacgcgttgc gcgagaagat 4260
tgtgcaccgc cgctttacag gcttcgacgc cgcttcgctc taccatcgac accaccaacgc 4320
tggcaccagc ttgatcggcg cgagatttaa tcgcccgcgc aatttgcgac ggcgcgtgca 4380
gggccagact ggaggtggca acgccaatca gcaacgactg tttgcccgcc agttgttgtg 4440
ccacgcggtt gggaatgtaa ttcagctccg ccategcgcc ttccactttt tcccgcggtt 4500
tcgcagaaac gtggctggcc tggttcacca cgcgggaaac ggtctgataa gagacaccgg 4560
catactctgc gacatcgtat aacgttactg gtttcacatt caccaccctg aattgactct 4620
cttccgggcg ctatcatgcc ataccgcgaa aggttttgcg ccattcgatg gtgtccggga 4680
tctcgacgct ctcccattat cgactcctgc attaggaagc agcccagtag taggttgagg 4740
ccggttgaca ccgcccgcgc aaggaatggt gcatgcaagg agatggcgcc caacagtccc 4800
ccggccacgg ggctgcacc cataccacg ccgaaacaag cgctcatgag cccgaagtgg 4860
cgagcccgat cttcccacg ggtgatgtcg gcgatatagg cgcagcaac cgcacctgtg 4920
gcgccggtga tgccggccac gatgcgtccg gcgtagagga tcgagatctc gatcccgcga 4980
aattaatacg actcactata ggggaattgt gagcggataa caattcccct ctagaataa 5040
ttttgttaa ctttaagaag gagatatacc atgggcagca gccatcatca tcatcatcac 5100
agcagcggcc tgggtcccgc cggcagccat atgtacgtga gatttgagg tcttgaggac 5160
atgcagaacg aagctctgag tctgctggag aaggttaggg agagcggtaa ggtaaagaaa 5220
ggtaccaacg agcagacaaa ggtgtggag aggggactgg caaagctcgt ttacatcgca 5280
gaggatgttg acccgcctga gatcgttct catctgcccc tctctgcga ggagaagaat 5340
gtgccgtaca tttacgttaa aagcaagaac gaccttgaa gggctgtggg cattgaggtg 5400
ccatgcgctt cggcagcgt aatcaacgag ggagagctga gaaaggagct tggaagcctt 5460
gtggagaaga ttaaaggcct tcagaagtaa ctcgagcacc accaccacca cactgagat 5520
ccggctgcta acaagcccg aaaggaagct gagttggctg ctgccaccgc tgagcaataa 5580
ctagcataac cccttggggc ctctaaacgg gtcttgaggg gtttttctg gaaaggagga 5640
actatatccg gat 5653

```

```

<210> SEQ ID NO 6
<211> LENGTH: 5826
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pcDNA3_1_L7Ae_myc_His6

```

```

<400> SEQUENCE: 6

```

```

gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgat 60
ccgcatagtt aagccagtat ctgctcctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag cgtttttgcg ctgcttcgcg atgtacgggc cagatatagc cgttgacatt 240

```

-continued

gattattgac tagttattaa tagtaataca ttacggggtc attagttcat agcccatata	300
tggagtcccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc	360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc	420
attgacgtca atgggtggag tattttacggt aaactgcccc cttggcagta catcaagtgt	480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt	540
atgcccagta catgacctta tgggactttc ctacttgca gtacatctac gtattagtca	600
tcgctattac catgggtgatg cggttttggc agtacctca tgggctgga tagcggtttg	660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttgccacc	720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggcg	780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaacca	840
ctgcttactg gcttatcgaa attaatcga ctcaactatg ggagacccaa gctggctagt	900
taagcttggg accgagctcg gatccatcat atgcccgcgc ttatgtacgt gagatttgag	960
gttctgagg acatgcagaa cgaagctctg agtctgctgg agaaggttag ggagagcggg	1020
aaggtaaaga aaggtaccaa cgagacgaca aaggctgtgg agaggggact ggcaaagctc	1080
gtttacatcg cagaggatgt tgaccgcct gagatcgttg ctcatctgcc cctcctctgc	1140
gaggagaaga atgtgccgta catttacgtt aaaagcaaga acgacctgg aagggtgtg	1200
ggcattgagg tgccatgcgc ttggcagcg ataatcaacg agggagagct gagaaaggag	1260
cttgaagcc ttgtggagaa gattaaaggc cttcagaaga gaattcaact cgagtctaga	1320
gggccttcg aacaaaaact catctcagaa gaggatctga atatgcatac cggatcatcat	1380
caccatcacc attgagtta aaccgcctga tcagcctcga ctgtgccttc tagttgccag	1440
ccatctgttg tttgcccctc ccccgctcct tecttgacc tggaaggtgc cactcccact	1500
gtcctttcct aataaaatga ggaattgca tcgattgtc tgagtaggtg tcattctatt	1560
ctgggggtg ggggtgggca ggacagcaag ggggaggatt gggaagacaa tagcaggcat	1620
gctgggatg cgggtggctc tatggcttct gaggcgaaa gaaccagctg gggctctagg	1680
gggatcccc acgcgcctg tagcggcgca ttaagcgcg cgggtgtggt ggttacgcgc	1740
agcgtgaccg ctacactgc cagcgccta gcgcccctc ctttogctt cttcccttc	1800
tttctcgca cgttgcgctg ctttcccctg caagctctaa atcgggggct ccttttaggg	1860
ttccgattta gtgctttacg gcaacctgac cccaaaaaac ttgattaggg tgatggttca	1920
cgtagtggc catcgccctg atagacggtt tttcgccctt tgacgttga gtccacgttc	1980
tttaatagt gactcttgtt ccaactgga acaacactca accctatctc ggtctattct	2040
tttgattat aagggtttt gccgatttcg gcctattggt taaaaatga gctgatttaa	2100
caaaaattta acgcgaatta attctgtgga atgtgtgca gttagggtg ggaaagtccc	2160
caggctccc agcaggcaga agtatgcaaa gcatgcatct caattagtca gcaaccagg	2220
gtggaagtcc cccaggctcc ccagcaggca gaagtatgca aagcatgcat ctcaattagt	2280
cagcaacct agtcccgcct ctaactccgc ccatcccgc cctaactccg cccagttccg	2340
cccattctcc gcccctggc tgactaattt tttttattt tgacagggcc gaggcgcct	2400
ctgctctga gctattccag aagtagtgag gaggctttt tggaggccta ggcttttgca	2460
aaaagctccc gggagcttgt atatccattt tcggatctga tcaagagaca ggatgaggat	2520

-continued

cgtttcgcat gattgaacaa gatggattgc acgcagggtc tccggccgct tgggtggaga	2580
ggctattcgg ctatgactgg gcacaacaga caatcgggtg ctctgatgcc gccgtgttc	2640
ggctgtcagc gcaggggcgc ccggttcttt ttgtcaagac cgacctgtcc ggtgccctga	2700
atgaactgca ggacgagga gcgcggctat cgtggctggc cacgacgggc gttccttgcg	2760
cagctgtgct cgacgttgtc actgaagcgg gaagggactg gctgctattg ggcgaagtgc	2820
cggggcagga tctcctgtca tctcaccttg ctctgcccga gaaagtatcc atcatggctg	2880
atgcaatgcg gcggctgcat acgcttgatc cggctacctg cccattcgac caccaagcga	2940
aacatcgcat cgagcgagca cgtactcgga tggaaagccg tcttgctgat caggatgatc	3000
tggacgaaga gcatcagggg ctgcgccag ccgaactgtt cgccaggctc aaggcgcgca	3060
tgcccgacgg cgaggatctc gtcgtgacct atggcgatgc ctgcttgccg aatcatatgg	3120
tggaaaatgg ccgcttttct ggattcatcg actgtggccg gctgggtgtg gcggaccgct	3180
atcaggacat agcgtttgct acccgtgata ttgctgaaga gcttggcggc gaatgggctg	3240
accgcttctc cgtgctttac ggtatcgccg ctcccgatcc gcagcgcac gccttctatc	3300
gccttcttga cgagtcttc tgagcgggac tctggggttc gcgaaatgac cgaccaagcg	3360
acgcccaccc tgccatcacg agatctcgat tccaccgccc ccttctatga aagggtgggc	3420
ttcggaatcg tttccggga gcgcggctgg atgatctccc agcgcgggga tctcatgctg	3480
gagttcttcg cccaccccaa cttgtttatt gcagcttata atggttaca ataaagcaat	3540
agcatcacia atttcacaaa taaagcattt ttttcaactg atctagttag tggttgttc	3600
aaactcatca atgtatctta tcatgtctgt ataccgtcga cctctagcta gagcttggcg	3660
taatcatggt catagctggt tctgtgtgga aattgttacc cgtccacaat tccacacaac	3720
atcagagccg gaagcataaa gtgtaagcc tggggtgcct aatgagtgag ctaactcaca	3780
ttaattgctg tgcgctcact gcccgcttcc cagtcgggaa acctgtcgtg ccagctgcat	3840
taatgaatcg gccaacgcgc ggggagaggc ggtttgcgta ttgggcgctc ttcgcttcc	3900
tgcctcactg actcgtcgcg ctcggtcggt cggctgcggc gagcggatc agctcactca	3960
aaggcggtaa tacggttacc cacagaatca ggggataacg caggaaagaa catgtgagca	4020
aaaggccagc aaaaggccag gaaccgtaaa aaggccgctg tgcctggcgtt tttccatagg	4080
ctccgcccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg	4140
acaggactat aaagatacca ggcgtttccc cctggaagct cctcgtgcg ctctcctggt	4200
ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt	4260
tctcatagct cacgctgtag gtatctcagt tccggttagg tcgttcgctc caagctgggc	4320
tgtgtgcacg aacccccctg tcagcccgac cgetgcgctc tatccggtaa ctatcgtctt	4380
gagtccaacc cggaagaca cgacttatcg ccaactggcag cagccactgg taacaggatt	4440
agcagagcga ggtatgtagg cgggtctaca gagttcttga agtgggtggc taactacggc	4500
tacactagaa gaacagtatt tggatctgct gctctgctga agccagtacc cttcggaaaa	4560
agagttggtg gctcttgatc cggcaaaaa accaccgctg gtagcggtag ttttttgggt	4620
tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct	4680
acggggtctg acgctcagtg gaacgaaaa tcacgttaag ggattttggt catgagatta	4740
tcaaaaagga tcttcaccta gatcctttaa aattaaat gaagttttaa atcaatctaa	4800

-continued

```

agtatatatg agtaaacttg gtctgacagt taccaatgct taatcagtga ggcacctatc 4860
tcagcgatct gtctatttcg ttcacccata gttgcctgac tcccgcgtgt gtagataact 4920
acgatacggg agggttacc atctggcccc agtgctgcaa tgataccgag agacccacgc 4980
tcaccggctc cagatttacc agcaataaac cagccagccg gaagggccga gcgcagaagt 5040
ggtcctgcaa ctttatccgc ctccatccag tctattaatt gttgccggga agctagagta 5100
agtagttcgc cagttaatag tttgcgcaac gttgttgcca ttgctacagg catcgtggtg 5160
tcacgctcgt cgtttggtat ggttcattc agctccggtt cccaacgata aaggcgagtt 5220
acatgatccc ccatgtttgtg caaaaagcg gttagctcct tcggtcctcc gatcgttgtc 5280
agaagtaagt tggccgagc gttatcactc atggttatgg cagcaactgca taattctctt 5340
actgtcatgc catccgtaag atgcttttct gtgactggtg agtactcaac caagtcattc 5400
tgagaatagt gtatgcccgc accgagttgc tcttgcctcg cgtaatacgg ggataatacc 5460
gcccacata gcagaacttt aaaagtgtc atcattgaa aacgttcttc ggggcgaaaa 5520
ctctcaagga tcttaccgct gttgagatcc agttcgatgt aacccactcg tgcacccaac 5580
tgatcttcag catcttttac tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa 5640
aatgccgcaa aaaagggaaat aagggcgaca cggaaatggt gaatactcat actcttcctt 5700
tttcaatatt attgaagcat ttatcagggg tattgtctca tgagcggata catatttgaa 5760
tgtatttaga aaaataaaca aataggggtt ccgcccacat ttccccgaaa agtgccacct 5820
gacgtc 5826

```

<210> SEQ ID NO 7

<211> LENGTH: 5493

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pcDNA3.1(+)-myc His A vector

<400> SEQUENCE: 7

```

gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtggt ggaggtcgt gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgag atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaataca ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgc tggtgaccg cccaacgacc 360
ccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggag tatttacggg aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggacttcc ctacttgcca gtacatctac gtattagtea 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag 780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctagt 900

```

-continued

taagcttggt accgagctcg gatccactag tccagtggtg tggaattctg cagatatcca	960
gcacagtggc ggccgctcga gtctagaggg cccttcgaac aaaaactcat ctcaagaag	1020
gatctgaata tgcataccgg tcatcatcac catcaccatt gagtttaaac ccgctgatca	1080
gcctcgaactg tgccttctag ttgccagcca tctgttggtt gccctcccc cgtgccttcc	1140
ttgacctggg aaggtgccac tcccactgtc ctttcctaataaaaatgagga aattgcatcg	1200
cattgtctga gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg	1260
gaggattggg aagacaatag caggcatgct ggggatgccc tgggctctat ggcttctgag	1320
gcggaaagaa ccagctgggg ctctaggggg tatccccacg cgcctgtag cggcgcatta	1380
agcgcggcgg gtgtgggtgt taecgcgacg gtgaccgcta cacttgccag cgccttagcg	1440
cccgtcctt tgccttctt ccttccttt ctgccacgt tgcgggctt tccccgtaa	1500
gtctaaatc ggggctccc tttaggggtc cgatttagtg ctttacggca cctcgacccc	1560
aaaaacttg attaggtgga tggttcacgt agtgggcat cgcctgata gacggttttt	1620
cgcctttga cgttgagtc cacgttctt aatagtgagc tctgttcca aactggaaca	1680
acactcaacc ctatctcggg ctattcttt gatataaag ggattttgcc gatttcggcc	1740
tattggttaa aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg	1800
tgtgtcagtt aggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca	1860
tgcactcaaa ttagtcagca accaggtgtg gaaagtcccc aggctcccc gcaggcagaa	1920
gtatgcaaa catgatctc aattagtcag caaccatagt cccgccccta actccgccc	1980
tccccccct aactccgccc agttccgccc attctccgcc ccatggctga ctaattttt	2040
ttatttatgc agaggccgag gccgcctctg cctctgagct attccagaag tagtgaggag	2100
gcttttttg aggcctaggc ttttgcaaaa agctcccggg agcttgata tccattttcg	2160
gatctgatca agagacagga ttaggatcgt ttccgatgat tgaacaagat ggattgcacg	2220
caggttctcc ggccgcttg gtggagaggc tattcggcta tgactgggca caacagacaa	2280
tggctgctc tgatgccgc gtgttccggc tgcagcgc ggggcgccc gttcttttg	2340
tcaagaccga cctgtccggg gccctgaatg aactgcagga caggcagcg cggctatcgt	2400
ggctggccac gacggcgctt ccttgcgacg ctgtgctcga cgttgctact gaagcgggaa	2460
gggactggct gctattgggc gaagtgcgg ggcaggatct cctgtcatct caccttgctc	2520
ctgccagaaa agtatccatc atggctgatg caatgcccgc gctgcatacg cttgatccgg	2580
ctacctgccc attcgaccac caagcgaac atcgcatcga gcgagcacgt actcgatgg	2640
aagccggtct tgcgatcag gatgatctg acgaagagca tcaggggctc gcgccagccg	2700
aactgttcgc caggctcaag gcgcgatgc ccgacggcga ggatctcgtc gtgacccatg	2760
gcgatgcctg cttgccgaat atcatggtgg aaaaatggccg cttttctgga ttcactgact	2820
gtggccggct ggggtggtgc gaccgctatc aggacatagc gttggctacc cgtgatattg	2880
ctgaagagct tggggcgcaa tgggtgacc gcttcctcgt gctttacggt atcgcgctc	2940
ccgattcga cgcgatcgc ttctatcgc ttcttgacga gttctctga gcgggactct	3000
ggggttcgag aaatgaccga ccaagcagc cccaacctgc catcagcaga tttcgattcc	3060
accgcccct tctatgaaag gttgggcttc ggaatcgtt tccgggacgc cggctggatg	3120
atcctccagc gcggggatct catgctggag ttcttcgccc accccaactt gtttattgca	3180

-continued

gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatttttt	3240
tcaactgcatt ctagtgtggt tttgtccaaa ctcatcaatg tatcttatca tgtctgtata	3300
ccgtcgacct ctagctagag cttggcgtaa tcatggatc agctgtttcc tgtgtgaaat	3360
tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagtg taaagcctgg	3420
ggtgcctaag gagtgagcta actcacatta attgcgttgc gctcactgcc cgctttccag	3480
tcgggaaacc tgtcgtgcca gctgcattaa tgaatcggcc aacgcgcggg gagaggggt	3540
ttgcgtattg ggcgctcttc cgcttccctc ctcaactgact cgctgcgctc ggtcgttccg	3600
ctgcggcgag cggatcagc tcaactcaaag gcggaatac gggtatccac agaactcagg	3660
gataacgcag gaaagaacat gtgagcaaaa gccagcaaaa aggccaggaa ccgtaaaaag	3720
gcccgcgttc tggcgttttt ccataggttc cccccctc acgagcatca caaaaatcga	3780
cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct	3840
ggaagctccc tcgtgcgctc tctgttccg accctgcgcg ttaccggata cctgtccgcc	3900
tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg	3960
gtgtaggtcg ttcgctccaa gctgggctgt gtgacgaac ccccgctca gcccgaccgc	4020
tgcccttat ccgtaacta tcgtcttgag tccaacccgg taagacacga cttatcgcca	4080
ctggcagcag ccaactgtaa caggattagc agagcgaggt atgtaggcgg tgctacagag	4140
ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg tatctgcgct	4200
ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg caaaaacc	4260
accgctggtg cgggtggttt tttgtttgc aagcagcaga ttacgcgcag aaaaaagga	4320
tctcaagaag atcctttgat cttttctacg gggctgacg ctcaagtggaa cgaaaactca	4380
cgtaagggg ttttggctcat gagattatca aaaaggatct tcacctagat ctttttaaat	4440
taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc tgacagttac	4500
caatgcttaa tcagttaggc acctatctca gcgatctgtc tatttcgttc atccatagtt	4560
gcctgactcc ccgctgtgta gataactacg atacgggagg gcttaccatc tggccccagt	4620
gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc aataaacag	4680
ccagccgaa gggccgagcg cagaagtgtt cctgcaactt tatccgcctc catccagtct	4740
attaattggt gccgggaagc tagagtaagt agttcgccag ttaaatgttt gcgcaacggt	4800
ggtgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc ttcattcagc	4860
tccggttccc aacgatcaag gcgagttaca tgatcccca tgggtgtgca aaaagcgggt	4920
agtcctctcg gtcctccgat cgttgcaga agtaagttgg ccgcaggtt atcaactatg	4980
ggtatggcag cactgcataa tctcttact gtcattgccat ccgtaagatg cttttctgtg	5040
actggtgagt actcaaccaa gtcattctga gaatagtgtg tgccgagacc gagttgtctc	5100
tgccccgct caatacggga taataccgag ccacatagca gaactttaaa agtgctcatc	5160
attgaaaaac gttcttcggg gcgaaaaact tcaaggatct taccgctgtt gagatccagt	5220
tcgatgtaac ccaactcgtc acccaactga tcttcagcat cttttacttt caccagcgtt	5280
tctgggtgag caaaaacag aaggcaaaat gccgcaaaa agggaataag ggcgacacgg	5340
aaatgttgaa tactcactct cttcttttt caatattatt gaagcattta tcagggttat	5400
tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat aggggttccg	5460

- continued

cgcacatttc cccgaaaagt gccacctgac gtc 5493

<210> SEQ ID NO 8
 <211> LENGTH: 3869
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: pENTR(TM)/H1/TO vector

<400> SEQUENCE: 8

ctttctcgcg ttatccccctg attctgtgga taaccgtatt accgcctttg agtgagctga 60
 taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga 120
 gcgccaata cgcgaaaccgc ctctccccgc gcgttgcccg attcattaat gcagctggca 180
 cgacaggttt cccgactgga aagcgggcag tgagcgcaac gcaattaata cgcgtaccgc 240
 tagccaggaa gagttttag aaacgcaaaa aggccatccg tcaggatggc cttctgctta 300
 gtttgatgcc tggcagttta tggcgggct cctgcccccc accctccggg cegtgtcttc 360
 acaacgttca aatcgcctcc cggcggattt gtcctactca ggagagcgtt caccgacaaa 420
 caacagataa aacgaaaggc ccagtcttc gactgagcct ttcgtttat ttgatgctg 480
 gcagttcct actctcgcgt taattcgcct ttagacatga taagatacat tgatgagttt 540
 ggacaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct 600
 attgctttat ttgtaacct tataagctgc aataaacaag ttgggtggg cgaagaactc 660
 cagcatgaga tccccgcct ggaggatcat ccagccggcg tcccgaaaa cgattccgaa 720
 gcccaacctt tcatagaagg cggcgggtga atcgaaatct cgtagcacgt gtcagtctg 780
 ctctcggcc acgaagtga cgcagttgcc ggccgggtcg cgcagggcga actcccgccc 840
 ccacggctgc tcgccgatct cggtcatggc cggcccgag gcgtcccga agttcgtgga 900
 cagcactcc gaccactcg cgtacagctc gtcaggcccg cgcaccaca cccaggccag 960
 ggtgtgtcc ggcaccatct ggtcctggac cgcgctgatg aacagggtca cgtcgtccc 1020
 gaccacaccg gcgaagtct cctccacgaa gtcccgggag aaccgagcc ggtcgttcca 1080
 gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggtaactt 1140
 ggccatggt tagttcctca cctgtctgta ttatactatg ccgatatact atgccgatga 1200
 ttaattgtca acacgtctg atcagatccg aaaatggata tacaagctcc cgggagcttt 1260
 ttgcaaaaag ctaggcctcc aaaaaagcct cctcaactact tctggaatag ctcagaggca 1320
 gagcggcct cggcctctgc ataataaaa aaaattagtc agccatggg cggagaatgg 1380
 gcggaactgg gcggagttag ggcgggatg ggcggagta gggcgggac tatggttgc 1440
 gactaattga gatgatgct ttgcatact ctgcctgctg gggagcctgg ggactttcca 1500
 cacctggttg ctgactaatt gagatgatg ctttgcatc ttctgcctgc tggggagcct 1560
 ggggacttcc cacaccctaa ctgacacaca ttccacagcc gaagggcgaa ttaacgctag 1620
 catggatggt tccccagtca cgaogttgta aaacgacggc cagtcttaag ctcgggcccc 1680
 aaataatgat tttattttga ctgatagtga cctgttcgtt gcaacaaatt gatgagcaat 1740
 gcttttttat aatgccaact ttgtacaaaa aagcaggctt taaaggaacc aattcagtcg 1800
 actggatccg gtaccgggcc cccctcgaa gatctaatat ttgcatgctg ctatgtgttc 1860
 tgggaaatca ccataaacgt gaaatcccta tcagtgatag agacttataa gttccctatc 1920

-continued

```

agtgatagag acaccttttt tgtcgagctt ccttcgggaa gctctccata ttttttggat 1980
ccactagttc tagaccagc tttctgtac aaagtggca ttataagaaa gcattgetta 2040
tcaatttgtt gcaacgaaca ggtcactatc agtcaaaaata aaatcattat ttgccatcca 2100
gctgatatcc cctatagtga gtcgtattac atggtcatag ctgtttcctg gcagctctgg 2160
cccgtgtctc aaaatctctg atgttacatt gcacaagata aaaatatatc atcatgaaca 2220
ataaaactgt ctgcttcat aaacagtaat acaaggggtg ttatgagcca tattcaacgg 2280
gaaacgtcga ggccgcgatt aaattccaac atggatgctg atttatatgg gtataaatgg 2340
gctcgcgata atgtcgggca atcagggtcg acaatctatc gcttgtatgg gaagcccgat 2400
gcccagagt tgtttctgaa acatggcaaa ggtagcgttg ccaatgatgt tacagatgag 2460
atggtcagac taaactggct gacggaattt atgcctcttc cgaccatcaa gcattttatc 2520
cgtactcctg atgatgatg gttactcacc actgcgatcc cggaaaaac agcattccag 2580
gtattagaag aatattctga ttcaggtgaa aatattgttg atgcgctggc agtgttcctg 2640
cgccggttgc attcgattcc tgtttgtaat tgtcctttta acagcgatcg cgtatttctg 2700
ctcgtcagc cgcaatcacg aatgaataac ggtttggtg atgcgagtga tttgatgac 2760
gagcgtaatg gctggcctgt tgaacaagtc tggaaagaaa tgcataaact tttgccattc 2820
tcaccggatt cagtcgtcac tcatggtgat ttctcacttg ataaccttat tttgacgag 2880
gggaaattaa taggttgtat tgatgttga cgagtcgaa tcgcagaccg ataccaggat 2940
cttgccatcc tatggaactg cctcgggtgag ttttctcctt cattacagaa acggcttttt 3000
caaaaatatg gtattgataa tctgatatg aataaattgc agtttcattt gatgctcgat 3060
gagtttttct aatcagaatt ggttaattgg ttgtaacct ggcagagcat tacgctgact 3120
tgacgggacg gcgcaagctc atgacaaaaa tcccttaacg tgagttacgc gtcgttccac 3180
tgagcgtcag acccctaga aaagatcaaa ggatcttctt gagatccttt ttttctgccc 3240
gtaactctgt ccttgcaaac aaaaaacca ccgctaccag cggtggtttg tttgccggat 3300
caagagctac caactctttt tccgaaggta actggcttca gcagagcgca gataccaaat 3360
actgttcttc tagttagacc gtatgttagc caccacttca agaactctgt agcaccgct 3420
acatacctcg ctctgctaat cctgttacca gtggctgctg ccagtggcga taagtcgtgt 3480
cttaccgggt tggactcaag acgatagttt cgggataagg cgcagcggtc gggctgaacg 3540
gggggttctg gcacacagcc cagcttgag cgaacgacct acaccgaact gagataccta 3600
cagcgtgagc tatgagaaag cgccacgctt cccgaaggga gaaaggcga caggatccg 3660
gtaagcggca gggcggaaac aggagagcgc acgagggagc ttccaggggg aaacgcctgg 3720
tatctttata gtctgtcgg gtttcgccac ctctgacttg agcgtcgatt tttgtgatgc 3780
tcgtcagggg ggcggagcct atgaaaaaac gccagcaacg cggccttttt acggttcctg 3840
gccttttctg ggccttttgc tccatggtt 3869

```

<210> SEQ ID NO 9

<211> LENGTH: 63

<212> TYPE: RNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: shRNA-BoxC/D-GFP

<400> SEQUENCE: 9

-continued

ggcaucaagg ugaacuucag cugacccgaa agggcgugau gcugaaguuc accuugaugc 60

cag 63

<210> SEQ ID NO 10
 <211> LENGTH: 59
 <212> TYPE: RNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: shRNA-GFP

<400> SEQUENCE: 10

ggcaucaagg ugaacuucaa gauccagcau agggauucuug aaguucaccu ugaugccag 59

<210> SEQ ID NO 11
 <211> LENGTH: 62
 <212> TYPE: RNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: shRNA-BoxC/D-mut-GFP

<400> SEQUENCE: 11

ggcaucaagg ugaacuucag cugcccgaaa gggcgucaug cugaaguca ccuugaugcc 60

ag 62

<210> SEQ ID NO 12
 <211> LENGTH: 59
 <212> TYPE: RNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: shRNA-GFP-mut

<400> SEQUENCE: 12

gcacuagcgu augaauaaaa gauccagcau agggauuuu caucuauacg cuagugcag 59

<210> SEQ ID NO 13
 <211> LENGTH: 82
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: L7Aer template

<400> SEQUENCE: 13

ctggcatcaa ggtgaacttc agcatcacgc cctttcgggt cagctgaagt tcaccttgat 60

gcctatagtg agtcgtatta gc 82

<210> SEQ ID NO 14
 <211> LENGTH: 52
 <212> TYPE: RNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: shRNA-U1A-4

<400> SEQUENCE: 14

ggcaucaagg ugaacuucag ggcgaaagcc cugaaguca ccuugaugcc ag 52

<210> SEQ ID NO 15
 <211> LENGTH: 81
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: L7AerN template

-continued

<400> SEQUENCE: 15

ctggcatcaa ggtgaacttc agcatgacgc cctttcgggc agctgaagtt caccttgatg 60
 cctatagtga gtcgtattag c 81

<210> SEQ ID NO 16

<211> LENGTH: 78

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: 481P template

<400> SEQUENCE: 16

ctggcatcaa ggtgaacttc aagatcccta tgctggatct tgaagttcac cttgatgcct 60
 atagtgagtc gtattagc 78

<210> SEQ ID NO 17

<211> LENGTH: 3930

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pENTR/H1/TO-shRNA-BoxC/D-GFP

<400> SEQUENCE: 17

ctttcctgcy ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga 60
 taccgctcgc cgcagccgaa cgaccgagcg cagcgagtcg gtgagcgagg aagcgggaaga 120
 gcgccaata cgcaaacgcg ctctcccgcg gcggtggcgg attcattaat gcagctggca 180
 cgacaggttt cccgactgga aagcgggagc tgagcgcaac gcaattaata cgcgtaccgc 240
 tagccaggaa gagttttagt aaacgcaaaa aggccatccg tcaggatggc cttctgctta 300
 gtttgatgcc tggcagttta tggcgggctg cctgcccgcc accctccggg cegtgtcttc 360
 acaacgttca aatccgctcc cggcggattt gtcctactca ggagagcgtt caccgacaaa 420
 caacagataa aacgaaaggc ccagtcctcc gactgagcct ttcgttttat ttgatgectg 480
 gcagttccct actctcgcgt taattcgccc ttagacatga taagatacat tgatgagttt 540
 ggacaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct 600
 attgctttat ttgtaacctat tataagctgc aataaacaag ttgggggtggg cgaagaactc 660
 cagcatgaga tcccgcgctg ggaggatcat ccagccggcg tcccggaaaa cgattccgaa 720
 gcccaacctt tcatagaagg cggcgggtgga atcgaaatct cgtagcacgt gtcagtctg 780
 ctctcggcc acgaagtgca cgcagttgcc ggccgggtcg cgcagggcga actcccgcc 840
 ccacggctgc tcgcgatct cggtcatggc cggccgggag gcgtcccgga agttcgtgga 900
 cacgaactcc gaccactcgg cgtacagctc gtccagggcg cgcacccaca cccagggcag 960
 ggtgtgtgcc ggcacatct ggtcctggac cgcgctgatg aacagggta cgtcgtccc 1020
 gaccacaccg gcgaagtctg cctccacgaa gtcccgggag aaccggagcc ggtcgggtca 1080
 gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggccaactt 1140
 ggccatggtt tagttcctca ccttgcgta ttatactatg ccgatatact atgccgatga 1200
 ttaattgtca acactgctg atcagatccg aaaaatggata tacaagctcc cgggagcttt 1260
 ttgcaaaaagc ctaggcctcc aaaaaagcct cctcaactact tctggaatag ctcagaggca 1320
 gaggcggcct cggcctctgc ataataaaaa aaaattagtc agccatgggg cggagaatgg 1380

-continued

gcggaactgg gcggagttag gggcgggatg ggcggagtta ggggcgggac tatggttgc	1440
gactaattga gatgatgct ttgcatactt ctgcctgctg gggagcctgg ggactttcca	1500
cacctggttg ctgactaatt gagatgcatg ctttgcatac ttctgcctgc tggggagcct	1560
ggggactttc cacaccctaa ctgacacaca ttccacagcc gaagggcgaa ttaacgctag	1620
catggatgtt tccccagtca cgacgttga aaacgacggc cagtcttaag ctcgggcccc	1680
aaataatgat tttattttga ctgatagtga cctgttcggt gcaacaaatt gatgagcaat	1740
gcttttttat aatgccaact ttgtacaaaa aagcaggctt taaaggaacc aattcagtcg	1800
actggatccg gtaccgggccc cccctcgaa gatctaatat ttgcatgtcg ctatgtgttc	1860
tgggaaatca ccataaacgt gaaatcccta tcagtgatag agacttataa gttccctatc	1920
agtgatagag acaccggcat caaggtgaac ttcagctgac ccgaaagggc gtgatgtgga	1980
agttcacctt gatgcctttt ttgtcagct tccttcggga agctctccat attttttga	2040
tccactagtt ctagaccag ctttcttga caaagttggc attataagaa agcattgctt	2100
atcaatttgt tgcaacgaac aggtcactat cagtcaaaat aaaatcatta tttgccatcc	2160
agctgatatc ccctatagtg agtcgtatta catggtcata gctgtttcct ggcagctctg	2220
gcccgtgtct caaaatctct gatgttacct tgcacaagat aaaaatatat catcatgaac	2280
aataaaaactg tctgcttaca taaacagtaa tacaaggggt gttatgagcc atattcaacg	2340
ggaaacgtcg aggcgcgat taaattccaa catggatgct gatttatatg ggtataaatg	2400
ggctcgcgat aatgtcgggc aatcaggtgc gacaatctat cgcttgatg ggaagcccga	2460
tgcgccagag ttgtttctga aacatggcaa aggtagcgtt gccaatgatg ttacagatga	2520
gatggtcaga ctaactggc tgacggaatt tatgcctctt ccgaccatca agcattttat	2580
ccgtactcct gatgatgcat ggttactcac cactgcgatc cccggaaaaa cagcattcca	2640
ggtattagaa gaatctctg attcaggtga aaatattgtt gatgcgctgg cagtgttcct	2700
gcgccggttg cattcgattc ctgtttgtaa ttgtcctttt aacagcgatc gcgtatttcg	2760
tctcgtcag gcgcaatcac gaatgaataa cggtttggtt gatgcgagtg attttgatga	2820
cgagcgaat ggctggcctg ttgaacaagt ctggaagaa atgcataaac ttttgccatt	2880
ctcaccgat tcagtcgca ctcatggtga tttctcactt gataacctta tttttgacga	2940
gggaaatta ataggttga ttgatgttg acgagtcgga atcgcagacc gataccagga	3000
tcttgccatc ctatggaact gcctcgggtg gttttctcct tcattacaga aacggctttt	3060
tcaaaaatat ggtattgata atcctgatat gaataaattg cagtttcatt tgatgctcga	3120
tgagtttttc taatcagaat tggttaattg gttgtaaac tggcagagca ttacgctgac	3180
ttgacgggac ggcgcaagct catgacccaa atccctaac gtgagttacg cgtcgttcca	3240
ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcy	3300
cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtgggtt gtttgccgga	3360
tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa	3420
tactgttctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc	3480
tacatacctc gctctgctaa tctgttacc agtggctgct gccagtggcg ataagtctg	3540
tcttacccgg ttggactcaa gacgatagtt accggataag gcgcagcggc cgggctgaac	3600
ggggggttcg tgcacacagc ccagcttga gcgaacgacc tacaccgaac tgagatacct	3660

-continued

```

acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc 3720
ggtaagcggc agggtcggaa caggagagcg cacgaggag cttccagggg gaaacgectg 3780
gtatctttat agtctctgctc ggtttcgcca cctctgactt gagecgtgat ttttgtgatg 3840
ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttctc 3900
ggccttttgc tggccttttg ctcacatggt 3930

```

```

<210> SEQ ID NO 18
<211> LENGTH: 65
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR L7Aer Top strand

```

<400> SEQUENCE: 18

```

caccggcatc aaggtgaact tcagctgacc cgaaaggcgg tgatgctgaa gttcaccttg 60
atgcc 65

```

```

<210> SEQ ID NO 19
<211> LENGTH: 65
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR L7Aer Bottom strand

```

<400> SEQUENCE: 19

```

aaaaggcatc aaggtgaact tcagcatcac gccctttcgg gtcagctgaa gttcaccttg 60
atgcc 65

```

```

<210> SEQ ID NO 20
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: H1 Forward Primer

```

<400> SEQUENCE: 20

```

tgttctggga aatcaccata 20

```

```

<210> SEQ ID NO 21
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: M13 Reverse Primer

```

<400> SEQUENCE: 21

```

caggaaacag ctatgac 17

```

```

<210> SEQ ID NO 22
<211> LENGTH: 3929
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR/H1/TO-shRNA-BoxC/D-mut-GFP

```

<400> SEQUENCE: 22

```

ctttctctgc ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga 60
taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga 120

```

-continued

gcgccaata cgcaaccgc ctctccccgc gcgttgccg attcattaat gcagctggca	180
cgacaggttt cccgactgga aagcgggcag tgagcgcaac gcaattaata cgcgtaccgc	240
tagccaggaa gagttttag aaacgcaaaa aggccatccg tcaggatggc cttctgctta	300
gtttgatgcc tggcagttta tggcgggct cctgccccgc accctccggg cegtgtctc	360
acaacgttca aatccgctcc cgcgggattt gtcctactca ggagagcgtt caccgacaaa	420
caacagataa aacgaaaggc ccagctctcc gactgagcct ttcgttttat ttgatgctg	480
gcagttccct actctcgcgt taattcgcgc ttagacatga taagatacat tgatgagttt	540
ggacaaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct	600
attgctttat ttgtaacct tataagctgc aataaacaag ttgggggtgg cgaagaactc	660
cagcatgaga tccccgcgct ggaggatcat ccagccggcg tccccgaaaa cgattccgaa	720
gccccacctt tcatagaagg cgcgggtgga atcgaaatct cgtagcacgt gtcagtcctg	780
ctcctcggcc acgaagtga cgcagttgcc ggccgggtcg cgcagggcga actccccccc	840
ccacggctgc tcgccgatct cggtcatggc cggcccgag gcgtcccga agttcgtgga	900
cacgacctcc gacctcgg cgtacagctc gtcaggccg cgcaccaca cccaggccag	960
ggtgtgtcc ggcaccatct ggtcctggac cgcgctgatg aacagggta cgtcgtccc	1020
gaccacaccg gcgaagtct cctccacgaa gtcccgggag aaccggagcc ggtcgggtca	1080
gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggtaactt	1140
ggccatggt tagttcctca cctgtcgtta ttatactatg ccgatatact atgccgatga	1200
ttaattgtca acacgtgctg atcagatccg aaaatggata tacaagctcc cgggagctt	1260
ttgcaaaagc ctaggcctcc aaaaaagcct cctcactact tctggaatag ctcagaggca	1320
gagggcgct cggcctctgc ataataaaa aaaattagtc agccatgggg cggagaatgg	1380
gcggaactgg cgggagttag gggcgggatg ggcggagtta gggcgggac tatggttct	1440
gactaattga gatgatgct ttgcatact ctgcctgctg gggagcctgg ggactttcca	1500
cacctggtg ctgactaatt gagatgatg ctttgcatc tctgcctgc tggggagcct	1560
ggggacttcc cacacctaa ctgacacaca tccacagcc gaagggcgaa ttaacgctag	1620
catggatgtt tcccagtc cgcagttgta aaacgacgac cagtcttaag ctcgggcccc	1680
aaataatgat tttatgttga ctgatagtga cctgttcgtt gcaacaaat gatgagcaat	1740
gcttttttat aatgccaact ttgtacaaaa aagcaggctt taaaggaacc aatcagtcg	1800
actggatccg gtaccgggcc cccctcgaa gatctaatat ttgcatgctg ctatgtgtc	1860
tgggaaatca ccataaacgt gaaatcccta tcagtgatag agacttataa gttccctatc	1920
agtgatagag acaccggcat caaggtgaac ttcagctgcc cgaaagggcg tcatgctgaa	1980
gttcaacctg atgccttttt tgcgagctt cctcgggaa gctctccata tttttggat	2040
ccactagttc tagaccagc tttctgtac aaagtggca ttataagaaa gcattgctta	2100
tcaatttgtt gcaacgaaca ggtcactatc agtcaaaata aaatcattat ttgccatcca	2160
gctgatatcc cctatagtga gtcgtattac atggcatag ctgtttcctg gcagctctgg	2220
cccgtgtctc aaaatctctg atgttacatt gcacaagata aaaatatatc atcatgaaca	2280
ataaaactgt ctgcttcat aaacagtaat acaaggggtg ttatgagcca tattcaacgg	2340
gaaacgtcga ggccgcgatt aaattccaac atggatgctg atttatatgg gtataaatgg	2400

-continued

```

gctcgcgata atgtcgggca atcaggtgcg acaatctatc gcttgatgg gaagcccgat 2460
gcgccagagt tgtttctgaa acatggcaaa ggtagcgttg ccaatgatgt tacagatgag 2520
atggtcagac taaactggct gacggaatth atgcctcttc cgaccatcaa gcattttatc 2580
cgtactcctg atgatgcatg gttactcacc actgcgatcc cgggaaaaac agcattccag 2640
gtattagaag aatatcctga ttcaggtgaa aatattgttg atgcgctggc agtgttcctg 2700
cgccggttgc attcgattcc tgtttgtaat tgtcctttta acagcgatcg cgtatttcgt 2760
ctcgtcagg cgcaatcacg aatgaataac ggtttggttg atgcgagtga tttgatgac 2820
gagcgtaatg gctggcctgt tgaacaagtc tggaaagaaa tgcataaact tttgccattc 2880
tcaccggatt cagtcgtcac tcattggtgat ttctcacttg ataaccttat ttttgacgag 2940
gggaaattaa taggttgat tgatgttga cgagtcggaa tgcgagaccg ataccaggat 3000
cttgccatcc tatggaactg cctcggtag ttttctcctt cattacagaa acggcttttt 3060
caaaaatag gtattgataa tctgatatg aataaattgc agtttcattt gatgctcgat 3120
gagtttttct aatcagaatt ggttaattgg ttgtaacct ggcagagcat tacgctgact 3180
tgacgggacg gcgcaagctc atgacaaaaa tcccttaacg tgagttacgc gtcgttcac 3240
tgagcgtcag accccgtaga aaagatcaaa ggatcttctt gagatccttt ttttctgccc 3300
gtaatctgct gcttgcaaac aaaaaacca ccgctaccag cgggtggttg tttgccggat 3360
caagagctac caactctttt tccgaaggta actggcttca gcagagcgca gataccaaat 3420
actgttcttc tagttagacc gtatgttagc caccacttca agaactctgt agcaccgcct 3480
acatactcgt ctctgctaat cctgttacca gtggctgctg ccagtggcga taagtctgtg 3540
cttaccgggt tggactcaag acgatagtta ccgataagg cgcagcggtc gggctgaacg 3600
gggggttcgt gcacacagcc cagcttgag cgaacgacct acaccgaact gagataccta 3660
cagcgtgagc tatgagaaag cggccagctt cccgaaggga gaaaggcga caggatccg 3720
gtaagcggca gggctggaac aggagagcgc acgagggagc ttccaggggg aaacgcctgg 3780
tatctttata gtcctgctgg gtttcgccac ctctgacttg agcgtcgatt tttgtgatgc 3840
tcgtcagggg ggcggagcct atggaaaaac gccagcaacg cggccttttt acggttctcg 3900
gccttttgct ggccttttgc tcacatggt 3929

```

<210> SEQ ID NO 23

<211> LENGTH: 64

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pENTR L7AerN Top strand

<400> SEQUENCE: 23

```

caccgcatc aaggtgaact tcagctgcc gaaaggcgt catgctgaag ttcacctga 60

```

tgcc

64

<210> SEQ ID NO 24

<211> LENGTH: 64

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pENTR L7AerN Bottom strand

<400> SEQUENCE: 24

-continued

```

aaaaggcatc aaggtgaact tcagcatgac gccctttcgg gcagctgaag ttcacctga      60
tgcc                                          64

<210> SEQ ID NO 25
<211> LENGTH: 3926
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR/H1/TO-shRNA-GFP

<400> SEQUENCE: 25
ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgccttg agtgagctga      60
taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcgggaaga    120
gcgcccaata cgcaaaccgc ctctcccgcg gcgttgcccg attcattaat gcagctggca    180
cgacaggttt cccgactgga aagcgggcag tgagcgcaac gcaattaata cgcgtaccgc    240
tagccaggaa gagttttag aaacgcaaaa aggccatccg tcaggatggc cttctgctta    300
gtttgatgcc tggcagttta tggcgggct cctgccgcc accctccggg ccgttgcttc    360
acaacgttca aatccgctcc cggcggattt gtcctactca ggagagcgtt caccgacaaa    420
caacagataa aacgaaaggc ccagctctcc gactgagcct ttcgttttat ttgatgctg    480
gcagttccct actctcgcgt taattcgcct ttagacatga taagatacat tgatgagtt    540
ggacaaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct    600
attgctttat ttgtaacat tataagctgc aataaacaag ttgggggtggg cgaagaactc    660
cagcatgaga tccccgcgct ggaggatcat ccagccggcg tccccgaaaa cgattccgaa    720
gccccacctt tcatagaagg cggcgggtgga atcgaaatct cgtagcacgt gtcagtcctg    780
ctcctcggcc acgaagtga cgcagttgcc ggcgggtcg cgcagggcga actcccggcc    840
ccacggctgc tcgccgatct cggtcatggc cggcccggag gcgtcccgga agttcgtgga    900
cacgacctcc gacctcggc cgtacagctc gtccaggccg cgcaccaca cccaggccag    960
ggtgttgctc ggcacatct ggtcctggac cgcgctgatg aacagggta cgtcgtcccg    1020
gaccacaccg gcgaagtct cctccacgaa gtcccgggag aaccggagcc ggtcgggtcca    1080
gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggtaactt    1140
ggccatggtt tagttcctca cctgtctgta ttatactatg ccgatatact atgccgatga    1200
ttaattgtca acacgtgctg atcagatccg aaaatggata tacaagctcc cgggagcttt    1260
ttgcaaaaagc ctaggcctcc aaaaaagcct cctcactact tctggaatag ctcagaggca    1320
gaggcggcct cggcctctgc ataaataaaa aaaattagtc agccatgggg cggagaatgg    1380
gcggaactgg gcggagttag ggcgggatg ggcggagtta gggcggggac tatggttgc    1440
gactaattga gatgatgct ttgcatactt ctgcctgctg gggagcctgg ggactttcca    1500
cacctggttg ctgactaatt gagatgcatg ctttgcatc tctgcctgc tggggagcct    1560
ggggactttc cacacctaa ctgacacaca ttccacagcc gaagggcgaa ttaacgctag    1620
catggatggt tccccagtc cgacgttgta aaacgacggc cagtcttaag ctcgggcccc    1680
aaataatgat tttatgttga ctgatagtga cctgttcggt gcaacaaatt gatgagcaat    1740
gcttttttat aatgccaact ttgtacaaaa aagcaggctt taaaggaacc aattcagtcg    1800
actggatccg gtaccgggcc cccctcgaa gatctaatat ttgcatgtcg ctatgtgttc    1860

```

-continued

tgggaaatca ccataaacgt gaaatcccta tcagtgatag agacttataa gttccctatc	1920
agtgatagag acaccggcat caagggtgaac ttcaagatcc agcatagga tcttgaagtt	1980
caccttgatg ccttttttgt cgagcttccct tcgggaagct ctccatattt tttggatcca	2040
ctagtcttag acccagcttt cttgtacaaa gttggcatta taagaaagca ttgcttatca	2100
at ttgttgc a cgaacaggt cactatcagt caaaataaaa tcattatttg ccatccagct	2160
gatatccct atagtgagtc gtattacatg gtcatagctg tttcctggca gctctggccc	2220
gtgtctcaaa atctctgatg ttacattgca caagataaaa atatatcctc atgaacaata	2280
aaactgtctg cttacataaa cagtaataca aggggtgta tgagccatat tcaacgggaa	2340
acgtcgagggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta taaatgggct	2400
cgcgataatg tcgggcaatc aggtgcgaca atctatcgtc tgatgggaa gcccgatgcg	2460
ccagagttgt ttctgaaaca tggcaaaggt agcgttgcca atgatgttac agatgagatg	2520
gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca ttttatccgt	2580
actcctgatg atgcatggtt actcaccact gcgatccccg gaaaaacagc attccaggtg	2640
ttagaagaat atcctgatc aggtgaaaat attgttgatg cgctggcagt gttcctgctc	2700
cggttgcatt cgattcctgt ttgtaattgt ccttttaaca gcgatcgcgt atttcgtctc	2760
gctcagggcg aatcacgaat gaataacggg ttggttgatg cgagtgattt tgatgacgag	2820
cgtaatggct ggctgttga acaagtctgg aaagaaatgc ataaactttt gccattctca	2880
ccggattcag tcgtcactca tggtgatttc tcaactgata acctattttt tgacgagggg	2940
aaattaatag gttgtattga tgttgacga gtcggaatcg cagaccgata ccaggatctt	3000
gccatcctat ggaactgcct cggtgagttt tctccttcat tacagaaacg gctttttcaa	3060
aaataggtg ttgataatcc tgatatgaat aaattgcagt ttcatttgat gctcgatgag	3120
tttttcta at cagaattggt taattgggtt taacctggc agagcattac gctgacttga	3180
cgggacggcg caagctcatg accaaaatcc cttaacgtga gttacgcgctc gttccactga	3240
gcgtcagacc ccgtagaaaa gatcaaaagga tcttcttgag atcctttttt tctgcgcgta	3300
atctgctgct tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa	3360
gagctaccaa ctctttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact	3420
gttcttctag tgtagccgta gttaggccac cactcaaga actctgtagc accgcctaca	3480
taactcgctc tgctaatect gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt	3540
accgggttgg actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg	3600
ggttcgtgca cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag	3660
cgtgagctat gagaagcgc cacgcttccc gaaggagaaa aggcggacag gtatccggta	3720
agcggcaggg tcggaacagg agagcgcacg agggagcttc cagggggaaa cgctggtat	3780
ctttatagtc ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg	3840
tcaggggggc ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc	3900
ttttgctggc cttttgctca catggt	3926

<210> SEQ ID NO 26

<211> LENGTH: 61

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

-continued

<223> OTHER INFORMATION: pENTR 481P Top strand

<400> SEQUENCE: 26

caccggcatc aaggtgaact tcaagatcca gcatagggat cttgaagttc accttgatgc	60
c	61

<210> SEQ ID NO 27

<211> LENGTH: 61

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pENTR 481P Bottom strand

<400> SEQUENCE: 27

aaaaggcatc aaggtgaact tcaagatccc tatgctggat cttgaagttc accttgatgc	60
c	61

<210> SEQ ID NO 28

<211> LENGTH: 3926

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pENTR/H1/TO-shRNA-GFP-mut

<400> SEQUENCE: 28

ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga	60
taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaaga	120
gcgccaata cgaaaccgc ctctcccgcg gcggtggccg attcattaat gcagctggca	180
cgacaggttt cccgactgga aagcgggagc tgagcgcaac gcaattaata cgcgtaccgc	240
tagccaggaa gagttttag aaacgcaaaa aggccatccg tcaggatggc cttctgctta	300
gtttgatgcc tggcagttta tggcgggctg cctgcccgcc accctccggg ccggttgctc	360
acaacgttca aatccgctcc cggcggattt gtccactca ggagagcgtt caccgacaaa	420
caacagataa aacgaaaggc ccagtcctcc gactgagcct ttcgttttat ttgatgctg	480
gcagttccct actctcgcgt taattcgcgc ttagacatga taagatacat tgatgagttt	540
ggacaaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct	600
attgctttat ttgtaacct tataagctgc aataaacaag ttgggggtggg cgaagaactc	660
cagcatgaga tcccgcgct ggaggatcat ccagccggcg tcccggaaaa cgattccgaa	720
gcccacctt tcatagaagg cggcgggtga atcgaaatct cgtagcacgt gtcagtcctg	780
ctcctcggcc acgaagtgc cgcagttgcc ggccgggtcg cgcagggcga actcccgcc	840
ccacggctgc tcgcgatct cggtcattgc cggccggag gcgtcccga agttcgtgga	900
cacgacctcc gacctcgg cgtacagctc gtccaggccg cgcaccaca cccaggccag	960
ggtgttgctc ggcaacctt ggtcctggac cgcgctgatg aacagggtea cgtcgtccc	1020
gaccacaccg gcgaagtct cctccacgaa gtcccgggag aaccgagcc ggtcgggtcca	1080
gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggtaactt	1140
ggccatggtt tagttcctca ccttgtcgtt ttatactatg ccgatatact atgccgatga	1200
ttaattgtca acacgtgctg atcagatccg aaaatggata tacaagctcc cgggagcttt	1260
ttgcaaaagc ctaggcctcc aaaaaagcct cctcactact tctggaatag ctcagaggca	1320

-continued

gaggcggcct	cggcctctgc	ataaataaaa	aaaattagtc	agccatgggg	cggagaatgg	1380
gcggaactgg	gcgagagtag	ggcggggatg	ggcgagtag	ggggcgggac	tatggttget	1440
gactaattga	gatgatgct	ttgcatactt	ctgcctgctg	gggagcctgg	ggactttcca	1500
cacctggttg	ctgactaatt	gagatgcatg	ctttgcatac	ttctgcctgc	tggggagcct	1560
ggggactttc	cacacocctaa	ctgacacaca	ttccacagcc	gaagggcgaa	ttaacgetag	1620
catggatggt	ttcccagtc	cgacgttgta	aaacgacggc	cagtcttaag	ctcgggcccc	1680
aaataatgat	tttattttga	ctgatagtga	cctgttcggt	gcaacaaatt	gatgagcaat	1740
gcttttttat	aatgccaact	ttgtacaaaa	aagcaggcct	taaaggaacc	aattcagtcg	1800
actggatccg	gtaccggggc	ccccctcgaa	gatctaatat	ttgcatgtcg	ctatgtgttc	1860
tgggaaatca	ccataaacgt	gaaatcccta	tcagtgatag	agacttataa	gttccctatc	1920
agtgatagag	acaccgcact	agcgtatgaa	tgaaagatcc	agcatagga	tctttcattc	1980
atacgctagt	gcttttttgt	cgagcttcct	tcgggaagct	ctccatattt	tttggatcca	2040
ctagtcttag	accagctttt	cttgtacaaa	gttggcatta	taagaaagca	ttgcttatca	2100
atgtgttga	acgaacaggt	cactatcagt	caaaataaaa	tcattatttg	ccatccagct	2160
gatatccct	atagtgtgac	gtattacatg	gtcatagctg	tttctggca	gctctggccc	2220
gtgtctcaa	atctctgatg	ttacattgca	caagataaaa	atatatcatc	atgaacaata	2280
aaactgtctg	cttacataaa	cagtaataca	aggggtgta	tgagccatat	tcaacgggaa	2340
acgtcgaggc	cgcgattaaa	ttccaacatg	gatgctgatt	tatatgggta	taaatgggct	2400
cgcgataatg	tcgggcaatc	aggtgcgaca	atctatcgct	tgtatgggaa	gcccgatgcg	2460
ccagagttgt	ttctgaaaca	tggcaaaagt	agcgttgcca	atgatgttac	agatgagatg	2520
gtcagactaa	actggctgac	ggaatttatg	cctcttccga	ccatcaagca	ttttatccgt	2580
actcctgatg	atgcatggtt	actcaccact	gcgatccccg	gaaaaacagc	attccaggta	2640
ttagaagaat	atcctgatcc	aggtgaaaat	attgttgatg	cgctggcagt	gttctctgct	2700
cggttgcatt	cgattcctgt	ttgtaattgt	ccttttaaca	gcgatcgctg	atttcgtctc	2760
gctcaggcgc	aatcacgaat	gaataacggc	ttggttgatg	cgagtgattt	tgatgacgag	2820
cgtaatggct	ggcctgttga	acaagtctgg	aaagaaatgc	ataaactttt	gccattctca	2880
ccggattcag	tcgtcactca	tgggtgattc	tcacttgata	accttatttt	tgacgagggg	2940
aaattaatag	gttgatttga	tgttgacga	gtcggaatcg	cagaaccgata	ccaggatctt	3000
gccatcctat	ggaactgcct	cggtgagttt	tctccttcat	tacagaaacg	gctttttcaa	3060
aaatatggta	ttgataatcc	tgatatgaat	aaattgcagt	ttcatttgat	gctcgatgag	3120
tttttcta	atcagaattg	taattgggtg	taaacctggc	agagcattac	gctgacttga	3180
cgggacggcg	caagctcatg	acccaaatcc	cttaacgtga	gttacgcgct	gttccactga	3240
gcgtcagacc	ccgtagaaaa	gatcaaaagg	tcttcttgag	atcctttttt	tctgctgcta	3300
atctgctgct	tgcaaacaaa	aaaaccaccg	ctaccagcgg	tggtttgttt	gccggatcaa	3360
gagctaccaa	ctctttttcc	gaaggttaact	ggcttcagca	gagcgcagat	accaaatact	3420
gttcttctag	tgtagccgta	gtaggcccac	cacttcaaga	actctgtage	accgctaca	3480
taoctogctc	tgctaactct	gttaccagtg	gctgctgcca	gtggcgataa	gctggtctct	3540
accgggttgg	actcaagacg	atagttaccg	gataaggcgc	agcggctcggg	ctgaacgggg	3600

-continued

```

ggttcgtgca cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag 3660
cgtgagctat gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta 3720
agcggcaggg tcggaacagg agagcgcaag agggagcttc cagggggaaa cgctcggtat 3780
ctttatagtc ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg 3840
tcaggggggc ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc 3900
ttttgctggc cttttgctca catggt 3926

<210> SEQ ID NO 29
<211> LENGTH: 61
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR Sk-7N Top strand

<400> SEQUENCE: 29
caccgcacta gcgtatgaat gaaagatcca gcatagggat ctttcattca tacgctagtg 60
c 61

<210> SEQ ID NO 30
<211> LENGTH: 61
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR Sk-7N Bottom strand

<400> SEQUENCE: 30
aaaagcacta gcgtatgaat gaaagatccc tatgctggat ctttcattca tacgctagtg 60
c 61

<210> SEQ ID NO 31
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: shRNA-U1A-4 template

<400> SEQUENCE: 31
ctggcatcaa ggtgaacttc agggctttcg cctgaagtt caccttgatg cctatagtg 60
gtcgtattag c 71

<210> SEQ ID NO 32
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: BamHI-NdeI-NotI-L7Ae-primer

<400> SEQUENCE: 32
aaggatccat catatgcggc cgcttatgta cgtgagattt gagg 44

<210> SEQ ID NO 33
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: L7Ae-EcoRI-XhoI-primer

<400> SEQUENCE: 33

```

-continued

cactcgagtt gaattctctt ctgaaggcct ttaatc 36

<210> SEQ ID NO 34
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: T7 promoter primer

<400> SEQUENCE: 34

taatacgact cactataggg 20

<210> SEQ ID NO 35
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: BGHrev primer

<400> SEQUENCE: 35

gctggcaact agaaggcaca g 21

<210> SEQ ID NO 36
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 481P Fwd

<400> SEQUENCE: 36

caaggaggac ggcaaca 17

<210> SEQ ID NO 37
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 481P Rev

<400> SEQUENCE: 37

ccttgatgcc gttcttctgc 20

<210> SEQ ID NO 38
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: GAPDH Fwd

<400> SEQUENCE: 38

agccacatcg ctgagacac 19

<210> SEQ ID NO 39
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: GAPDH Rev

<400> SEQUENCE: 39

gcccaatag accaatcc 19

<210> SEQ ID NO 40

- continued

<211> LENGTH: 6548

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: pcDNA3.1-AsRed2-L7Ae-myc-His6

<400> SEQUENCE: 40

gacggatcgg gagatctccc gatcccctat ggtgcaactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggctcgt gagtagtgcg 120
cgagcaaaa ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag cgcgtttgcg ctgcttcgcg atgtacgggc cagatatcgc cgttgacatt 240
gattattgac tagttattaa tagtaataca ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgc tggctgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggag tatttacggg aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtagcggc cctattgacg tcaatgacgc taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacaataa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagaccca gctggctagt 900
taagcttggg accgagctcg gatccactag tccagtgtgg tggaaattccc accatggcct 960
ctttgctgaa gaagaccatg cccttcagga ccaccatcga gggcaccgtg aacggccact 1020
acttcaagtg caccggcaag ggcgagggca accccctgga gggcaccag gagatgaaga 1080
tcgaggtgat cgagggcggc cccctgcctt tgccttcca catcctgtcc acctcctgca 1140
tgtacggctc caaggccttc atcaagtagc tgtccggcat ccccgactac ttcaagcagt 1200
ccctccccga gggcttacc tgggagcgca ccaccaccta cgaggacggc ggcttcctga 1260
cgcgccacca ggacacctcc ctggacggcg actgcctggt gtacaagggtg aagatcctgg 1320
gcaacaactt ccccgccgac ggcctcgtga tgcagaacaa ggccggcgcg tgggagccct 1380
ccaccgagat cgtgtacgag gtggacggcg tgetgcgcgg ccagtcctg atggccctgg 1440
agtgcctcgg cggctgccc acctgacctc acctgcacac cacctaccgc tccaagaagc 1500
ccgctccgc cctgaagatg cccggcttcc acttcgagga ccaccgcatc gagatcctgg 1560
aggaggtgga gaagggaag tgctacaagc agtacaggc gcctgtgggc cgctactgcg 1620
acgcccggcc ctccaagctg ggcacacaac aaggcgggcc gcttatgtac gtgagatttg 1680
aggttctcga ggacatgcag aacgaagctc tgagtctgct ggagaagggt agggagagcg 1740
gtaaggtaaa gaaaggtacc aacgagacga caaaggctgt ggagagggga ctggcaaacg 1800
tcgtttacat cgcagaggat gttgacccgc ctgagatcgt tgctcatctg cccctcctct 1860
gcgaggagaa gaatgtgccc tacatttacg ttaaaagcaa gaacgacctt ggaagggtcg 1920
tgggcattga ggtgcatgc gcttcggcag cgataataca cgagggagag ctgagaaagg 1980
agcttggaag ccttggggag aagattaaag gccttcagaa gagaattcaa ctcgagtcta 2040

-continued

gagggccctt	cgaacaaaa	ctcatctcag	aagaggatct	gaatatgcat	accggtcac	2100
atcaccatca	ccattgagtt	taaaccgct	gatcagcctc	gactgtgcct	tctagttgcc	2160
agccatctgt	tgtttgcccc	tccccgctg	cttccttgac	cctggaaggt	gccactceca	2220
ctgtcctttc	ctaataaaat	gaggaaattg	catcgcattg	tctgagttagg	tgtcattcta	2280
ttctgggggg	tggggggggg	caggacagca	agggggagga	ttgggaagac	aatagcaggc	2340
atgctgggga	tgcggtgggc	tctatggctt	ctgaggcgga	aagaaccagc	tggggctcta	2400
gggggtatcc	ccacgcgccc	tgtagcggcg	cattaagcgc	ggcgggtgtg	gtggttacgc	2460
gcagcgtgac	cgctacactt	gccagcggcc	tagcggccgc	tcctttcgct	ttcttcctt	2520
cctttctcgc	cacgttcgcc	ggttttcccc	gtcaagctct	aaatcggggg	ctccctttag	2580
ggttccgatt	tagtgcttta	cggcacctcg	acccccaaaa	acttgattag	ggtgatggtt	2640
cacgtagtgg	gccatcggcc	tgatagacgg	tttttcggcc	tttgacgttg	gagtccacgt	2700
tctttaatag	tggactcttg	ttccaaactg	gaacaacact	caaccctatc	tgggtctatt	2760
cttttgattt	ataagggatt	ttgccgattt	cggcctattg	gttaaaaaat	gagctgattt	2820
aacaaaaatt	taacgcgaat	taattctgtg	gaatgtgtgt	cagttagggt	gtggaaagtc	2880
cccaggctcc	ccagcaggca	gaagtatgca	aagcatgcat	ctcaattagt	cagcaaccag	2940
gtgtggaag	tccccaggt	cccagcagg	cagaagtatg	caaagcatgc	atctcaatta	3000
gtcagcaacc	atagtcccg	ccctaactcc	gcccatcccg	cccctaactc	cgcccagttc	3060
cgccattct	cgccccatg	gctgactaat	tttttttatt	tatgcagagg	cggaggccgc	3120
ctctgctct	gagctattcc	agaagtagtg	aggaggcttt	ttggaggcc	taggcttttg	3180
caaaaagctc	ccgggagctt	gtatatccat	tttcggatct	gatcaagaga	caggatgagg	3240
atcgtttcgc	atgattgaac	aagatggatt	gcacgcagg	tctccggccg	cttgggtgga	3300
gaggctatcc	ggctatgact	gggcacaaca	gacaatcggc	tgctctgatg	ccgccgtgtt	3360
ccggctgtca	gcgcaggggc	gcccggttct	ttttgtcaag	accgacctgt	ccgggtccct	3420
gaatgaactg	caggacgagg	cagcgcggct	atcgtggctg	gccacgacgg	gctttccttg	3480
cgcagctgtg	ctcagcgttg	tactgaagc	gggaagggac	tggctgctat	tggggaagt	3540
gcccgggag	gatctcctgt	catctcacct	tgctcctgcc	gagaaagtat	ccatcatggc	3600
tgatgcaatg	eggcggtgc	atacgttga	tccggctacc	tgccattcg	accaccaagc	3660
gaaacatcgc	atcagcggag	cacgtactcg	gatggaagcc	ggtcttgtcg	atcaggatga	3720
tctggacgaa	gagcatcagg	ggctcgcgcc	agccgaactg	ttcgccaggc	tcaaggcgcg	3780
catgcccgac	ggcgaggatc	tcgtcgtgac	ccatggcgat	gcctgcttgc	cgaatatcat	3840
ggtgaaaaat	ggcgcctttt	ctggattcat	cgactgtggc	cggctgggtg	tggcggaccg	3900
ctatcaggac	atagcgttgg	ctaccctgga	tattgtgaa	gagcttggcg	gcgaatgggc	3960
tgaccgcttc	ctcgtgcttt	acggtatcgc	cgctcccgat	tcgcagcgca	tcgccttcta	4020
tcgccttctt	gacgatttct	tctgagcggg	actctgggtt	tcgcgaaatg	accgaccaag	4080
cgacgcccc	cctgccatca	cgagatttcg	attccaccgc	cgcttctat	gaaaggttgg	4140
gcttcggaat	cgttttccgg	gaecgcggct	ggatgatcct	ccagcgcggg	gatctcatgc	4200
tggagtcttt	cgcccacccc	aacttgttta	ttgcagctta	taatggttac	aaataaagca	4260
atagcatcac	aaatttaca	aataaagcat	tttttctact	gcattctagt	tgtggtttgt	4320

-continued

ccaaactcat caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg	4380
cgtaatcatg gtcatactg ttcctgtgt gaaattgta tccgctcaca attccacaca	4440
acatacgagc cggaagcata aagtgtaaag cctgggggtc ctaatgagtg agctaactca	4500
cattaattgc gttgocgctca ctgcccgtt tccagtcggg aaacctgtcg tgccagctgc	4560
attaatgaat cggccaacgc gcggggagag gcggtttgcg tattggggcg tcttccgctt	4620
cctcgctcac tgactcgtcg cgctcggtcg ttcggctcgc gcgagcggta tcagctcact	4680
caaagggcgt aatacgggta tccacagaat caggggataa cgcaggaag aacatgtgag	4740
caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata	4800
ggctccgccc ccctgacgag catcacaata atcgacgctc aagtcagagg tggcgaacc	4860
cgacaggact ataaagatac caggcgtttc ccctggaag ctccctcgtg cgctctctg	4920
ttccgacct gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcg	4980
tttctcatag ctacagctgt aggtatctca gttcgggtga ggctgctgc tccaagctgg	5040
gctgtgtgca cgaaccccc gttcagccc accgctgcgc cttatccggt aactatcgtc	5100
ttgagtcaa cccggtaaga cagcacttat ccgcaactgg agcagccact ggtaacagga	5160
ttagcagagc gaggtatgta ggcgggtgta cagagttctt gaagtgggtg cctaactacg	5220
gtacactag aagaacagta tttggtatct gcgctctgct gaagccagtt accttcgaa	5280
aaagagttgg tagctctga tccggcaaac aaaccaccgc tggtagcggg ggtttttttg	5340
tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt	5400
ctacggggtc tgacgctcag tggaacgaaa actcacgta agggattttg gtcatgagat	5460
tatcaaaaag gatcttcacc tagatccttt taaattaaaa atgaagtttt aatcaatct	5520
aaagtataata tgagtaaaact tggcttgaca gttaccaatg cttaatcagt gaggcaccta	5580
tctcagcgat ctgtctatct cgttcacca tagttgctg actccccgct gtgtagataa	5640
ctacgatacg ggagggctta ccactcggcc ccagtgctgc aatgataccg cgagaccac	5700
gctcaccggc tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa	5760
gtggtcctgc aactttatcc gctccatcc agtctattaa ttggtgcccg gaagctagag	5820
taagtagtcc gccagttaat agtttgccca acggtgctgc cattgctaca ggcatcgtgg	5880
tgtaacgctc gtcggttggg atggcttcat tcagctccgg tteccaaagc tcaaggcgag	5940
ttacatgata ccccatggtg tgcaaaaaag cggttagctc cttcggctct ccgatcgttg	6000
tcagaagtaa gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc	6060
ttactgtcat gccatccgta agatgctttt ctgtgactgg tgagtactca accaagctat	6120
tctgagaata gtgtatgccc cgaaccagtt gctcttgcgc ggcgtcaata cgggataata	6180
ccgcgccaca tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa	6240
aaactcctcaag gatcttaccg ctggtgagat ccagttcgat gtaaccact cgtgcacca	6300
actgatcttc agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc	6360
aaaatgccgc aaaaaaggga ataaggcgca cacgaaatg ttgaatactc atactcttcc	6420
tttttcaata ttattgaagc atttatcagg gttattgtct catgagcggg tacatatttg	6480
aatgtattta gaaaaataaa caaatagggg ttcgocgac atttcccga aaagtgcac	6540
ctgacgctc	6548

- continued

<210> SEQ ID NO 41
<211> LENGTH: 6203
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pcDNA3.1-EGFP-myc-His6

<400> SEQUENCE: 41
gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctcccctg cttgtgtggtt ggaggctcgt gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaataca ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgc tggtgaccg cccaacgacc 360
ccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggag tatttacggt aaactgcca cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctta tgggactttc ctacttgca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgctgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatacga ctcaactatag ggagaccca gctggctagt 900
taagcttggg accgagctcg gatccactag tccagtgtgg tggaaattccc accatggtga 960
gcaagggcga ggagctgttc accgggggtg tgcccacct ggtcgagctg gacggcgacg 1020
taaacggcca caagttcagc gtgtccggcg agggcgaggg cgatgccacc taeggcaagc 1080
tgacctgaa gttcatctgc accaccggca agctgcccgt gccctggccc accctcgtga 1140
ccaccctgac ctacggcgtg cagtgttca gccgctacce cgaccacatg aagcagcacg 1200
acttcttcaa gtccgccatg cccgaaggct acgtccagga gcgcaccatc ttcttcaagg 1260
acgacggcaa ctacaagacc cgcgccgagg tgaagttcga gggcgacacc ctggtgaacc 1320
gcatcgagct gaagggcatc gacttcaagg aggacggcaa catcctgggg cacaagctgg 1380
agtacaacta caacagccac aacgtctata tcatggccga caagcagaag aacggcatca 1440
aggtgaactt caagatccgc cacaacatcg aggacggcag cgtgcagctc gccgaccact 1500
accagcagaa caccoccatc ggcgacggcc ccgtgctgct gcccgacaac cactacotga 1560
gcaccagtc gcgccgagc aaagaccca acgagaagcg cgatcacatg gtctctgctg 1620
agttcgtgac cgcgccggg atcactctcg gcatggcga gctgtacaag gaagggcggc 1680
cgcaactcga gtctagaggg cccttcgaac aaaaactcat ctcagaagag gatctgaata 1740
tgcataccgg tcatcatcac catcaccatt gaggttaaac ccgctgatca gcctcgactg 1800
tgcttctag ttgccagcca tctgttgttt gccctcccc cgtgccttcc ttgacctg 1860
aagtgccac tcccactgct ctttccctaat aaaatgagga aattgcatcg cattgtctga 1920
gtaggtgtca ttctattctg ggggggtggg tggggcagga cagcaagggg gaggattggg 1980

-continued

aagacaatag caggcatgct ggggatgceg tgggctctat ggcttctgag gcggaagaa	2040
ccagctgggg ctctaggggg tatccccacg cgcctgtag cggcgatta agcgcggcgg	2100
gtgtgggtgt tacgcgcagc gtgaccgcta cacttgccag cgcctagcg cccgctcctt	2160
tcgctttctt cccttctttt ctgcaccagt tcgcccgtt tccccgtcaa gctctaaatc	2220
ggggctccc tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg	2280
attagggtga tggttcacgt agtgggcat cgcctgata gacggttttt cgccttttga	2340
cgttggagtc cacgtttttt aatagtggac tcttgttcca aactggaaca aactcaacc	2400
ctatctcggc ctattctttt gatttataag ggattttgcc gatttcggcc tatttggtta	2460
aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg tgtgtcagtt	2520
aggggtgtga aagccccag gctccccagc aggcagaagt atgcaaagca tgcactcaaa	2580
ttagtcagca accagggtgtg gaaagtcccc aggcctccca gcaggcagaa gtatgcaaag	2640
catgcatctc aattagtcag caaccatagt cccgcccta actccgcca tcccgccctt	2700
aactccgccc agttccgccc attctccgcc ccattggtga ctaatttttt ttatttatgc	2760
agaggccgag gccgcctctg cctctgagct attccagaag tagtgaggag gcttttttgg	2820
aggcctaggc ttttgcaaaa agctcccggg agcttgata tccattttcg gatctgatca	2880
agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc	2940
ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc	3000
tgatgccccc gtgttccggc tgcagcgca ggggcgccc gttctttttg tcaagaccga	3060
cctgtccggt gccctgaatg aactgcagga cagggcagcg cggctatcgt ggctggccac	3120
gacggcgctt ccttgccgag ctgtgctcga cgttgcact gaagcgggaa gggactggct	3180
gctattgggc gaagtgcggg ggcaggatct cctgtcatct caccttgctc ctgccgagaa	3240
agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgcc	3300
attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct	3360
tgtcagtcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc	3420
caggctcaag gcgcgcagtc ccgacggcga ggatctcgtc gtgacctatg gcgatgctg	3480
cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcacgact gtggccggct	3540
gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct	3600
tggcgggaa tgggtgacc gcttctcgt gctttacggc atcgcgctc ccgattcgca	3660
gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga gcgggactct ggggttcgcg	3720
aaatgaccga ccaagcgacg cccaacctgc catcaogaga tttcgattcc accgcccct	3780
tctatgaaag gttgggcttc ggaatcgttt tccgggacgc cggctggatg atcctccagc	3840
gcggggatct catgctggag ttcttcgccc accccaactt gtttattgca gcttataatg	3900
gttacaata aagcaatagc atcacaatt tcacaaataa agcatttttt tcaactgatt	3960
ctagttgtgg tttgtccaaa ctcatcaatg tatcttatca tgtctgtata ccgtcgacct	4020
ctagctagag cttggcgtaa tcatggtcat agctgtttcc tgtgtgaaat tgttatccgc	4080
tcacaattcc acacaacata cgagccggaa gcataaagtg taaagcctgg ggtgcctaat	4140
gagtgagcta actcacatta attgcgttgc gctcaactgcc cgtttccag tcgggaaacc	4200
tgctgtgcca gctgcattaa tgaatcggcc aacgcgcccg gagaggcggg ttgcgtattg	4260

- continued

```

ggcgctcttc cgcttctctg ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag 4320
cggtatcagc tcaactcaaag gcggaatac ggttatccac agaatacagg gataacgcag 4380
gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc 4440
tggcgttttt ccataggctc cgccccctg acgagcatca caaaaatcga cgctcaagtc 4500
agagtgggcg aaacccgaca ggactataaa gataccaggc gtttccccct ggaagctccc 4560
tcgtgcgctc tcctgttccg acctgcccgc ttaccggata cctgtcccgc tttctccctt 4620
cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg gtgtaggtcg 4680
ttcgcctcaa gctgggctgt gtgcaagaa cccccgttca gcccgaccgc tgcgccttat 4740
ccggtaaacta tcgctttgag tccaaccccg taagacacga cttatcgcca ctggcagcag 4800
ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag ttcttgaagt 4860
ggtggcctaa ctacggctac actagaagaa cagtatttgg tatctgcgct ctgctgaagc 4920
cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaacc accgctggta 4980
gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag aaaaaagga tctcaagaag 5040
atcctttgat cttttctacg gggctctgacg ctcagtggaa cgaaaactca cgtaaggga 5100
ttttggtcat gagattatca aaaaggatct tcacctagat ctttttaaat taaaaatgaa 5160
gttttaaatc aatctaaagt atatatgagt aaacttggtc tgacagttac caatgcttaa 5220
tcagtggagc acctatctca gcgatctgtc tatttcgctc atccatagtt gcctgactcc 5280
ccgtcgtgta gataactacg atacgggagg gcttaccatc tggccccagt gctgcaatga 5340
taccgcgaga cccacgctca ccggctccag atttatcagc aataaaccag ccagccggaa 5400
gggcccagcg cagaagtggc cctgcaactt tatccgcctc catccagtct attaattggt 5460
gccgggaagc tagagtaagt agttcgccag ttaatagttt gcgcaacggt gttgccattg 5520
ctacaggcat cgtgggtgca cgctcgtcgt ttggtatggc ttcattcagc tccggttccc 5580
aacgatcaag gcgagttaca tgatccccca tgttgtgcaa aaaagcgggt agctccttcg 5640
gtcctccgat cgttgtcaga agtaagttgg ccgcagtggt atcactcatg gttatggcag 5700
cactgcataa ttctcttact gtcatgcat ccgtaagatg cttttctgtg actggtgagt 5760
actcaaccaa gtcattctga gaatagtgtg tgccggcgacc gagttgctct tgcccggcgt 5820
caatacggga taataccgcg ccacatagca gaactttaa agtgctcatc attggaaaac 5880
gttcttcggg gcgaaaaact tcaaggatct taccgctggt gagatccagt tcgatgtaac 5940
ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcgtt tctgggtgag 6000
caaaaacagg aaggcaaaat gccgcaaaa agggaataag ggcgacacgg aaatggtgaa 6060
tactcactact cttccttttt caatattatt gaagcattta tcagggttat tgtctcatga 6120
gcggatacat atttgaatgt atttgaaaa ataaacaaat aggggttccg cgcacatttc 6180
ccgaaaagt gccacctgac gtc 6203

```

<210> SEQ ID NO 42

<211> LENGTH: 6182

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pcDNA3.1-AsRed2-myc-His6

<400> SEQUENCE: 42

-continued

gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgetctgatg	60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg	120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc	180
ttagggttag cgtttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt	240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagtcat agcccatata	300
tggagttccg cgttacataa cttacggtaa atggcccgc tggctgaccg cccaacgacc	360
ccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc	420
attgacgtca atgggtggag tatttacggt aaactgccc cttggcagta catcaagtg	480
atcatatgcc aagtagcccc cctattgacg tcaatgacgg taaatggccc gcctggcatt	540
atgcccgta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca	600
tcgctattac catggtgatg cgtttttggc agtacatcaa tggcggtgga tagcggtttg	660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc	720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc ccattgacg caaatggcg	780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaacca	840
ctgcttactg gcttatcgaa attaatacga ctcaactatag ggagacccaa gctggctagt	900
taagcttggt accgagctcg gatccactag tccagtgttg tggaaattccc accatggcct	960
ctttgctgaa gaagaccatg cccttcagga ccaccatcga gggcaccgtg aacggccact	1020
acttcaagtg caccggcaag ggcgagggca acccctgga gggcaccag gagatgaaga	1080
tcgaggtgat cgagggcggc ccctgccct tcgcttcca catcctgttc acctcctgca	1140
tgtacggctc caaggccttc atcaagtacg tgtccggcat ccccgactac tcaagcagt	1200
ccctcccga gggcttcacc tgggagcgca ccaccaccta cgaggacggc ggcttctgca	1260
ccgcccacca ggacacctcc ctggacggcg actgcctggt gtacaagggtg aagatcctgg	1320
gcaacaactt ccccgccgac ggccccgtga tgcagaacaa ggccggcgcg tgggagccct	1380
ccaccgagat cgtgtacgag gtggacggcg tgcctgcggc ccagtccctg atggccctgg	1440
agtgccccg cggtgccac ctgacctgcc acctgcacac cacctaccgc tccaagaagc	1500
ccgcctccgc cctgaagatg cccggcttcc acttcgagga ccaccgcatc gagatcctgg	1560
aggaggtgga gaagggcaag tctacaagc agtacgagc cgccgtgggc cgtactgcg	1620
acgcccccc ctccaagctg ggcacaacg aaggggggcc gcaactcgag tctagagggc	1680
ccttcgaaca aaaactcatc tcagaagagg atctgaatat gcataccggt catcatcacc	1740
atcaccattg agtttaaac cgtgatcag cctcgactgt gccttctagt tgccagccat	1800
ctgtgtttg cccctcccc gtgccttctc tgacctgga aggtgccact cccactgtcc	1860
tttctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg	1920
ggggtggggt ggggcaggac agcaaggggg aggattggga agacaatagc aggcattgctg	1980
gggatgcggt gggctctatg gcttctgagg cggaaagaac cagctggggc tctagggggt	2040
atccccacgc gccctgtagc ggcgcattaa gcgcggcggg tgtggtggtt acgcgacgcg	2100
tgaccgctac acttgccagc gccctagcgc ccgctcctt cgctttcttc ccttccttc	2160
tcgccacgtt cgccggcttt ccccgtaag ctetaaatcg ggggtccct ttagggttcc	2220
gatttagtgc tttacggcac ctgcaccca aaaaacttga ttaggtgat ggttcacgta	2280

-continued

gtgggccatc gccctgatag acggtttttc gccctttgac gttggagtcc acgttcttta	2340
atagtggact cttgttccaa actggaacaa cactcaacct tatctcggtc tattcttttg	2400
atataaagg gattttgccc atttcggcct attggtaaa aaatgagctg atttaacaaa	2460
aatttaacgc gaattaattc tgtggaatgt gtgtcagtta ggggtgtggaa agtccccagg	2520
ctccccagca ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa ccagggtggtg	2580
aaagtcccca ggctcccag caggcagaag tatgcaaagc atgcatctca attagtcagc	2640
aaccatagtc ccgcccctaa ctccgcccct cccgccccta actccgcccc gttccgcccc	2700
ttctccgccc catggctgac taattttttt tatttatgca gaggccgagg ccgcctctgc	2760
ctctgagcta ttccagaagt agtgaggagg cttttttgga ggcctaggct tttgcaaaaa	2820
gctcccggga gcttgatat ccattttcgg atctgatcaa gagacaggat gaggatcgtt	2880
tcgcatgatt gaacaagatg gattgcacgc aggttctccg gccgcttggg tggagaggct	2940
attcggctat gactgggac aacagacaat cggctgctct gatgccgccg tgttccggct	3000
gtcagcgcag gggcgcccgg ttctttttgt caagaccgac ctgtccggtg cctggaatga	3060
actgcaggac gaggcagcgc ggctatcgtg gctggccacg acgggcgttc cttgcgcagc	3120
tgtgctcgac gttgtcactg aagcgggaag ggactggctg ctattgggcg aagtgccggg	3180
gcaggatctc ctgtcatctc accttctctc tgccgagaaa gtatccatca tggctgatgc	3240
aatgcggcgg ctgcatacgc ttgatccggc tacctgcccc ttcgaccacc aagcgaaca	3300
tcgcatcgag cgagcacgta ctgggatgga agccggtctt gtcgatcagg atgatctgga	3360
cgaagagcat caggggctcg ccgaccgca actgttcgcc aggctcaagg cgcgcatgcc	3420
cgacggcgag gatctcgtcg tgaccatgg cgatgcctgc ttgccgaata tcatggtgga	3480
aaatggccgc tttctcgat tcactcgactg tggccggctg ggtgtggcgg accgctatca	3540
ggacatagcg ttggctaccc gtgatattgc tgaagagctt ggcggcgaat gggctgaccg	3600
cttctcgtg ctttacggta tcgccctcc cgattcgcag cgcctcgcct tctatcgcct	3660
tcttgacgag ttcttctgag cgggactctg gggttcgcga aatgaccgac caagcagcgc	3720
ccaacctgcc atcaagagat ttcgattcca ccgcccctt ctatgaaagg ttgggcttcg	3780
gaatcgtttt ccgggacgcc ggctggatga tctccagcg cgggatctc atgctggagt	3840
tcttcgcccc ccccaacttg tttattgcag cttataatgg ttacaaataa agcaatagca	3900
tcacaaattt cacaaataaa gcattttttt cactgcattc tagttgtggt ttgtccaaac	3960
tcataaatgt atcttatcat gtctgtatac cgtcgacctc tagctagagc ttggcgtaat	4020
catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacacatac	4080
gagccggaag cataaagtgt aaagcctggg gtgcctaata agtgagctaa ctacattaa	4140
ttgcgttgcc ctactgccc gctttccagt cgggaaacct gtcgtgccag ctgcattaat	4200
gaatcggcca acgcgcgggg agaggcgggt tgcgtattgg gcgctcttc gcttcctcgc	4260
tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg	4320
cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaa	4380
gccagcaaaa ggccaggaac cgtaaaaagg ccgctgtgct ggcgtttttc cataggctcc	4440
gccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aaccgacag	4500
gactataaag ataccaggcg tttcccctg gaagctccct cgtgcgctct cctgttcgca	4560

-continued

```

cctgcccgt taccggatac ctgtccgct ttctccctc gggaaagcgtg gcgctttctc 4620
atagctcacg ctgtaggtat ctgagttcgg ttaggtcgt tcgctccaag ctgggctgtg 4680
tgcacgaacc ccccgttcag cccgaccgct gcgccttacc cggtaactat cgtcttgagt 4740
ccaacccggg aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca 4800
gagcgaggtg ttagggcggg gctacagagt tcttgaagtg gtggcctaac tacggctaca 4860
ctagaagaac agtatttggg atctgcgctc tgctgaagcc agttaccttc ggaaaaagag 4920
ttggtagctc ttgatccggc aaaaaacca ccgctggtag cgggtggtttt tttgtttga 4980
agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg 5040
ggtctgacgc tcagtggaac gaaaaactac gtttaaggat tttggtcatg agattatcaa 5100
aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta 5160
tatatgagta aacttggctc gacagttacc aatgcttaat cagtgaggca cctatctcag 5220
cgatctgtct atttcgttca tccatagttg cctgactccc cgtegtgtag ataactacga 5280
tacggggaggg cttaccatct gggcccagtg ctgcaatgat accgcgagac ccacgctcac 5340
cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggc 5400
ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta 5460
gttcgccagt taatagtgtg cgcaacgttg ttgccattgc tacaggcatc gtgggtgtcac 5520
gctcgtcgtt tggatggct tcattcagct ccggttccca acgatcaagg cgagttacat 5580
gatccccat gttgtgcaaa aaagcgggta gctccttcgg tcctccgatc gttgtcagaa 5640
gtaagttggc cgcagtgta tcaactatgg ttatggcagc actgcataat tctcttactg 5700
tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag 5760
aatagtgtat gcggcgaccg agttgctctt gcccgcgctc aatacgggat aataccgctc 5820
cacatagcag aactttaaaa gtgctcatca ttgaaaaacg ttcttcgggg cgaaaaactc 5880
caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca cccaactgat 5940
cttcagcatc ttttacttcc accagcgttt ctgggtgagc aaaaacagga aggcaaatg 6000
ccgcaaaaaa gggaaataag gcgacacgga aatgttgaat actcatactc ttccttttcc 6060
aatattattg aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta 6120
tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg ccacctgacg 6180
tc 6182

```

```

<210> SEQ ID NO 43
<211> LENGTH: 63
<212> TYPE: RNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: shRNA-BoxC/D- Bcl-xL

```

```

<400> SEQUENCE: 43

```

```

gcuuugaaca gguagugaau gugaccgaa agggcgugau cauucacuac cuguucaaag 60
cag 63

```

```

<210> SEQ ID NO 44
<211> LENGTH: 82
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:

```


-continued

```

<223> OTHER INFORMATION: shRNA-BoxC/D-BclxL template

<400> SEQUENCE: 44

ctgctttgaa caggtagtga atgatcacgc cctttcgggt cacattcact acctgttcaa      60
agctatagtg agtcgtatta gc                                             82

<210> SEQ ID NO 45
<211> LENGTH: 62
<212> TYPE: RNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: shRNA-BoxC/D mut-Bcl-xL

<400> SEQUENCE: 45

gcuuugaaca gguagugaau gugcccgaag gggcgucauc auucacuacc uguucaaagc      60
ag                                             62

<210> SEQ ID NO 46
<211> LENGTH: 81
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: shRNA-BoxC/D mut-BclxL template

<400> SEQUENCE: 46

ctgctttgaa caggtagtga atgatgacgc cctttcgggc acattcacta cctgttcaaa      60
gctatagtga gtcgtattag c                                             81

<210> SEQ ID NO 47
<211> LENGTH: 59
<212> TYPE: RNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: shRNA-Bcl-xL

<400> SEQUENCE: 47

gcuuugaaca gguagugaau gaacuagcau agagucauu cacuaccugu ucaaagcag      59

<210> SEQ ID NO 48
<211> LENGTH: 78
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: shRNA-Bcl-xL template

<400> SEQUENCE: 48

ctgctttgaa caggtagtga atgaactcta tgctagtcca ttcactacct gttcaaagct      60
atagtgagtc gtattagc                                             78

<210> SEQ ID NO 49
<211> LENGTH: 3930
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR/H1/TO-shRNA-BoxC/D-Bcl-xL

<400> SEQUENCE: 49

ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgctttg agtgagctga      60
taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga      120

```

- continued

gcgccaata cgcaaacgc ctctccccgc gcgttgccg attcattaat gcagctggca	180
cgacaggttt cccgactgga aagcgggag tgagcgcaac gcaattaata cgcgtaccgc	240
tagccaggaa gagttttag aaacgcaaaa aggccatccg tcaggatggc cttctgctta	300
gtttgatgcc tggcagttta tggcgggct cctgccccgc accctccggg cgtttgcttc	360
acaacgttca aatccgctcc cgcgggattt gtcctactca ggagagcgtt caccgacaaa	420
caacagataa aacgaaaggc ccagctctcc gactgagcct ttcgttttat ttgatgctg	480
gcagttccct actctcgcgt taattcgcgc ttagacatga taagatacat tgatgagttt	540
ggacaaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct	600
attgctttat ttgtaacct tataagctgc aataaacaag ttggggtggg cgaagaactc	660
cagcatgaga tccccgcgct ggaggatcat ccagccggcg tccccgaaaa cgattccgaa	720
gccccacctt tcatagaagg cgcgggtgga atcgaaatct cgtagcacgt gtcagtcctg	780
ctcctcggcc acgaagtga cgcagttgcc ggccgggtcg cgcagggcga actccccccc	840
ccacggctgc tcgccgatct cggtcatggc cggcccgag gcgtcccga agttcgtgga	900
cacgacctcc gacctcgcgt cgtacagctc gtcaggccg cgcaccaca cccaggccag	960
ggtgttgctc ggcaccatct ggtcctggac cgcgctgatg aacagggta cgtcgtccc	1020
gaccacaccg gcgaagtct cctccacgaa gtcggggag aaccggagcc ggtcgggtca	1080
gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggtaactt	1140
ggccatggtt tagttcctca cctgtcgtta ttatactat ccgatatact atgcccgatga	1200
ttaattgtca acacgtgctg atcagatccg aaaatggata tacaagctcc cgggagcttt	1260
ttgcaaaagc ctaggcctcc aaaaaagcct cctcactact tctggaatag ctcagaggca	1320
gaggcggcct cggcctctgc ataataaaa aaaattagtc agccatgggg cggagaatgg	1380
gcggaactgg cgggagttag gggcgggatg ggcggagtta gggcggggac tatggttgc	1440
gactaattga gatgatgct ttgcatact ctgcctgctg gggagcctgg ggactttcca	1500
cacctggttg ctgactaatt gagatgcatg ctttgcatatc ttctgcctgc tggggagcct	1560
ggggacttcc cacacctaa ctgacacaca tccacagcc gaagggcga ttaacgctag	1620
catggatggt tcccagtcga cgcagttgta aaacgacggc cagtottaag ctcgggcccc	1680
aaataatgat tttatgttga ctgatagtga cctgttcgtt gcaacaaatt gatgagcaat	1740
gcttttttat aatgccaact ttgtacaaaa aagcaggctt taaaggaacc aatcagtcg	1800
actggatccg gtaccgggcc cccctcgaa gatctaatat ttgcatgctg ctatgtgttc	1860
tgggaaatca ccataaacgt gaaatcccta tcagtgatag agacttataa gttccctatc	1920
agtgatagag acaccgcttt gaacaggtag tgaatgtgac ccgaaagggc gtgatcattc	1980
actacctggt caaagctttt ttgtcgagct tccttcggga agctctccat attttttgga	2040
tccactagtt ctgacccag ctttcttgta caaagttggc attataagaa agcattgctt	2100
atcaatttgt tgcaacgaac aggtcactat cagtcacaaat aaaatcatta tttgccatcc	2160
agctgatatc ccctatagtg agtcgtatta catggtcata gctgttctcc ggcagctctg	2220
gcccgtgtct caaaatctct gatgttacat tgcacaagat aaaaatatat catcatgaac	2280
aataaaactg tctgcttaca taaacagtaa tacaaggggt gttatgagcc atattcaacg	2340
ggaaacgtcg aggcgcgat taaattccaa catggatgct gatttatatg ggtataaatg	2400

- continued

```

ggctcgcgat aatgtcgggc aatcaggtgc gacaatctat cgcttgtatg ggaagcccga 2460
tgcgccagag ttgtttctga aacatggcaa aggtagcggt gccaatgatg ttacagatga 2520
gatggtcaga ctaaaactggc tgacggaatt tatgcctctt ccgaccatca agcattttat 2580
ccgtactcct gatgatgcat ggttactcac cactgcgac cccggaaaaa cagcattcca 2640
ggtattagaa gaatatcctg attcaggtga aaatattgtt gatgcgctgg cagtgttcct 2700
gcgccggttg cattcgatc ctgtttgtaa ttgtcctttt aacagcgac gcgtatttcg 2760
tctcgctcag gcgcaatcac gaatgaataa cggtttggtt gatgcgagtg attttgatga 2820
cgagcgaat ggctggcctg ttgaacaagt ctggaagaa atgcataaac ttttgccatt 2880
ctcaccggat tcagtcgca ctcattggtga tttctcactt gataacctta tttttgacga 2940
gggaaatta ataggttgta ttgatgttg acgagtcgga atcgcagacc gataccagga 3000
tcttgccatc ctatggaact gcctcgggta gttttctcct tcattacaga aacggctttt 3060
tcaaaaat ggtattgata atcctgatat gaataaattg cagtttcatt tgatgctcga 3120
tgagtttttc taatcagaat tggtaattg gttgtaacac tggcagagca ttacgctgac 3180
ttgacgggac ggcgcaagct catgaccaa atcccttaac gtgagttacg cgtcgttcca 3240
ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg 3300
cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga 3360
tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa 3420
tactgttctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc 3480
tacatacctc gctctgctaa tctgttacc agtggtgct gccagtgccg ataagtcgtg 3540
tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggc cgggctgaa 3600
ggggggttcg tgcacacagc ccagcttga gcgaacgacc tacaccgaac tgagatacct 3660
acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc 3720
ggtaagcggc agggtcgga caggagagcg cacgagggag cttccagggg gaaacgectg 3780
gtatctttat agtctgtcg ggtttcgcca cctctgactt gagegtcgat ttttgatg 3840
ctcgtcaggg gggcggagcc tatggaaaaa cgcagcaac gcggcctttt tacggttct 3900
ggccttttgc tggccttttg ctcacatggt 3930

```

<210> SEQ ID NO 50

<211> LENGTH: 65

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: BoxC/D Bcl-xL Top strand

<400> SEQUENCE: 50

```

caccgctttg aacaggtagt gaatgtgacc cgaaagggcg tgatcattca ctacctgttc 60

```

aaagc

65

<210> SEQ ID NO 51

<211> LENGTH: 65

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: BoxC/D Bcl-xL Bottom strand

<400> SEQUENCE: 51

-continued

```

aaaagctttg aacaggtagt gaatgatcac gccctttcgg gtcacattca ctacctgttc 60
aaagc 65

<210> SEQ ID NO 52
<211> LENGTH: 3929
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pENTR H1 TO-shRNA-BoxC/D mut-Bcl-xL

<400> SEQUENCE: 52

ctttcctgcy ttatcccctg attctgtgga taaccgtatt accgccttg agtgagctga 60
taccgctcgc cgcagccgaa cgcaccgagcg cagcgagtca gtgagcgagg aagcgggaaga 120
gcgccaata cgaaccgcgc ctctcccgcg gcgttgcccg attcattaat gcagctggca 180
cgacaggttt cccgactgga aagcgggagc tgagcgcaac gcaattaata cgcgtaccgc 240
tagccaggaa gagttttag aaacgcaaaa aggccatccg tcaggatggc cttctgttta 300
gtttgatgcc tggcagttta tggcgggct cctgccgcc accctccggg ccgttgcttc 360
acaacgttca aatccgctcc cggcggattt gtcctactca ggagagcgtt caccgacaaa 420
caacagataa aacgaaaggc ccagctctcc gactgagcct ttcgttttat ttgatgctg 480
gcagttccct actctcgcgt taattcgcgc ttagacatga taagatacat tgatgagttt 540
ggacaaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct 600
attgctttat ttgtaacct tataagctgc aataaacaag ttgggggtggg cgaagaactc 660
cagcatgaga tccccgcgct ggaggatcat ccagccggcg tccccgaaaa cgattccgaa 720
gccccacctt tcatagaagg cggcgggtgga atcgaaatct cgtagcacgt gtcagtcctg 780
ctcctcggcc acgaagtgca cgcagttgcc ggcgggtcg cgcagggcga actcccggcc 840
ccacggctgc tcgccgatct cggtcatggc cggcccggag gcgtcccgga agttcgtgga 900
cacgacctcc gacctcggc cgtacagctc gtcagggccg cgcaccaca cccaggccag 960
ggtgttgtcc ggcacctct ggtcctggac cgcgctgatg aacagggta cgtcgtccc 1020
gaccacaccg gcgaagtct cctccacgaa gtcggggag aaccgagcc ggtcgggtca 1080
gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggtaactt 1140
ggccatggtt tagttcctca ccttgcgta ttatactatg ccgatatact atgccgatga 1200
ttaattgtca acacgtgctg atcagatccg aaaatggata tacaagctcc cgggagcttt 1260
ttgcaaaaagc ctaggcctcc aaaaaagcct cctcactact tctggaatag ctcagaggca 1320
gaggcggcct cggcctctgc ataaataaaa aaaattagtc agccatgggg cggagaatgg 1380
gcggaactgg gcggagttag ggcgggatg ggcggagttt gggcggggac tatggttgc 1440
gactaattga gatgatgct ttgcatact ctgcctgctg gggagcctgg ggactttcca 1500
cacctggttg ctgactaatt gagatgcatg ctttgcatc tctgcctgc tggggagcct 1560
ggggactttc cacacctaa ctgacacaca ttccacagcc gaagggcgaa ttaacgctag 1620
catgatggtt tccccagtc cgcagttgta aaacgacggc cagtcttaag ctcgggcccc 1680
aaataatgat tttattttga ctgatagtga cctgttcgtt gcaacaaatt gatgagcaat 1740
gcttttttat aatgccaact ttgtacaaaa aagcaggctt taaaggaacc aattcagtcg 1800
actggatccg gtaccgggcc cccctcgaa gatctaatat ttgcatgtcg ctatgtgttc 1860

```

-continued

tgggaaatca ccataaacgt gaaatcccta tcagtgatag agacttataa gttccctatc	1920
agtgatagag acaccgcttt gaacaggtag tgaatgtgcc cgaagggcg tcatcattca	1980
ctacctgttc aaagcttttt tgtcgagctt ccttcgggaa gctctccata ttttttgat	2040
ccactagttc tagaccagc tttctgtac aaagttggca ttataagaaa gcattgctta	2100
tcaatttgtt gcaacgaaca ggccactatc agtcaaaaata aaatcattat ttgccatcca	2160
gctgatatcc cctatagtga gtcgtattac atggtcatag ctgtttcctg gcagctctgg	2220
cccgtgtctc aaaatctctg atgttacatt gcacaagata aaaatatatc atcatgaaca	2280
ataaaactgt ctgcttcat aaacagtaat acaaggggtg ttatgagcca tattcaacgg	2340
gaaacgtcga ggccgctgatt aaattccaac atggatgctg atttatatgg gtataaatgg	2400
gctcgcgata atgtcgggca atcagggtgc acaatctatc gcttgatgg gaagcccgat	2460
gcccagagt tgtttctgaa acatggcaaa ggtagcgttg ccaatgatgt tacagatgag	2520
atggtcagac taaactggct gacggaatth atgcctcttc cgaccatcaa gcattttatc	2580
cgtactcctg atgatgatg gttactcacc actgcgatcc cgggaaaaac agcattccag	2640
gtattagaag aatatcctga ttcagggtgaa aatattgttg atgcgctggc agtggtcctg	2700
cgccggttgc attcgattcc tgtttgtaat tgcctttta acagcgcgctg cgtatttctg	2760
ctcgcctcag cgcaatcacg aatgaataac ggtttggttg atgcgagtgga tttgatgac	2820
gagcgtaatg gctggcctgt tgaacaagtc tggaaagaaa tgcataaact tttgccattc	2880
tcaccggatt cagtcgtcac tcatgggtgat ttctcacttg ataaccttat ttttgacgag	2940
gggaaattaa taggttgtat tgatgttggga cgagtcggaa tgcagaccg ataccaggat	3000
cttgccatcc tatggaactg cctcgggtgag ttttctcctt cattacagaa acggcttttt	3060
caaaaatag gtattgataa tcttgatag aataaattgc agtttcattt gatgctcgat	3120
gagtttttct aatcagaatt ggttaattgg ttgtaaacct ggcagagcat tacgctgact	3180
tgacgggacg gcgcaagctc atgacaaaaa tcccttaacg tgagttacgc gtcgttcac	3240
tgagcgtcag accccgtaga aaagatcaaa ggatcttctt gagatccttt ttttctgcgc	3300
gtaactctgt gcttgcaaac aaaaaaacca ccgctaccag cgggtggttg tttgccggat	3360
caagagctac caactctttt tccgaaggta actggcttca gcagagcgc gataccaaat	3420
actgttcttc tagttagacc gtagttaggc caccacttca agaactctgt agcaccgcct	3480
acataactcg ctctgtaaat cctgttacca gtggctgctg ccagtggcga taagtctgt	3540
cttaccgggt tggactcaag acgatagtta ccgataagg cgcagcggtc gggctgaacg	3600
gggggttctg gcacacagcc cagcttgag cgaacgacct acaccgaact gagataccta	3660
cagcgtgagc tatgagaaag cgcaccgctt cccgaaggga gaaagggcga caggtatccg	3720
gtaagcggca gggctggaac aggagagcgc acgagggagc ttccaggggg aaacgcctgg	3780
tatctttata gtcctgtcgg gtttcgccac ctctgacttg agcgtcgatt tttgtgatgc	3840
tcgctcaggg ggcggagcct atggaaaaac gccagcaacg cggccttttt acggttctctg	3900
gccttttgct ggccttttgc tcacatggt	3929

<210> SEQ ID NO 53

<211> LENGTH: 64

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

-continued

<223> OTHER INFORMATION: BoxC/D mut Bcl-xL Top strand

<400> SEQUENCE: 53

caccgctttg aacaggtagt gaatgtgccc gaaagggcgt catcattcac tacctgttca 60

aagc 64

<210> SEQ ID NO 54

<211> LENGTH: 64

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: BoxC/D mut Bcl-xL Bottom strand

<400> SEQUENCE: 54

aaaagctttg aacaggtagt gaatgatgac gccctttcgg gcacattcac tacctgttca 60

aagc 64

<210> SEQ ID NO 55

<211> LENGTH: 3926

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: pENTR/H1/TO-shRNA-Bcl-xL

<400> SEQUENCE: 55

ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga 60

taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcgggaaga 120

gcgccaata cgcaaaccgc ctctcccgcg gcggtggccg attcattaat gcagctggca 180

cgacaggttt cccgactgga aagcgggagc tgagcgcgcaac gcaattaata cgcgtaccgc 240

tagccaggaa gagttttag aaacgcaaaa aggccatccg tcaggatggc cttctgctta 300

gtttgatgcc tggcagttta tggcgggctg cctgcccgcc accctccggg cgttgcttc 360

acaacgttca aatccgctcc cggcggattt gtccactca ggagagcgtt caccgacaaa 420

caacagataa aacgaaaggc ccagctctcc gactgagcct ttcgttttat ttgatgctg 480

gcagttccct actctcgcgt taattcgcgc ttagacatga taagatacat tgatgagttt 540

ggacaaaacca caactagaat gcagtgaaaa aaatgcttta tttgtgaaat ttgtgatgct 600

attgctttat ttgtaacctat tataagctgc aataaacaag ttgggggtggg cgaagaactc 660

cagcatgaga tcccgcgctg ggaggatcat ccagccggcg tcccggaaaa cgattccgaa 720

gcccacctt tcatagaagg cggcgggtgga atcgaaatct cgtagcacgt gtcagtcctg 780

ctcctcggcc acgaagtgca cgcagttgcc ggccgggtcg cgcagggcga actcccgcc 840

ccacggctgc tcgcgatct cggtcattgc cggccggag gcgtcccga agttcgtgga 900

cacgacctcc gaccactcgg cgtacagctc gtccaggccg cgcaccaca cccaggccag 960

ggtgttgctc ggcaacctct ggtcctggac cgcgctgatg aacagggtea cgtcgtccc 1020

gaccacaccg gcgaagtctg cctccacgaa gtcccgggag aaccgagcc ggtcgggtca 1080

gaactcgacc gctccggcga cgtcgcgcgc ggtgagcacc ggaacggcac tggtaactt 1140

ggccatggtt tagttcctca ccttgtctga ttatactatg ccgatatact atgcccgatga 1200

ttaattgtca acacgtgctg atcagatccg aaaatggata tacaagctcc cgggagcttt 1260

ttgcaaaagc ctaggcctcc aaaaaagcct cctcactact tctggaatag ctcagaggca 1320

-continued

gaggcggcct cggcctctgc ataaataaaa aaaattagtc agccatgggg cggagaatgg	1380
gcggaactgg gcggagttag gggcgggatg gcgggagta gggcgggac tatggttget	1440
gactaattga gatgatgct ttgcatactt ctgcctgctg gggagcctgg ggactttcca	1500
cacctggttg ctgactaatt gagatgcatg ctttgcatatc ttctgcctgc tggggagcct	1560
ggggactttc cacacocctaa ctgacacaca ttccacagcc gaagggcgaa ttaacgetag	1620
catggatggt ttcccagtc cgcagttgta aaacgacggc cagtcttaag ctcgggcccc	1680
aaataatgat tttattttga ctgatagtga cctgttcggt gcaacaaatt gatgagcaat	1740
gctttttat aatgccaaact ttgtacaaaa aagcaggcct taaaggaacc aattcagtcg	1800
actggatccg gtaccgggcc ccccctcgaa gatctaatat ttgcatgtcg ctatgtgttc	1860
tgggaaatca ccataaacgt gaaatcccta tcagtgatag agacttataa gttccctatc	1920
agtgatagag acaccgcttt gaacaggtag tgaatgaact agcatagagt tcattcacta	1980
cctgttcaaa gcttttttgt cgagcttcct tegggaagct ctccatattt tttggatcca	2040
ctagtcttag acccagcttt cttgtacaaa gttggcatta taagaaagca ttgcttatca	2100
atgtgttga acgaacaggt cactatcagt caaaataaaa tcattatttg ccatccagct	2160
gatatccct atagtgtgac gtattacatg gtcatagctg tttcctggca gctctggccc	2220
gtgtctcaaa atctctgatg ttacattgca caagataaaa atatatcatc atgaacaata	2280
aaactgtctg cttacataaa cagtaataca aggggtgta tgagccatat tcaacgggaa	2340
acgtcgaggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta taaatgggct	2400
cgcgataatg tggggcaatc aggtgcgaca atctatcgtg tgatgggaa gcccgatgcg	2460
ccagagttgt ttctgaaaca tggcaaaagt agcgttgcca atgatgttac agatgagatg	2520
gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca ttttatccgt	2580
actcctgatg atgatgggt actcaccact gcgatccccg gaaaaacagc attccaggta	2640
ttagaagaat atcctgatc aggtgaaaat attgttgatg cgctggcagt gttcctgctc	2700
cggttgcatt cgattcctgt ttgtaattgt ccttttaaca gcgatcgcgt atttcgtctc	2760
gctcaggcgc aatcacgaat gaataacggc ttggttgatg cgagtgattt tgatgacgag	2820
cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt gccattctca	2880
ccggattcag tgcactca tggtgatttc tcaactgata accttatttt tgacgagggg	2940
aaattaatag gttgtattga tgttgacga gtcggaatcg cagaccgata ccaggatctt	3000
gccatcctat ggaactgcct cggtgagttt tctcctcat tacagaaacg gctttttcaa	3060
aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat gctcgatgag	3120
tttttctaat cagaattggt taattgggtg taacctggc agagcattac gctgacttga	3180
cgggacggcg caagctcatg accaaaatcc cttaacgtga gttacgcgct gttccactga	3240
gcgtcagacc ccgtagaaaa gatcaaagga tctctttgag atcctttttt tctgcgcgta	3300
atctgctgct tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa	3360
gagctaccaa ctctttttcc gaaggttaact ggcttcagca gagcgcagat accaaatact	3420
gttcttctag tgtagccgta gttaggccac cactcaaga actctgtage accgcctaca	3480
taoctgctc tgctaactct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt	3540
accgggttgg actcaagacg atagttaccg gataaggcgc agcggctcggg ctgaacgggg	3600

-continued

```

ggttcgtgca cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag 3660
cgtgagctat gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta 3720
agcggcaggg tcggaacagg agagcgcaag agggagcttc cagggggaaa cgctcggtat 3780
ctttatagtc ctgtcggggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg 3840
tcaggggggc ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc 3900
ttttgctggc cttttgctca catggt 3926

```

```

<210> SEQ ID NO 56
<211> LENGTH: 61
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Bcl-xL Top strand

```

```

<400> SEQUENCE: 56

```

```

caccgctttg aacaggtagt gaatgaacta gcatagagtt cattcactac ctgttcaaag 60
c 61

```

```

<210> SEQ ID NO 57
<211> LENGTH: 61
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Bcl-xL Bottom strand

```

```

<400> SEQUENCE: 57

```

```

aaaagctttg aacaggtagt gaatgaactc tatgctagtt cattcactac ctgttcaaag 60
c 61

```

```

<210> SEQ ID NO 58
<211> LENGTH: 6173
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pcDNA-AmCyan-myc-His6

```

```

<400> SEQUENCE: 58

```

```

gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctcctcg cttgtgtggt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacy cgttgacatt 240
gattattgac tagttattaa tagtaataa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggag tatttacgggt aaactgccca cttggcagta catcaagtggt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttgcca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcaagggg atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacy ggaactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780

```


- continued

gtaggcgtgt acgggtgggag gtctatataa gcagagctct ctggctaact agagaacca	840
ctgcttactg gcttatcgaa attaatcga ctcactatag ggagaccaa gctggctagt	900
taagcttggg accgagctcg gatccactag tccagtgtgg tggaattccc accatggctc	960
tttcaacaa gtttatcgga gatgacatga aaatgacct ccatatggat ggctgtgtca	1020
atgggcatta ctttaccgtc aaagggtgaag gcagcgggaa gccatacgaa gggacgcaga	1080
cctcgacttt taaagtcaac atggccaacg gtgggcccct tgcattctcc tttgacatac	1140
tatctacagt gttcatgtat ggaatcgat gctttactgc gtatcctacc agtatgcccg	1200
actatttcaa acaagcattt cctgacggaa tgtcatatga aaggactttt acctatgaag	1260
atggaggagt tgctacagcc agttgggaaa taagccttaa aggcaactgc tttgagcaca	1320
aatccacgtt tcatggagtg aactttctcg ctgatggacc tgtgatggcg aagatgacaa	1380
ctggttggga cccatctttt gagaaaatga ctgtctgcga tggaatattg aagggtgatg	1440
tcaccgcgtt cctcatgctg caaggaggtg gcaattacag atgccaatc cacacttctt	1500
acaagacaaa aaaaccggtg acgatgccac caaacctgc ggtggaacat cgcattgcca	1560
ggaccgacct tgacaaaggt ggcaacagtg ttcagctgac ggagcacgct gttgcacata	1620
taacctctgt tgtcccttc gaagggcggc cgcaactcga gtctagaggg ccttcgaa	1680
aaaaactcat ctcagaagag gatctgaata tgcataccgg tcatcatcac catcaccatt	1740
gagtttaaac ccgctgatca gcctcgactg tgccttctag ttgccagcca tctgttgttt	1800
gcccctccc cgtgccttc ttgacctgg aagggtccac tcccactgc ctttcctaat	1860
aaaatgagga aattgcatcg cattgtctga gtaggtgtca ttctattctg gggggtggg	1920
tggggcagga cagcaagggg gaggattggg aagacaatag caggcatgct ggggatgagg	1980
tgggctctat ggcttctgag gcggaaagaa ccagctgggg ctctaggggg tatccccacg	2040
cgccctgtag cgggcatta agcgcggcgg gtgtgggtgt tacgcgcagc gtgaccgcta	2100
cacttgccag cgccttagcg cccgctcctt tgccttctt cccctcctt ctcgccagct	2160
tgcgggctt tcccgcctca gctcctaatc ggggctccc tttagggctc cgatttagtg	2220
ctttacggca cctcgacccc aaaaaacttg attagggatg tggttcacgt agtgggcat	2280
cgccctgata gacggttttt cgcctttga cgttgagtc cacgttcttt aatagtgagc	2340
tcttgttcca aactggaaca aactcaacc ctatctcggg ctattctttt gatttataag	2400
ggattttgcc gatttcggcc tatttggttaa aaaatgagct gatttaacaa aaatttaacg	2460
cgaattaatt ctgtggaatg tgtgtcagtt aggggtgtga aagtocccag gctcccagc	2520
aggcagaagt atgcaaagca tgcactcaa ttagtcagca accaggtgtg gaaagtcccc	2580
aggctcccca gcaggcagaa gtagtcaaag catgcatctc aattagtcag caaccatagt	2640
cccggccccta actcggccca tcccggcccct aactcggccc agttccgccc attctcggc	2700
ccatggctga ctaatTTTTT ttatttatgc agaggccgag gccgcctctg cctctgagct	2760
attccagaag tagtgaggag gcttttttg aggctaggc ttttgcaaaa agctccggg	2820
agcttgata tccatTTTtc gatctgatca agagacagga tgaggatcgt ttcgcatgat	2880
tgaacaagat ggattgcacg caggttctcc ggcgcttggt gtggagagge tattcggtca	2940
tgactgggca caacagacaa tcggctgctc tgatgccgcc gtgttccggc tgtcagcgca	3000
ggggcggccg gttctTTTTg tcaagaccga cctgtccggt gccctgaatg aactgcagga	3060

- continued

cgaggcagcg	cggtatcgt	ggctggccac	gacgggctt	ccttgccag	ctgtgctcga	3120
cgttgtcact	gaagcgggaa	gggactggct	gctattgggc	gaagtgccgg	ggcaggatct	3180
cctgtcatct	caccttgctc	ctgccgagaa	agtatccatc	atggctgatg	caatgcggcg	3240
gctgcatacg	cttgatccgg	ctacctgcc	attcgaccac	caagcgaaac	atcgcatcga	3300
gcgagcacgt	actcggatgg	aagccggctc	tgtcgatcag	gatgatctgg	acgaagagca	3360
tcaggggctc	gcgccagccg	aactgttcgc	caggctcaag	gcgcgatgc	ccgacggcga	3420
ggatctcgtc	gtgacctg	gcgatgctg	cttgccgaat	atcatggtgg	aaaatggccg	3480
ctttctgga	ttcatcgact	gtggccggct	gggtgtggcg	gaccgctatc	aggacatagc	3540
gttggtacc	cgtgatattg	ctgaagagct	tggcggcga	tgggctgacc	gcttcctcgt	3600
gctttacggt	atcccgctc	ccgattcgca	gcgcgatgcc	ttctatcgcc	ttcttgacga	3660
gttcttctga	gcgggactct	ggggttcgcg	aaatgaccga	ccaagcgacg	cccaacctgc	3720
catcacgaga	tttcgattcc	accgccgctc	tctatgaaag	gttgggcttc	ggaatcgttt	3780
tcggggacgc	cggtggatg	atcctccagc	gcggggatct	catgctggag	ttcttcgcc	3840
accccaactt	gtttattgca	gcttataatg	gttacaata	aagcaatagc	atcacaat	3900
tcacaaataa	agcatttttt	tcactgcatt	ctagtgtgg	tttgtccaaa	ctcatcaatg	3960
tatcttatca	tgtctgtata	ccgtcgacct	ctagctagag	cttggcgtaa	tcatggtcat	4020
agctgtttcc	tgtgtgaaat	tgttatccgc	tcacaattcc	acacaacata	cgagccggaa	4080
gcataaagtg	taaagcctgg	ggtgccta	gagtgaagct	actcacatta	attgcgttgc	4140
gctcactgcc	cgctttccag	tcgggaaacc	tgtcgtgcca	gctgcaata	tgaatcgccc	4200
aacgcgcggg	gagaggcgg	ttcgctattg	ggcgtctctc	cgcttcctcg	ctcactgact	4260
cgctgcgctc	ggctgttcgg	ctgcggcgag	cggtatcagc	tcactcaaag	ggcgtaatac	4320
ggttatccac	agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	4380
aggccaggaa	ccgtaaaaag	gccgcgttgc	tggcgttttt	ccataggtc	cgccccctg	4440
acgagcatca	caaaaatcga	cgctcaagtc	agaggtggcg	aaaccgcaca	ggactataaa	4500
gataccaggc	gtttcccctc	ggaagctccc	tcgtgcgctc	tctgttccg	accctgccgc	4560
ttaccggata	cctgtccgcc	ttctcctct	cgggaagcgt	ggcgcttct	catagctcac	4620
gctgtaggta	tctcagttcg	gtgtaggctg	ttcgctccaa	gctgggctgt	gtgcacgaac	4680
cccccgttca	gcccgaccgc	tgcgcttat	ccggtaaacta	tcgtcttgag	tccaaccgg	4740
taagacacga	cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	4800
atgtaggcgg	tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagaa	4860
cagtatattg	tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	4920
cttgatccgg	caaaacaacc	accgctggta	gcggtggttt	ttttgttgc	aagcagcaga	4980
ttacgcgcag	aaaaaaagga	tctcaagaag	atcctttgat	ctttctacg	gggtctgacg	5040
ctcagtgtaa	cgaaaactca	cgtaaggga	ttttggtcat	gagattatca	aaaaggatct	5100
tcacctagat	ccttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	5160
aaacttggtc	tgacagttac	caatgcttaa	tcagtggagc	acctatctca	gcgatctgtc	5220
tatttctg	atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	atcggggagg	5280
gcttaccatc	tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	5340

-continued

atztatcagc aataaaccag ccagccgga gggccgagcg cagaagtgg cctgcaactt	5400
tatccgcctc catccagtct attaattggt gccgggaagc tagagtaagt agttcgccag	5460
ttaatagttt gcgcaacggt gttgccattg ctacaggcat cgtgggtgca cgctcgctgt	5520
ttggtatggc ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca	5580
tgttggtgcaa aaaagcgggt agctccttcg gtcctccgat cgttgtcaga agtaagttgg	5640
ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact gtcatgcat	5700
ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgt	5760
tgccggcacc gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca	5820
gaactttaa agtgcctcctc attggaaac gttcttcggg gcgaaaactc tcaaggatct	5880
taccgctggt gagatccagt tcgatgtaac ccaactcgtc acccaactga tcttcagcat	5940
cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaat gccgcaaaa	6000
agggaaataag ggcgacacgg aaatgtgaa tactcatact cttccttttt caatattatt	6060
gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa	6120
ataaacaaat aggggttcg cgcacatttc cccgaaaagt gccacctgac gtc	6173

1. An shRNA comprising:
 - a guide strand having a sequence complementary to a target sequence;
 - a passenger strand which forms a duplex with the guide strand; and
 - a linker strand which links the guide strand and the passenger strand, wherein the linker strand comprises an RNP-derived protein-binding motif sequence.
2. The shRNA according to claim 1, wherein the RNP-derived protein-binding motif sequence is a Box C/D sequence.
3. An RNAi control system comprising:
 - an shRNA according to claim 1 or 2; and
 - an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.
4. An RNAi control system comprising:
 - a vector for expression of an shRNA according to claim 1 or 2; and
 - a vector for expression of an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA.
5. An RNAi control method comprising the steps of:
 - contacting an shRNA according to claim 1 or 2 with an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA, in a solution; and
 - introducing the solution containing the shRNA and the protein into a cell.
6. An intracellular RNAi control method comprising the steps of:
 - introducing an shRNA according to claim 1 or 2 or a vector for expression of the shRNA into a cell; and
 - introducing an RNP-derived protein which specifically binds to a protein-binding motif sequence in the shRNA or a vector for expression of the protein, into the cell.
7. An RNAi control system responsive to a protein expressed in a cell, the system comprising:
 - an shRNA according to claim 1, wherein the RNP-derived protein-binding motif sequence is a sequence specifically binding to the protein expressed in the cell, or a vector for expression of the shRNA.
8. An RNAi control method responsive to a protein expressed in a cell, the method comprising the step of:
 - introducing an shRNA according to claim 1, wherein the RNP-derived protein-binding motif sequence is a sequence specifically binding to the protein expressed in the cell, or a vector for expression of the shRNA, into a cell.
9. The RNAi control system according to claim 7, wherein the target sequence of the shRNA is Bcl-xL mRNA, and the RNAi control system controls the expression of an apoptosis regulatory protein.
10. An artificial protein information conversion system using an shRNA according to claim 1, wherein information of a protein specifically binding to the RNP-derived protein-binding motif sequence is converted to information of a protein encoded by an RNA of a target sequence of the shRNA.

* * * * *